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Prostate cancer is one of the most challenging global medical issues today. In 2011, 
prostate cancer was the most diagnosed malignancy in the United States, making up 29% of new 
cancer cases. In that year it was the second leading cause of cancer related deaths among men in 
the USA and the second most common cause of cancer related death overall from the EU. The 
prostate remains, however, an under studied organ, making insights into the anatomy and biology 
of prostate cancer difficult to achieve. After 30 years, PSA screening of men of the appropriate 
age is still the first step in prostate cancer diagnosis, usually followed by a manual prostate exam 
which may lead to a transrectal biopsy. This study makes use of Next Generation Sequencing to 
successfully identify a superior miRNA based urinary assay for the detection of prostate cancer. 
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A receiver operating curve AUC of 0.90 was achieved for patients vs. non-patients using an 
additive risk model defined by empirically derived critical threshold values of eight urinary 
miRNAs identified with this method. This is superior to the PSA blood test’s AUC of 0.66 which 
illustrates that a miRNA profile such as this has the potential to surpass protein biomarkers such 
as PSA in terms of specificity and sensitivity. It was also demonstrated that a geometric mean of 
three urinary miRNAs were useful for endogenous normalization. 
One significant risk factor for prostate cancer is being African American. Again using 
Next Generation Sequencing technology, we have established a miRNA expression profile for 
the stages of a prostate cancer cell line progression model derived from the normal prostate 
epithelium of an African American man. Normal prostate epithelium was immortalized only with 
SV40 large T antigen (P69) and passaged three times in nude mice, producing the highly 
aggressive and metastatic M12 cell line. The M2182 cell line is an intermediate between the 
P69s and M12s having only been passaged twice and not yet having acquired metastatic 
potential. The F6 cell line was derived by reintroducing a copy of chromosome 19 missing from 
the M12 cell line via microcell mediated chromosome transfer. These profiles show a large 
downregulation of miRNAs early in tumorigenesis (from P69 toM2182) affecting the DLK1-
DIO3 megacluster and the miR-200 family. The later acquisition of metastatic potential (from 
M2182 to M12) is concomitant with the upregulation of specific miRNAs including the HOX 
gene miRNAs miR-10a and miR-196 and miR-9. Thus, the analysis of this progression model 
has uncovered relevant miRs and genes the dysregulation of which contribute to prostate 
tumorigenesis.  
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INTRODUCTION 
The Prostate  
The prostate is a ductal exocrine organ located at the junction between the bladder and 
the urethra that makes an alkaline contribution to the seminal fluid designed to facilitate the 
survival of spermatozoa in the hostile environment of the vagina. As an exocrine organ, the bulk 
of the prostate is made up of tubuloalveolar glandular tissue from which 95% of prostate cancers 
(adenocarcinomas) originate.5 This glandular tissue is divided up into the four distinct zones 
based on the location and appearance of their ductal openings in the urethra with reference to the 
verumontanum (seminal colliculus), the microscopic appearance of their glands, and the 
branching pattern of the tubular network.5 Approximately 50-75% of glandular tissue makes up 
the peripheral zone constituting most of the base and lateral areas of the prostate’s conical shape. 
Approximately 10-25% of the prostate’s glandular tissue, the majority of the tissue that does not 
reside in the peripheral zone, resides in the central zone. Between 5% and 10% of glandular 
tissue resides in the transition zone which is separated from the rest of the prostate by a 
fibromuscular band. Finally the periurethral glands make up less than 1% of glandular tissue.5  
Prostate Cancer 
One inherent problem to the characterization of miRNA involvement in prostate 
carcinogenesis is that, compared to other more well studied malignancies, little is known about 
crucial molecular mechanisms driving pCa, leaving us with no place to start looking. It is hoped 
at this stage that as miRNA studies move forward in tandem to studies involving more classical 
oncogenes, that the two will complement each other, with an integrative model being the final 
goal. However, some key molecular aberrations in prostate cancer that have been observed 
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include the TMPRSS2:ETS genetic rearrangement, GSTP1, NKX3.1, PTEN, p27, and the 
androgen receptor (AR)8 and many reports show aberrant miRNA contribution to prostate 
carcinogenesis.2  
The Relevance of miRNAs 
Non-coding RNA (ncRNA) has been reported to account for up to 90% of transcription in 
eukaryotes, and yet for a long time was considered to make no significant contribution to the 
biology of the cell.1 The discovery of the importance of miRNAs and the many other functional 
ncRNAs has helped to overturn this thinking. miRNAs are phylogenetically conserved3, 19-24 
nucleotide (nt) long non-coding RNAs that make up an endogenous and extremely diverse part 
of translational regulation. Based on Watson-Crick base paring alone, it is estimated that 60% of 
protein encoding genes could be regulated directly by miRNAs.1 However, a more modern view 
of miRNA targeting allowing for G:U wobbles and the possibility for strong binding despite 
central mismatches has led contemporary researchers to expand that estimation to as high as 
90%.38 In addition to this, most genes contain multiple binding sites for different miRNAs 
allowing for the formation of complex regulatory networks. What is known is that miRNAs have 
been shown to regulate almost all physiological processes and to be involved to some degree in 
the pathology of all tissues.1 In the last decade, more than 10,000 papers reporting on the 
involvement of miRNAs in cancer were deposited to PubMed.58   
Extracellular miRNAs and the Tumor Microenvironment  
 The ability of miRNAs to act on local or even distant tissues has captured the imagination 
of many researchers. Evidence has accumulated for many possible secretory mechanisms 
including passive diffusion from platelets and cells undergoing apoptosis, and active secretion 
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via exosomes, microvesicles, apoptotic bodies, and exocytosis in complex with proteins and 
lipoproteins.3,19 However, none of these has received more attention in the past decade than 
exosomes. Exosomes range from 30-100 nm and are formed through inward budding of 
endocytic membranes, resulting in multivesicular bodies that eventually fuse with the cell 
membrane to release the exosomes into the extracellular milieu. Studies have suggested that a 
common 3’ UTR motif may allow for selective packaging of certain mRNAs into exosomes, 
perhaps via interactions with as of yet unidentified ribonucleoproteins (RNPs).11 Upon reaching 
their destination, miRNAs can enter target cells by endocytosis, membrane fusion, binding to 
specific receptors, or passive diffusion.9  
 Exosome production occurs in most healthy cells but it has been demonstrated that 
exosomes are shed in greater numbers from cancer cells. In fact circulating exosome levels have 
been demonstrated to be upregulated in breast cancer patients when compared to healthy 
controls34 and cancer patients in general have been shown to have more RNA from extracellular 
vesicles (EVs) in their blood. This is thought to serve cancer cells both in the cultivation of the 
tumorigenic microenvironment and in the shedding of proteins and RNAs that hinder their 
proliferation.11 The tumor microenvironment is integral to the development of every in vivo 
tumor. It is mostly populated by cells other than tumor cells such as cancer associated 
fibroblasts, endothelial cells, stromal progenitor cells, pericytes, and inflammation mediating 
immune cells such as macrophages.3,4 Studies have shown that communication between tumor 
cells and these cells that make up the surrounding environment is strongly mediated by non-
coding RNA (ncRNA) and a majority of these are miRNAs.3 To illustrate the importance of 
exosomes in tumor associated miRNA signaling, it has been established that in normal tissues, of 
the miRNAs that reside in the ECM, 90% are bound to proteins of the AGO family and 10% 
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reside in exosomes and other vesicles of various origins. However, in a tumor’s “sphere of 
influence”, the concentration of miRNAs residing specifically in exosomes dominates.9,19  
Canonical and Non-Canonical Pathways   
About 40% of miRNAs in Homo sapiens are encoded in clusters and co-transcribed 
together as one long primary miRNA (pri-miRNA) transcript. These pri-miRNAs sport multiple 
local hairpin structures each of which contains a future mature miRNA.1 Pri-miRNA transcripts 
are on the average 1kb long, have 5’ caps, polyA tails and are transcribed mostly in a Pol II 
dependent manner. Evidence does exists for a Pol III dependent mechanism for the transcription 
of viral miRNAs and miRNAs encoded within Alu sequences.1 In the “canonical” pathway, pri-
miRNAs are processed in the nucleus by an RNaseIII type enzyme called Drosha in complex 
with the essential cofactor DGCR8 (together referred to as the Microprocessor), and other non-
essential cofactors such as p68 and p72.61 Together, these proteins produce a 60-110 nt hairpin 
structure with a single 3’-OH 2 nt overhang referred to as a pre-miRNA.7 Pre-miRNAs are 
transported from the nucleus into the cytoplasm by Exportin-5 in a Ran-GTP dependent manner 
where they are further processed by Dicer1, another RNaseIII type enzyme, in complex with 
multiple cofactors such as TRBP and KSRP.7,61 Dicer processing produces a dsRNA 19-24 
nucleotides long with two 2 nt 3’ overhangs. The duplex is then loaded into one of four Argonaut 
(AGO) proteins with the help of RISC Loading Complex (RLC). A principal component of the 
RLC is the Heat Shock Cognate 70- Heat Shock Protein 90 complex which upon hydrolysis of  
an ATP, manipulates the conformation of the apo-AGO protein to allow for loading. Once inside 
the AGO protein, the passenger strand is most likely degraded by an unconfirmed nuclease or 
unwound by AGO. The mature single stranded miR and the Ago protein constitute the minimal 
RNA Induced Silencing Complex (RISC) and once properly loaded, the miRNA sets to guiding 
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the RISC to its targets. The target sequence is usually located in the 3’-UTR of a cytoplasmic 
mRNA transcript but a few complementary sequences are also found in coding regions and in the 
5’UTRs.1,10 The favoring of 3’-UTR target sites could possibly reflect the mechanism of 
acquisition of target transcripts by the RISC complex.  
The processing of some miRNAs are Drosha or Dicer independent, and are thus referred 
to collectively as “non-canonical” pathways. For Instance, the processing of pre-miRNA-451, the 
single most abundant circulating miRNA, is Dicer independent and instead relies on AGO2’s 
RNaseH –like endonuclease activity to produce its mature miRNA transcript (miR).27 However, 
despite some high profile exceptions like this one, a vast majority of miRNAs are processed via 
the canonical pathway with only about 1% of conserved miRNAs being either Dicer or Drosha 
independent.61  
miRNA Action  
Animal miRNAs tend to recognize targets via a 6-8 nt seed sequence located at position 
2-7 from the 5’ end of the miRNA. Bases at positions 8 and 13-16 also play a smaller role in 
target recognition.61 Near perfect matching allows Ago2 mediated mRNA cleavage of mRNA 
transcripts.1 However, as opposed to in plants, the vast majority of animal miRNAs only have 
partial complementarity to their target sequences which leads to translational inhibition or 
mRNA destabilization. One promising model for translational repression suggests that mRNA-
miRNA complexes are sequestered in P bodies where they are de-capped. Another suggests that 
the RISC complex can repress the activity of eIFs, stalling translation at the initiation stage.1 
Interestingly, the most recent evidence suggests that translational inhibition might take a back 
seat to mRNA destabilization, although this has yet to be fully accepted by the scientific 
community. Some evidence has suggested that recruitment of CCR4 and CAF1 deadenylases by 
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GW182 is the most common pathway for regulation  in mammals.27  On the whole, it is likely 
that miRNAs are capable of inhibiting protein expression through many mechanisms although 
the context and relative contribution of each remains to be explored. 
These mechanisms function to two important effects. miRNAs create overlapping 
networks of regulation2 in order to achieve sharp spatial and temporal control of fluctuating 
mRNA levels. This is especially important during embryonic development and during modular 
cellular mechanisms, which are controlled by homeostatic regulation of various determinates of 
the cell state. miRNAs are known to play a part in almost all cellular processes including but not 
limited to proliferation, development, apoptosis, EMT, and differentiation. miRNA are also 
known to at least participate in, if not truly define, the signaling architecture that establishes and 
protects the state of the cell through the propagation of an elegantly complex web of positive and 
negative loops. See below for a more detailed explanation. 
 
miRNA Expression and Regulation  
Some miRNAs are autonomously expressed and their promoters are very similar to those 
of protein encoding genes. Many feature CpG islands, TATA boxes, response elements, 
initiation elements, and other classic promoter components.1 Interestingly, miRNAs are often 
found to regulate the transcription factors (TFs) that activate or repress them either positively or 
negatively creating various control loops.1 For instance, the transcription factor PIT3 upregulates 
the transcription of miR-133b which targets the mRNA that codes for PIT3, forming a negative 
loop that controls dopaminergic neuron differentiation. Another, more elaborate example of this 
is how the miRNAs lys6 and miR-273-5p interact with the transcription factors DIE-1 and COG-
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1 to form a double negative loop that controls the two alternative fates for chemosensory neurons 
in C. elegans.27 During development and during the determination and maintenance of the cell 
state, auto-regulatory feedback loops are the most common form of miRNA regulation. miRNAs 
are uniquely suited to participate in regulatory loops due to the fact that they do not need to be 
translated in order to act. It is easy to imagine how this might be attractive in terms of a 
conservation of energy and precision of timing and targeting due to their immediate and direct 
effect. In keeping with this concept, it has been discovered that some miRNAs can actually 
directly self-regulate, binding to their own primary transcripts in a feed forward manner.1  
Another facet of miRNA regulation is the global control of miRNA production by 
various mechanisms. For instance, miRNA activity is related to the concentration of the Drosha 
and DGCR8 complex in the nucleus. The concentration of this complex is controlled by an 
interesting auto-regulatory relationship between these two proteins. Drosha is stabilized by 
DGCR8 and without it, it has almost no RNase activity. However, the functional Drosha/DGCR8 
complex destabilizes DGCR8 mRNA by excising a miRNA-like hairpin from one of its 
exons.61,1 This relationship is deeply conserved across the animal kingdom and, although the 
overall levels of this complex can be manipulated by other factors, its expression is homeostatic. 
A similar relationship exists between the Dicer1 mRNA and miRNA-let-7, which is also 
hypothesized to contribute to homeostatic control of miRNA production. Overall miRNA 
activity can also be perturbed by different post-translational modifications on miRNA processing 
machinery and by some transcription factors such as p53, MYC, ZEB1/2, and MYOD1.61  
Activation of different RNA binding (RBD) proteins that function along with the 
microprocessor to either upregulate or down regulate a group of miRNAs also plays a large part 
in control of miRNA expression. For example KSRP binds to the terminal loops of the primary 
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transcript of miRNA-let-7 to facilitate Drosha/DGCR8 processing while LIN28A/B, which is 
exclusively expressed in undifferentiated cells, functions in a similar way to suppress it.61 
Seventy-five % of 3’-UTRs that contain miRNA binding sites also contain a binding site for 
HuR, an RBD that functions by directly binding mRNAs in a way that protects them from the 
RISC, but allows for translation.1 Controlling the expression of the many different types of 
RBDs is an important aspect of global miRNA control.  
3p vs 5p 
Until recently, it was widely believed that only the duplex strand that comes from the 5’ 
end of the pre-miR became the active strand in the RISC complex, but now we know that both 
the 5’ and 3’ ends can be active strands.1 This is reflected in the recent change in “official” 
nomenclature from the miRNA/miRNA* designation to the miRNA-5p/miRNA-3p. Much 
evidence suggests that, for the most part, it is the strand with the lowest free energy of its 5’ end 
within the miRNA duplex that becomes the active strand.27 It also seems to be the case that AGO 
proteins preferentially select for guide strands with a U at their 5’-end. However, it has been 
demonstrated that for some miRNAs, both strands can function as the active strand, with their 
relative use varying depending on tissue and context.1 For instance, miR-142-5p is the dominant 
strand in adult brain, testes, and ovary tissue while miR-142-3p is the dominant strand in 
embryonic and neonatal tissues.61 Interestingly, despite having completely different seed 
sequences, the targets of the  3’ and 5’strand sometimes overlap to some degree, suggesting that 
alternate strands could be intentionally selected to regulate alternate portions of the same 
pathways. How this selection is made is beyond what we currently understand, but it could be 
related to alternate Drosha/DGCR8 processing.65   
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Many examples illustrate the importance of strand selection phenomenon in cancer. 
Specifically, one study found arm switching in colorectal cancer of miR-28 could be explained 
by the fact that expression of miR-28-5p reduced cell proliferation by targeting the CCND1 and 
HOXB3 proteins while miR-28-3p expression increased in vivo migration and invasion by 
targeting the metastasis suppressor protein NM23-H1.58  
The General Silencing of miRNAs in Cancer  
The general dysregulation of homeostatic control of miRNA signaling is the most 
common miRNA related phenomenon seen in cancers.66 For a vast majority of miRNAs, this 
general dysregulation amounts to suppression, with only a small subset of miRNA families 
governing oncogenic events experiencing upregulation. Considering the vastly complicated 
regulation of miRNA machinery, there are many ways in which global miRNA signaling can be 
perturbed, but two of the most common aberrations seen in cancers are hypermethylation of CpG 
islands and a loss of core miRNA machinery genes.  
 Under normal physiological conditions, most CpG island promoters are unmethylated 
(although not necessarily active) while in most tumors, a majority of genes are hypermethylated.4 
This leads to a general silencing of tumor suppressor genes.1 The tumorigenic effect of this 
illustrates that tumor suppressors are more important to lose than oncogenes are to gain. About 
half of all miRNA genes are associated with CpG islands and so, the general hypermethylation 
associated with tumors leads to a global dampening of miRNA networks. In fact, this is currently 
thought to be the most common cause of miRNA silencing in miRNAs.58 As a further 
complication, miRNAs can themselves regulate important components of the epigenetic 
machinery.1  
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Knockdown of Dicer and Drosha leads to tumorigenesis.7 There is evidence that Dicer1 
acts as a haplo-insufficient tumor suppressor in mice61 and in breast cancer cell lines, Dicer1 
expression was found to be lower in cells that displayed a mesenchymal phenotype than an 
epithelial one.61 The same observation was made by a different group for breast cancer 
metastases derived from a cell line.7 It could be that inactivation of Dicer1 is a simple way of 
breaking down the protection that miRNA signaling gives to the cell state. However, Dicer1 is 
not downregulated in all cancer types and in fact, in prostate cancer it is much more commonly 
upregulated.7 Knockdown of EXP5 results in a reduction of miRNA levels without an 
accumulation of pre-miRNAs in the nucleus, which suggests that there is a certain level of 
nuclease activity in the nucleus and EXP5 functions to protect the pre-miRNAs before they are 
delivered to the cytoplasm. In some tumors, XPO5, the gene that encodes EXP5, is mutated.61 
Prostate cancer is a malignancy in which mutations in the XPO5 gene are seen in appreciable 
levels.66 Interestingly, AGO2 specifically is commonly seen to be upregulated in cancers, 
including 14.8% of metastatic prostate adenocarcinoma.  This phenomenon correlates well with 
EGFR amplification or upregulation.66  
Another mechanism for global miRNA dysregulation that is less commonly discussed is 
the hyper expression of viral miRNAs. Several viruses encode both stolen human microRNAs 
and novel unique viral microRNAs that participate in the establishment of viral latency, entry 
into the lytic life cycle, cellular proliferation, immune evasion, and tumor progression.57 It has 
been demonstrated that in lymphoma cells infected by Kaposi sarcoma associated herpesvirus, 
viral encoded microRNAs represent the majority (more than 80%) of expression.57 This suggests 
that the concentration of miRNA machinery in the cell is rate limiting and that a miRNA that is 
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pathogenically over expressed may dominate the miRNA profile of a cell in a way that 
effectively silences other tumor suppressor miRs. 
The Epithelial-Mesenchymal Transition  
Complications due to metastasis is the main cause of cancer related death, responsible for 
up to 90% of deaths in patients with solid tumors.7 Considerable research has been done in the 
field of miRNA involvement in the EMT, due to their known role in this modular process and the 
crucial part that the EMT plays in the escape of clonal cells from the local tumor environment. 
Most impressively, a double negative loop involving the miRNA-200 family and the ZEB1/2 
transcription factors has been demonstrated to stabilize either the epithelial or mesenchymal 
phenotype in a mutually exclusive manner.28 This research can be retroactively applied to the 
stratification of prostate cancer patients on the basis of tumor aggressiveness and likelihood for 
post-surgery recurrence. This is very relevant clinical information as knowing whether or not 
recurrence is likely could spare an elderly patient the consequences of chemotherapy.  
Why Next Generation Sequencing (NGS) 
Several factors such as their size, high homology, and low abundance, make the profiling 
of microRNAs technically challenging. The most crucial factor affecting the outcome of any 
profiling study is the choice of platform as inter-platform differences have been demonstrated to 
be high.45 Our choice to pursue NGS as opposed to microarray or qRT-PCR technology was a 
direct result of the advantages that it posed to our specific study.  
Firstly, it is more sensitive, providing a picture of miRNAs present at very low copy 
numbers that would have been impossible to see on any microRNA array. In addition to this, a 
recent review of miRNA platforms demonstrated that of all available technologies, Illumina 
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sequencing specifically demonstrated one of the highest abilities to differentiate between small 
differences in gene expression.45 These advantages opened us to the possibility of more deeply 
evaluating changes in low copy number miRNAs as opposed to high copy miRNAs. The 
importance of low copy miRNAs is discussed in the discussion section of Chapter 1. However,  
one caveat of NGS is that the number of adaptor sequences within a sample lane is rate limiting 
and so high copy miRNAs can be disproportionately represented in the resulting sequencing 
profile compared to low copy miRNAs. This should be kept in mind so as not to unnecessarily 
disregard potentially impactful miRNAs when choosing candidates for further validation. 
Secondly, NGS has the ability to distinguish miRNAs that differ by as little as a single 
nucleotide. As with the multiple members of the Let-7 family, singular differences that fall in a 
miRNA’s seed region can drastically effect the genes that it targets, which means that 
differentiating between them is of significant clinical importance.78 This also means that NGS 
can discriminate between isomiRs, which are a result of post transcriptional additions to the 3’ 
end, and less frequently the 5’ end, of mature miRs. Although this was not utilized in this current 
study, the sequencing data can be reanalyzed in future experiments to highlight these differences. 
Last but not least, it was reasoned that the greatest potential advantage in using miRNAs as 
biomarkers stems from their diversity and investigating only a selective panel for which primers 
are available was considered an unacceptable limitation. The profiling by sequencing approach 
does not have this limitation. For the same reason, NGS also allows for the discovery of novel 
miRNA transcripts whose validation in future experiments will be valuable irrespective of their 
relationship with prostate cancer or their utility as a biomarker.35  
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Chapter 1: A Urinary Assay for the Detection of Prostate Cancer 
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Specific Aims 
In the 1970’s, only the healthiest and most promising of patients could hope to survive a 
surgical cure for prostate cancer. However, Dr. Patrick Walsh’s accurate anatomical descriptions 
of the 1980’s led to the improved management of the dorsal penile veins allowing for a careful 
operation to occur in a field cleared of blood. This, in turn, led to the improved management of 
both the striated sphincter and the newly described autonomic neurovascular bundle of the 
prostate. These advancements made low risk prostatectomy with the retention of potency and 
urinary continence a potentially curative option for prostate cancer patients.5 However, the 
curative potential of surgical treatment depends on the stage of the disease at the time of 
diagnosis with truly localized cancer having the greatest success rate.5   
The next advancement in prostate cancer medicine was the advent of PSA testing in the 
1980’s. It is estimated that PSA screening affords patients and their physicians a lead time of 5.4 
to 6.9 years, resulting in patients who present with lower grade disease at the time of diagnosis.67 
Despite a 70% increase in prostate cancer incidence since 1980, by 2008 prostate cancer 
mortality rates had dropped by 40% in the United States. This is in contrast to 12% reduction in 
mortality in the United Kingdom where routine PSA screening was never adopted.67 However, 
PSA testing is plagued by a low sensitivity that makes it less than optimal. Today, more than 
15% of pCa patients present with a serum PSA level below the empirically defined cut off point 
for biopsy referral of 4 ng/ml, suggesting that many prostate cancers go undetected for a long 
time.37 Currently, 4% of patients have progressed all the way to metastasis at the time of 
diagnosis giving them limited treatment options.28 The low specificity of PSA testing is also a 
cause for major concern in terms of patient outcomes. Circulating PSA levels can also be the 
result of other, non-malignant pathologies of the prostate such as benign prostate hyperplasia 
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(BPH) and prostatic intraepithelial neoplasia (PIN). Because PSA screening and digital rectal 
examination are the only diagnostic criteria in use for the recommendation for biopsy, an 
astounding 75% of biopsies come back negative for pCa.20  
microRNAs (miRNAs) are short non-coding RNAs (18-24 nt) involved in an expansive 
list of biological processes. Generally speaking, miRNAs effect gene regulation at the level of 
translation by either inhibiting translation or by destabilizing mRNA transcripts. However, in 
addition to their intracellular functions, miRNAs are increasingly being recognized for the role 
they play outside of the cell. In fact, it has been proposed that non-coding RNAs may dominate 
the bulk of signaling between tumor and tumor associated cells that propagate the tumor 
microenvironment. The modern development of detection technologies such as RT-PCR, 
microarrays, and deep sequencing, has produced evidence that almost all of the body fluids, 
including blood, urine, saliva, and semen of cancer patients possess distinct miRNA profiles 
from those of healthy individuals.3,9 Surprisingly, these miRNA body fluid profiles have been 
found to be less variable and more powerfully correlated to individual pathologies than any 
combination of mRNA or proteins, making them a promising potential source of accurate 
biomarkers.21 In this study, we took advantage of next generation, high throughput sequencing 
technology to identify potential biomarkers for prostate cancer in the urine of patients and 
controls. 
Urine Over Blood and Semen. 
 In general, urine was thought to be a good biofluid candidate for diagnosis because it was 
thought that due to the necessity of urine to pass through the prostatic urethra and the prostate’s 
direct connection to the urethra via its multiple large ducts, the urine may be particularly 
enriched for miRNAs derived from the prostate. Urine was chosen over blood because 
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circulating miRNAs thought to be derived from all of the tissues in the body constitute a large 
signal whereas the miRNA population of the urine is much smaller and derived from a smaller 
subset of tissues. This means that miRNA signals in the urine associated with changes in the 
prostate will have less background noise with which to compete. Also, biomarkers that are 
secreted by prostate cancer into the urine are diluted into a smaller volume than biomarkers that 
are secreted into the blood (a few ounces of urine vs. 5 liter of blood), making biological 
differences in gene express easier to detect.  
 Also, it was thought that in the case of urine, sufficient amounts of sample could be 
obtained from each subject in order to perform sequencing with high confidence. Urine was 
chosen over semen because it was thought that older patients with prostate problems would be 
less likely to produce a semen sample, making sample acquisition difficult, and that even the 
most robust of the samples obtained may not provide enough material to perform sequencing 
with an acceptable level of confidence. However, because the prostate normally contributes 
about 50-70% of the seminal fluid, semen deserves further investigation for the purposes of 
prostate cancer diagnosis as it is likely to be greatly enriched in material from the prostate as 
compared to other candidate biological fluids. 
 
Materials and Methods 
 
RNA Extraction from Urine 
Many past studies have used the pellet obtained from urine after a low speed spin for 
further analysis of miRNA content. However, it has been discovered that a large amount of low 
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quality and degraded RNA exists in this compartment, possibly due to the high level of RNase 
activity characteristic of the urinary tract.31 These low quality RNA fragments create noise and 
introduce a high rate of false positives in miRNA sequencing studies due to their small size and 
alignment to the genome. Considering this, we opted to analyze the cell free component of urine, 
as the centrifugation steps used to remove whole cells and cell fragments are not likely to remove 
either free miRNAs or those contained in exosomes or in complex with AGO2 proteins, which 
would require ultracentrifugation speeds to pellet. 
The cell content of the urine is vastly smaller than that of the blood and only 10% of the 
cells that are found in the urine are from the prostate. On top of that, the portion of these prostate 
cells that are derived from the tumor is negligible, except in rare and extraordinary 
circumstances. Also, since it has been established that the tumor derived signal in blood is 
independent of the presence of circulating whole cells,23 we reasoned that excluding the cellular 
compartment from the urine would not significantly reduce our chances of finding a diagnostic 
marker. Urine samples were subjected to a 2,000 x g spin for 30 min in order to pellet any intact 
cells in the fluid. After transfer to new tubes, each sample was then subjected to a 12,000 g spin 
to pellet any remaining large cell fragments. It cannot be ruled out, that some miRNAs derived 
from whole cells or cell fragments lysed during the extraction process are still present in the 
samples. 
Because it is difficult to obtain sufficient RNA from urine to construct cDNA libraries for 
high throughput deep sequencing, many past researchers have pooled patient samples together.31 
However, in an attempt to preserve individual variability, we used a slurry based total RNA 
extraction method capable of concentrating RNAs from large urine volumes into a small (<200 
ul) eluent. It was also thought that this would be an interesting approach because the intact 
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population of miRNAs extracted from this compartment, without enrichment for exosomes, has 
yet to be analyzed, especially not for individual, un-pooled samples. For sequencing, extracted 
RNA from a select number of samples was concentrated further under lyophilization conditions 
using a rotovap at low temperature and pressure in order to meet the minimum concentration 
(100ng RNA/6ul) required for sequencing. However, RT-PCR validation was performed 
separately on un-concentrated samples due the sensitivity of RT-PCR. 
Illumina  
For the urine profiling experiment, 9 patient and 5 control samples were prepared as 
described above and sent to the Nucleic Acids Research Facility at Virginia Commonwealth 
University for paired end sequencing on the Illumina platform using the manufacturer’s 
recommended protocols. It should be noted that this standard protocol included a gel 
electrophoresis size fractionation step that restricts sequencing to the appropriate size range of 
cDNA products. Samples identifiers, their cancer stage, and “miRNA” concentration as reported 
by the Agilent Bioanalyzer’s small RNA chip are recorded below. When Gleason score was not 
available, pCa was used to designate patients. Downstream analysis was performed using 
multiple programs including Partek Flow, RStudio, and edgeR. 
Trimming of the bases and adaptors attached to the 3’ and 5’ ends of the read sequences 
by the Illumina sequencing TruSeq Small RNA sample preparation kits 
(AGATCGGAAGAGCACACGTCT) was performed in Partek Flow. Two deviations from the 
default settings were used to appropriately accomplish this for our unique project. Firstly, match 
times were increased from the default of 1 to 3 to allow sequences to be cleaved multiple times. 
Trimming multiple times is important because it is possible for adaptors to anneal more than 
once to a single read. Trimming of bases further increases quality scores by removing partial 
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junk sequences that could affect alignment. Secondly, the minimum read length was changed 
from the default of 25 nt to 16 nt to accommodate the size of miRNAs. A pre-alignment QA/QC 
report was generated to assess RNA quality (Phred) and the results are reported in Figure X. A 
Phred score of higher than 30 is considered exceptional and is defined as (10)(–log10X) where X 
is the chance that an incorrect base has been incorporated into a sequence. For instance a Phred 
score of 30 indicates that 1/1000 (10-3) bases is incorporated incorrectly, indicating a base call 
accuracy of 99.9%. After trimming, the reads were aligned to the human genome (GRCh38) 
using the Bowtie Aligner. The Bowtie Aligner was chosen because it is the most suitable for 
short reads with high similarity but unique alignments. Seed mismatch was decreased from 2 to 1 
to increase stringency and the alignments reported per read was increased from 1 to 3. Again, the 
minimum read length was altered from 28 to 16 to accommodate the size of miRNAs. Trimmed 
reads and alignments (3x) are reported in Figure X.  
 
RT- PCR 
In a recent study comparing commercially available miRNA profiling technologies based 
on NGS, microarray, or qRT-PCR, the greatest overlap between any two platforms in terms of 
the validation of differential gene expression in a set of mixed standards was only 54.6%.45 
Because of this low level of confidence, it is considered good practice to validate profiling 
results using another platform. For this purpose, we have chosen qRT-PCR because of all of the 
microRNA platforms, qRT-PCR possesses the greatest consistency and sensitivity.45  
The quanta kit, which employs a universal tailing method to prime miRNAs for cDNA 
synthesis, was chosen based on the results of a study that reported that this platform possessed a 
higher sensitivity than a similar competitor and it was thought that this would be useful given the 
 
22 
 
possible importance of low miRNA abundance in urine.42 cDNA synthesis and qPCR were 
performed according to the manufacturer’s protocol with the exception that each qPCR reaction 
was scaled down to save reagents as follows: 6.25 ul SYBR Green Master Mix, 0.25 ul primer, 
4.0 ul RNase Free H2O, 2.0 ul cDNA for a final volume of 12.5 uL. 
Although it is true that it becomes more difficult to specifically target RNAs as they get 
smaller, modern primer specificity is such that size selection is not necessary for qPCR 
experiments and they can be performed on total RNA samples.57 However, the universal tailing 
system employed by the Qiagen RT-PCR assay has been demonstrated to confer a likelihood for 
false positives related to non-specific amplification.57 Because of this, low expressed qPCR 
results were held to the highest possible scrutiny. 
 
Results 
 
NGS Normalization 
RNA ligase preferences, factors pertaining to reverse transcription, library PCR 
amplification efficiencies, the length of each individual gene transcript, the overall sequencing 
depth, and RNA composition of individual samples are all factors likely to contribute technical 
biases to the final data output of next generation sequencing results.56 For these reasons it is 
important to carefully  normalize across different samples in order to  detect true biological 
differences in expression.76 However, currently no consensus exists as to how to do this and 
many RNA sequencing studies do not report on their normalization methods at all. Thus, 
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normalization methods must first be discussed and stablished before proceeding with subsequent 
data analysis.  
It is common practice to normalize RNA sequencing results using either the “Reads Per 
Kilobase Per Million mapped reads” (RPKM) method, the “total counts” (TC) method, or the 
“Trimmed Mean of M values” (TMM) method. This first method, RPKM, is designed around the 
concept that the number of reads of a particular gene in a sequencing data set is proportional to 
the length of that gene and corrects for this mathematically.70 This particular issue however 
seemed to be of little impact to our size fractionated library, since microRNAs are of the same 
approximate size. The second method, TC, takes the number of transcript raw reads  from a 
sample and simply divides it by the total number of raw reads in that sample. In this way, each 
gene product is adjusted for library size in each sample.71 These two methods attempt to 
minimize the effect that different library sizes (or disproportionate library fractions) may have on 
sequencing depth by taking into account gene length and relative expression level. However, 
both these methods are susceptible to RNA composition bias, limiting their utility in situations 
where comparisons are made between samples of very different composition such as between 
tissue types.56 It results when technical bias is introduced by highly expressed genes in a data set 
overriding the representation of rare genes within a sample. (Please look to Chapter 2 for a 
discussion on high copy number vs low copy number miRNAs.) This can have a powerful 
impact on downstream analysis by producing an unacceptably inflated false positive rate.69  
Composition bias was likely to be an obstacle in our study for two reasons. Firstly, we 
intended to compare data from samples composed of whole tumor tissue, obtained from The 
Cancer Genome Atlas (Chapter 2), to data from our own cell line samples (Chapter 2), from both 
of these tissue samples to our body fluids (Chapter 1), urine and blood, and between these  body 
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fluids. The rationale behind this last comparison was that blood and urine samples taken from the 
same patients might yield clues as to where in the body a particular miRNA signal originated. 
For instance, if a miRNA seemed to be simultaneously upregulated in the blood and urine of the 
same patient, it might be reasoned that this miRNA is seeping into the circulation from the 
prostate and filtering into the urine through the kidneys. If a miRNA is upregulated in the urine 
but not the blood, it might be possible that it is making its way into the urine through the 
prostate’s ductal connections to the urethra. If a miRNA is elevated in the blood but not the 
urine, it could be that this miRNA is not coming from the prostate tumor at all. The second 
reason why composition bias became an important factor in our experiment was because, when 
comparing the results of the Bioanalyzer data used to determine small RNA concentration, it 
became clear that RNA composition was likely to be drastically different between individual 
urine samples.  
 
 
 
 
 
 
 
 
 
25 
 
Figure 1: A comparison between samples of RNA in small size range. A) An 
electropherogram in the small RNA range of a typical control sample (1ul) . B) An 
electropherogram in the small RNA range of a typical patient sample (1ul). A comparison of the 
electropherograms of controls and patients demonstrates that patients are more likely to have 
more material of this size range in their urine. 
A) 
 
B)  
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For example, as illustrated in Figure 1, controls typically contained much less material in the 
small RNA size range than patients. 
The TMM method normalizes for the RNA composition with a scaling constant called a TMM 
factor calculated individually for each sample library with one middle sized sample library acting 
as a reference.69 The TMM factor is calculated as a weighed mean of the log ratio between the 
expression of the most abundant genes in the reference library to those same genes in each test 
sample.73 Firstly, for pairwise comparison, the log fold change for each gene is defined as                                            
 
(1) Mg = log2(Ygk/Nk)/(Ygk’/Nk’) 
 
where “Mg” is the value of the fold change of gene g, commonly referred to as the “M value,” 
“Ygk” is the raw read count for gene g in library k, and “Nk” is the total number of raw reads in 
library k. Then the absolute expression is calculated for each gene by                                                   
 
(2) Ag = (½)log2[(Ygk/Nk)(Ygk’/Nk’)] 
 
where, “Ag” is the “A value,” a relative measure of absolute expression for gene g. After the M 
value and A value were calculated for all genes, genes with exceptional values were trimmed by 
excluding the top and bottom, 30% of M values and 5% of A values, and a “weighted” mean is 
calculated from the remaining genes by the edgeR program. These correction factors were used 
to populate a Generalized Linear statistical Model (GLM) and analysis of the normalized reads 
was performed with the appropriate tests (Fisher’s exact test and GLM likelihood ratio test).72 
Although the TMM method does rely on the assumption that the majority of genes common to 
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both patient and control samples are not differentially expressed72, something that we cannot 
assume about our body fluid samples, it has been demonstrated to be relatively resistant to 
deviations from this assumption.56 Adjusted P values, referred to as the False Detection Rate or 
FDR, were obtained with the Benjamin-Hochberg method, which mitigates familywise error for 
multiple comparisons.76 A false positive rate lower than 0.2 was considered to be significant. The 
Likelihood Ratio (LR) is a number generated by the edgeR statistical analysis program which is 
reported below. %GC is usually reported in sequencing studies in an effort to assess technical 
differences. 
RNA-sequencing 
 9 patients and 5 controls were chosen for sequencing. When a Gleason score was not 
available, pCa was used to designate patients. 
Table 1: Candidates for RNA Sequencing 
Sample name  Stage 
miRNA concentration 
(pg/ul) 
12042014-EMR G6 935.1 
03082013 G6 323.1 
10242013 G6 6233.7 
11202014-KAB G7 269.6 
11262014-CTL G7 1096 
04192013-2 G8 1782.6 
010812 G9 474 
04042013-Pre G9 + mets 796.1 
111612 pCa 11826.6 
07152014 Control 1076.7 
08062013-Post Control 2127.5 
10212014 Control 356.9 
WMH Control 3028.0 
GCC Control 1601.8 
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Table 2: Sequencing Statistics  
Sample name  Stage Total reads Total alignments  Avg. length 
 Avg. quality 
(Phret) %GC 
10242013 G6 2,525,470 6,049,884 29.09 38.59 50.41% 
03082013- G6 344,505 480,916 26.08 38.38 50.96% 
12042014-EMR G6 415,779 974,864 29.7 36.48 53.81% 
11202014-KAB G7 398,747 1,009,080 24.97 36.51 43.33% 
11262014-CTL G7 1,964,389 3,726,877 25.91 36.21 55.08% 
04192013-2 G8 1,908,994 2,803,715 28.29 38.51 51.33% 
010812- G9 2,111,229 4,717,551 29.49 38.64 52.66% 
04042013-Pre G9 1,170,650 2,363,672 20.12 37.85 58.45% 
111612 pCa 2,342,875 5,436,338 30.98 38.71 53.42% 
07152014- Control 3,225,726 8,762,098 31.66 36.59 56.53% 
08062013-Post Control 2,165,549 5,545,114 32.78 36.67 55.98% 
10212014- Control 2,246,868 5,786,297 31.19 36.68 52.17% 
GCC Control 383,885 641,523 25.68 38.25 52.88% 
WMH Control 1,981,890 3,715,430 26.59 38.4 53.52% 
 
 These results show that a high number of total reads in the appropriate size range align to 
the genome and are indeed validated human miRNAs. The disparities between the average 
lengths and total amount of reads between samples suggests that there are indeed considerable 
compositional differences, reaffirming our choice of TMM as our normalization method. %GC is 
consistently around 50% and Phret scores are consistently well above 30.00 confirming that our 
sequencing data is of high quality.  
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Table 3: microRNA Sequencing Results of Urine Samples 
Gene Name logFC logCPM LR PValue FDR 
hsa-miR-223-3p 5.940734 10.614319 16.24019 5.58E-05 0.013336 
hsa-miR-223-5p 5.95683 7.6441786 13.45336 0.000245 0.029226 
hsa-miR-142-3p 6.801603 9.4414229 12.68913 0.000368 0.0293 
hsa-miR-199a-3p 4.884872 8.3158747 11.69224 0.000628 0.0375 
hsa-miR-363-3p -2.4222 11.602927 11.15461 0.000838 0.040067 
hsa-miR-199b-5p 4.974522 7.5241254 10.1309 0.001458 0.058079 
hsa-miR-199b-3p 4.59329 7.3669649 9.558437 0.00199 0.067955 
hsa-miR-143-3p 3.957342 10.998673 8.453135 0.003644 0.108869 
hsa-miR-184 5.863426 12.214555 7.873185 0.005017 0.133238 
hsa-miR-629-5p 2.227044 9.2003383 7.185232 0.007351 0.175679 
hsa-miR-941 2.812312 10.376636 6.913948 0.008553 0.185825 
hsa-miR-205-5p 2.799235 11.093862 6.44201 0.011145 0.221976 
hsa-miR-146a-5p 2.617289 11.905298 6.268341 0.012291 0.224996 
hsa-miR-185-5p 1.792165 10.981644 6.009805 0.014227 0.224996 
hsa-miR-34c-5p 4.915895 9.5787856 5.939451 0.014806 0.224996 
hsa-miR-375 -2.25697 15.598242 5.837234 0.01569 0.224996 
hsa-miR-618 4.634886 8.8283879 5.737391 0.016607 0.224996 
hsa-miR-204-5p -2.28501 11.863405 5.651272 0.017443 0.224996 
hsa-miR-221-3p 2.323762 11.741003 5.607212 0.017887 0.224996 
hsa-miR-145-5p 4.683413 7.6031015 5.48455 0.019185 0.229264 
hsa-miR-135a-5p -2.25086 9.7143463 5.31853 0.0211 0.240002 
hsa-miR-3613-5p 2.656422 8.6492001 5.238507 0.022092 0.240002 
 
12 Candidates were selected for further investigation (bold above) with qRT-PCR based 
on their adjusted p value and considering a maximum FDR of 0.2. miRNA candidates were 
excluded from further investigation based on the range of read counts between samples. 135a-5p 
was considered for further validation despite its poor FDR because when the data was 
reconsidered deleting one particular outlier sample (10242013 G6), 135a-5p became the second 
most dysregulated miRNA (see Appendix). An interesting thirteenth candidate, 126-3p, was 
selected, not based on the sequencing data, as described below. Before validation with qRT-PCR 
could be performed, an appropriate normalization method had to be selected.   
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Possible prostate specific miRNAs: 126-3p  
 Some miRNAs, and their subsequent role in tumor progression, seem to be organ 
specific. For instance, down regulation of miR-122-5p, which is normally highly expressed in the 
liver and nowhere else, allows for the formation of intrahepatic metastases.17 Likewise, the 
expression of miR-208 is restricted to cardiomyocytes and the 46 miRNAs of the chromosome 
19 mega cluster are restricted to the embryonic placenta.80 An analogous prostate specific 
miRNA could drastically increase the specificity of a new biomarker assay even if that miRNA 
plays no role in prostate cancer progression. The logic behind this idea is that if the prostate is 
the only tissue that makes a particular miRNA, then the amount of that miRNA in the urine or in 
circulation could specifically indicate pathology in the prostate. The PSA assay functions under 
the same logic. However, so far, no such miRNA marker has been found. A similar alternative 
would be a miRNA that acts differently in the prostate or prostate cancer than in any other cancer 
or tissue. For instance, miR-221-5p has been demonstrated to be upregulated a variety of 
cancers, but is downregulated in the tissue of TMPRSS2:ERG fusion positive pCa.15 However, 
our sequencing data did not support further investigation of this miRNA as a urinary biomarker.  
miR-126-3p was included in the qRT-PCR validation step despite dysregulation not 
being supported by our sequencing data as an intellectual experiment. miR-126-5p has been 
shown to play a positive role in the acquisition of angiogenesis and metastasis of multiple 
cancers, including prostate.80 Among its many validated targets is a prostate specific protein 
called prostein, also called prostate cancer-associated protein 6, encoded by the Solute carrier 
family 45 member 3 SLC45A3 gene. The expression of this protein has been demonstrated to 
decrease with the progression of prostate cancer, possibly because of putative tumor suppressor 
properties or because this protein is prostate specific and looses expression as prostate cancer 
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cells become more dedifferentiated. Surprisingly, this validated target is shared by its 3’ 
counterpart, despite having different seed sequences. Since 126-3p has few other predicted 
targets, it was hypothesized that its expression would be more powerfully effected by changes in 
the presence of this lonely target.  
Normalization of qRT PCR Analysis of Urine 
Currently, there is a lack of consensus on how to normalize for qRT-PCR experiments 
that require high resolution such as those dealing with miRNAs.19 It is for this reason that special 
attention will be paid to the method used here. The normalization strategy that we used has three 
parts. Firstly, total RNA was extracted from an equal volume of each urine sample (40 mL). This 
method is easy to criticize due to the inherent difficulty there is in being precise with 
heterogeneous biological samples. Secondly, an equal amount of small RNA in the 10 – 40 
nucleotide size range, as measured by an Agilent Bioanalyzer, was used to make cDNA for each 
experiment (1.5 ng). It is important to control for the different overall concentrations of 
microRNA within each sample as there are many reasons other than the presence or absence of 
cancer for why they might be variable. For instance, it has been established that blood samples 
from HIV patients that suffer from an advanced stage of immune suppression will produce less 
RNA than healthy individuals due to their low CD4 cell count.33 However, this approach is 
easily confounded by the presence of varying amounts of degradation products in this size range. 
Also, the reproducibility of quantitative values produced by the bioanalyzer small RNA chip has 
been reported to represent a Coefficient of Variance (CV) of as large as 25%.49 In fact, it was 
found that every sample normalized by the previous two methods consistently produced either 
higher or lower Ct values within each sample for all miRNAs tested. This suggested that the 
actual amount of miRNA present in each sample was still variable and an endogenous 
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normalization was needed. Also, this approach was partially abandoned in a later round of 
validation by PCR that was intended to fill in missing data for low expression miRNAs by 
utilizing the highest RNA content possible. 
A normalization factor was obtained from the combined expression of three endogenous 
miRNAs for use in the comparative ΔΔCt method of Livak using the Normfinder program. 
Multiple miRNAs were incorporated in an effort to increase the resolution of the experiment and 
because it is the opinion of most miRNA researchers that due to the natural level of individual 
miRNA expression between individuals, normalizing to a single miRNA is not  appropriate.56 
The use of this strategy to find a non-classical endogenous normalization standard, as opposed to 
one commonly used for miRNA experiments such as RNU48, was necessitated by the unusual 
and cell free content of the sample  under examination. For these reasons, it is the  growing 
opinion that the classical reference genes, such as RNU48, are inappropriate for quantitative 
experiments of this level of resolution.33 It has been argued that normalization is best performed 
between genes of the same class so as to ensure that the factor used for normalization accurately 
mirrors the physiochemical properties of the target molecule.56 All things considered, it is the 
opinion of many in the field that the best way to normalize miRNA expression data is via a 
global mean normalization of three or more stable reference miRNA genes. This is achieved by 
taking the geometric mean of the reference genes and controls best for outliers and differences in 
sample size, which are the most common sources of error in miRNA analyses.57   
To identify potential endogenous miRNAs for normalization, 6 candidate genes were 
selected based on abundance and minimal overall variance of normalized reads as reported by 
the NGS data, presence in the literature as a potential normalization factor, and by long hand 
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pairwise comparison of exploratory RT-PCR data. They were miR-197-3p, miR-16-5p, miR141-
3p, miR-let7g-5p, miR-let7d-5p, and miR20a-5p.  
Table 4: NGS Sequencing Results for Normalization Candidates 
Gene Name logFC logCPM LR PValue FDR 
hsa-miR-20a-5p -0.46117 9.7100253 0.238656 0.625178 0.820976 
hsa-let-7g-5p 0.946926 14.97011 1.145196 0.284557 0.647706 
hsa-let-7d-5p -0.1593 10.553354 0.026416 0.870888 0.954781 
hsa-miR-197-3p 1.519523 9.8423829 1.736972 0.187523 0.558102 
hsa-miR-141-3p -1.29889 10.741446 1.405796 0.235755 0.604689 
hsa-miR-16-5p 1.028633 9.5983274 2.064657 0.150749 0.551875 
 
A RT-PCR experiment was designed to test the expression of these six miRNAs in eight 
control urine samples and eight patient urine samples for subsequent Normfinder program 
analysis. The program dictates the use of a constant number of control and experimental samples 
and a minimum of 5 gene candidates to be analyzed. Everything was performed in duplicate 
instead of in triplicate due to budgetary constraints.  It was felt more weight should be given to 
biological replicates over technical ones in search of possible normalizing microRNAs.46 Since 
few PCR reactions were unsuccessful and the quality and number of replicates was satisfactory, 
missing values were dealt with not by unit imputation but by simple exclusion from downstream 
analysis. This approach was chosen over the various methods of unit imputation so as not to 
inflate or unjustifiably skew the stability value for our normalization factor.46 The least variable 
three genes were found to be miR-20a-5p, miR-let7g-5p, and miR-let7d-5p, in that order. Thus, 
for all subsequent validation RT-PCRs, a geometric mean of these three genes was used to 
generate a ΔCt. 
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Table 5: Normfinder Stability Values 
Gene name Stability value 
20a-5p 0.008 
let7g-5p 0.013 
let7d-5p 0.016 
16-5p 0.017 
141-3p 0.020 
197-3p 0.021 
 
Normalizing to small RNA concentration therefor further reduces the error due to 
variable sample size. It must be noted however that normalizing to sRNA concentration instead 
of total RNA concentration produced data that reflects the concentration of single miRNAs 
compared to the whole miRNA population, essentially a ratio, and will hide the fact that each 
sample might have different overall miRNA expression levels. However, since the Bioanalyzer 
data provides a measure of overall RNA expression for a wide range of sizes, this did not seem 
to be a great loss of information. Also, normalization to total RNA was not a more attractive 
option due to the fact that cell free urine has very little ribosomal RNA and  other species present 
in the urine are expressed at comparatively low levels and are otherwise uncharacterized in terms 
of expression.33 
Why Normfinder  
The apparent difference in gene expression between two samples for a given gene as 
assessed by RT-PCR is a combination of two values. These are the actual biological difference in 
expression and a sum of confounding factors that result in non-specific variation such as 
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extraction yields, differences in enzymatic activity, and input variation between technicians. 
Normalization is meant to eliminate as much of these non-specific effects as possible, but which 
normalization method is best is often in dispute. The use of endogenous reference genes is 
currently the favorite when considering microRNA assays. However, this method presents a 
special challenge when working on miRNAs present in the urine. A good reference gene is both 
stably expressed between patients and controls and is also of a character so as to best represent 
the biological context of the target genes, in this case microRNAs.41 In the past, a favorite 
control has been RNU48, a snoRNA that has been demonstrated to be present in significant 
amounts the urine. However, this candidate falls short on the above two points as it has been 
demonstrated to vary to an unacceptable degree under different experimental conditions and it is 
not a miRNA. Therefore, we determined that new endogenous controls were needed. However, 
how can a candidate for normalization be evaluated if there does not exist a reliable method to 
normalize the candidate? The Normfinder program represents a user friendly, excel based 
version of an algorithm developed to assess the stability of a set of candidate genes and produce 
the best possible combined normalization factor should no single gene be suitable. This is 
usually the case for fine measurement required of validation of microRNA expression via qRT-
PCR where differences of 2 or 3 fold are considered to be significant. 
Normfinder was chosen over other such programs because the authors demonstrated that 
their model based approach is not susceptible to bias related to the co-regulation of normalization 
candidates in the way that the pair-wise comparison approach is.44 In order to evaluate the 
systemic error introduced by the use of a particular gene as a normalizer, the program uses a 
linear mixed effects model where overall variation of the candidates and the overall variation 
between sample groups is taken into account. The intergroup and intragroup variation are then 
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combined into a single value by which the candidate reference genes are ranked. This advantage 
is of particular interest to miRNA studies because the relationships between microRNAs are 
difficult to predict and have been shown to change confusingly in different contexts and in 
different tissues. Also, the rate limiting nature of the miRNA processing machinery could have 
confounding effects on miRNA expression ratios that could resemble co-regulation, particularly 
since many miRs are processed from a single precursor transcript, but differ in amounts of final 
mature miR product due to differential processing. This may be especially true of prostate cancer 
where the loss of Dicer1 is a common hallmark. This might threaten the integrity of a 
normalization factor derived by a pair-wise comparison approach. For these reasons, it is this 
author’s opinion that co-regulation between individual miRNA’s is difficult to predict. 
Therefore, it may be inappropriate to rely solely on the pairwise comparison approach as 
advocated by programs such as Bestkeeper to provide an endogenous normalization factor, 
where even a small degree of co-regulation introduces bias. This discussion is at the forefront of 
miRNA research as it is possible that standardizing normalization methods could do a lot to 
resolve some of the ambiguous results between seemingly similar microRNA experiments from 
the past. 
qPCR samples  
It has been demonstrated that the non-specific amplification methods used to prepare 
RNA samples for qPCR analysis have a negative effect on the linearity of the final assay.57 
Considering this, all samples that did not possess a sufficient concentration to meet the 
empirically derived minimum of 1.5 ng miRNA equivalent/PCR reaction were excluded from the 
first round of validation (6ul of cDNA are allowed per PCR reaction). This left us with the 
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following 17 patients and 12 controls in which we tested all thirteen candidate miRNAs 
identified by the data from RNA sequencing. 
Table 6: Samples Used for the First Round of Validation 
Sample Name Stage 
miRNA concentration 
(pg/ul) 
11262014-QMA G6 450.6 
09172014 G6 895.6 
12042014-EMR G6 935.1 
03082013 G6 323.1 
11202014-KAB G7 269.6 
11202014-PYJ G7 306 
12042014-DT G7 524.6 
01222015-DLD G7 674.2 
11262014-CTL G7 1096 
02102015-EWJ G8 257.3 
11262014-WJC G8 415.3 
010812 G9 474 
07112013-Pre G9 225.9 
04042013-Pre G9 796.1 
111512-PreB pCa 287.8 
03052013-Post pCa 7158.4 
111612 pCa 13494.5 
111512-Pre Control 222.2 
10212014 Control 356.9 
07092014-pnp Control 516.2 
07112014- nps Control 519.4 
07152014 Control 719.5 
08062013-Post Control 1292.5 
07112014- wps Control 1606.3 
09172014 Control 1693.9 
10172014a Control 1926.4 
12162014 Control 2450.3 
10242013 Control 5312.6 
10232013 Control 532.7 
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However, in an attempt to strengthen our conclusions about the final assay, the best eight 
miRNAs from the first round of validation were tested in an additional 10 patients and 6 controls 
that either did not meet the original concentration criteria or otherwise could not be included in 
the first round of validation. 
Table 7: Additional Samples used for the Second Round of Validation 
 
 
 
 
 
 
 
 
 
In total, our final assessment included 27 patients and 18 controls. When a Gleason score 
was not available, pCa was used to designate prostate cancer patients.  
Accuracy vs Area Under the Curve 
Two metrics of evaluation are commonly used to describe the usefulness of a biomarker. 
The first is the accuracy metric which is obtained simply by dividing the number of accurate 
classifications by the total number of attempted classifications. The threshold value at which 
Patients Stage 
miRNA Concentration 
(pg/ul) 
02102015-WHC G6 164.2 
02052015-RLJ G6 110.9 
12042014-HEW G6 111.7 
10242013 G6 7248.5 
03022015-JRD G7 102.3 
12172014a- G7 173.9 
10172014c- G7 162.2 
04192013-2 G7 1166.6 
04042013-2 G8 139.4 
101112-Pre pCa 699.1 
12192014-51 Control 168.4 
09082014-66 Control 102.1 
Rhdad Control 195.5 
09032014-66 Control 233.8 
09302014- Control 777.2 
08212014- Control 704.6 
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each marker is evaluated can either be a single critical value consistently applied to all markers 
under consideration, or the value that produces the highest accuracy for each individual 
candidate. All of the accuracies reported in this study were produced by this second approach. 
One drawback to using this metric is that it is less useful for data sets with unevenly distributed 
values. If one range of values within the data set is more common than others, then a particular 
classifier may receive a higher accuracy if it correctly classifies the common range of values, but 
fails to classify the less common ones. This situation would be unacceptable in the clinic, which 
brings us to our second metric.  
The Area Under a receiver operating Curve (AUC) is a metric that is not affected by data 
skewedness and can be interpreted as the probability that the classifier in question will assign a 
higher value to a randomly chosen positive instance than to a randomly chosen negative instance. 
It is a combined metric that is indirectly derived from both the sensitivity and specificity of a 
binary classification system. Sensitivity can be defined statistically as the chance that a sick 
individual will be assigned a positive classification by the assay and is represented by the 
following equation: Sensitivity = (# of true positives)/(# of true positives + # of false negatives). 
Specificity is defined as the chance that an individual who does not have the disease will be 
assigned a negative classification and is represented by the following equation: Specificity = (# 
of true negatives)/(# of true negatives + # of false positives). A ROC curve can be obtained by 
plotting sensitivity against 1 – specificity for all possible critical values of the classifier in 
question. The AUC is defined as the area under the resulting curve.20    
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qRT-PCR Results  
 
MicroRNAs from Table C were subjected to qRT-PCR and AUC analysis. All qRT-PCR 
values are normalized to the global mean of the three normalizers (let 7d, let7g and miR 20a) and 
recorded as the ∆∆Ct. For each miR, individual Ct values from patient and control samples are 
shown as Box plots (Figures 2-9).  ROC curves and box plots are included for eight miRNAs* 
with the most diagnostic potential as judged by their AUC.   
 
Table 8: Summary of qRT-PCR Results  
Gene name DDCt P Value Accuracy 
AUC 
(fitted) 
204-5p* 2.348913 0.0146 0.821429 0.756* 
205-5p* 3.545608 0.0341 0.75 0.736* 
223-3p* 2.565212 0.0800 0.714286 0.688* 
199a-3p* 1.804074 0.0973 0.714286 0.637* 
223-5p* 1.150305 0.1285 0.714286 0.618* 
126-3p* 0.980553 0.231 0.642857 0.638* 
143-3p* 1.315572 0.231 0.642857 0.648* 
184-5p* 1.509285 0.2919 0.714286 0.599* 
146a-5p 0.753938 0.3814 0.678571 0.597 
375-5p 1.18963 0.519 0.642857 0.561 
135a-5p 0.478416 0.6784 0.607143 0.559 
363-3p -0.16605 0.7125 0.571429 0.509 
142-3p 0.430455 0.8538 0.535714 0.536 
 
 
 
 
 
41 
 
  
 
Figure 2: RT-PCR Analysis for miR-204-5p. A) Box plot for miR-204-5p. Center line 
demonstrates the mean ∆Ct while the box’s edges demonstrate the second (above) and third 
(below) quartiles. Whiskers demonstrate the minimum and the maximum. A p-value of 0.0146 
demonstrates a statistically significant difference between patients and controls. B) ROC curve 
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for miR-204-5p. An AUC of 0.756 demonstrates a diagnostic potential superior to the PSA blood 
test (AUC = 0.678103). 
 
 
 
 
43 
 
 
Figure 3: RT-PCR Analysis for miR-205-5p. A) Box plot for miR-205-5p. Center line 
demonstrates the mean ∆Ct while the box’s edges demonstrate the second (above) and third 
(below) quartiles. Whiskers demonstrate the minimum and the maximum. A p-value of 0.0341 
demonstrates a statistically significant difference between patients and controls. B) ROC curve 
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for miR-205-5p. An AUC of 0.736 demonstrates a diagnostic potential superior to the PSA blood 
test (AUC = 0.678103). 
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 Figure 4: RT-PCR Analysis for miR-223-3p. A) Box plot for miR-223-3p. Center line 
demonstrates the mean ∆Ct while the box’s edges demonstrate the second (above) and third 
(below) quartiles. Whiskers demonstrate the minimum and the maximum. A p-value of 0.080 
demonstrates an almost statistically significant difference between patients and controls with 
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only 28 samples. B) ROC curve for miR-223-3p. An AUC of 0.688 demonstrates a diagnostic 
potential slightly superior to the PSA blood test (AUC = 0.678103). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47 
 
Three miRNAs miR-204-5p, miR-205-5p, and miR-223-3p (Box plots Figure C-H) 
display relevant dysregulation of expression comparing patients to controls.  More importantly, 
these three miRs demonstrate a larger AUC value than the PSA blood test (0.756, 0.736, and 
0.688 vs 0.678103 respectively), suggesting that they perform better in terms of specificity and 
sensitivity as a diagnostic marker than the current PSA blood test. 
However, 5 others (Figures 5-9) miR-199a-3p, miR-223-5p, miR-126-3p, miR-143-3p, 
and miR-184-5p all demonstrate some dysregulation by box plot analysis and AUC values 
greater or equal to 0.60, suggesting that they too have significant diagnostic value despite their 
lack of statistical significance within this small sampling group. 
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Figure 5: RT-PCR Analysis for miR-199a-3p. A) Box plot for miR-199a-3p. Center line 
demonstrates the mean DCt while the box’s edges demonstrate the second (above) and third 
(below) quartiles. Whiskers demonstrate the minimum and the maximum. A p-value of 0.0973 
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demonstrates an almost statistically significant difference between patients and controls with 
only 28 samples. B) ROC curve for miR-199a-3p. An AUC of 0.637 demonstrates a diagnostic 
potential comparable to the PSA blood test (AUC = 0.678103). 
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Figure 6: RT-PCR Analysis for miR-223-5p. A) Box plot for miR-223-5p. Center line 
demonstrates the mean ∆Ct while the box’s edges demonstrate the second (above) and third 
(below) quartiles. Whiskers demonstrate the minimum and the maximum. A p-value of 0.1285 
demonstrates an almost statistically significant difference between patients and controls with 
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only 28 samples. B) ROC curve for miR-223-5p. An AUC of 0.618 demonstrates a diagnostic 
potential comparable to the PSA blood test (AUC = 0.678103). 
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Figure 7: RT-PCR Analysis for miR-126-3p. A) Box plot for miR-126-3p. Center line 
demonstrates the mean ∆Ct while the box’s edges demonstrate the second (above) and third 
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(below) quartiles. Whiskers demonstrate the minimum and the maximum. A p-value of 0.231 
does not demonstrate a statistically significant difference between patients and controls within 
the primary 28 sample group. However, an expansion of sample group size to 45, as described 
above, may reveal a more significant difference. B) ROC curve for miR-126-3p. An AUC of 
0.638 demonstrates a diagnostic potential comparable to the PSA blood test (AUC = 0.678103). 
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Figure 8: RT-PCR Analysis for miR-143-3p. A) Box plot for miR-143-3p. Center line 
demonstrates the mean ∆Ct while the box’s edges demonstrate the second (above) and third 
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(below) quartiles. Whiskers demonstrate the minimum and the maximum. A p-value of 0.231 
does not demonstrate a statistically significant difference between patients and controls within 
the primary 28 sample group. However, an expansion of sample group size to 45, as described 
above, may reveal a more significant difference. B) ROC curve for miR-143-3p. An AUC of 
0.648 demonstrates a diagnostic potential comparable to the PSA blood test (AUC = 0.678103). 
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Figure 9: RT-PCR Analysis for miR-184-5p. A) Box plot for miR-184-5p. Center line 
demonstrates the mean ∆Ct while the box’s edges demonstrate the second (above) and third 
(below) quartiles. Whiskers demonstrate the minimum and the maximum values. A p-value of 
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0.2919 does not demonstrate a statistically significant difference between patients and controls 
within the primary 28 sample group. However, an expansion of sample group size to 45, as 
described above, may reveal a more significant difference. B) ROC curve for miR-184-5p. An 
AUC of 0.599 demonstrates a diagnostic potential comparable to the PSA blood test (AUC = 
0.678103). 
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 It was hypothesized that the diagnostic power of a combined assay could be more 
significant than any single miRNA on its own. A threshold value was determined by hand for the 
8 most significant miRNAs that would most accurately segregate patients and controls. Then, 
each patient or control sample received a numerical classification 1-6 representative of the 
number of miRNAs out of the top eight for which it showed expression above that threshold. 
Having 4 points out of 6 (5 miRNAs out of 8) resulted in a positive classification while 3 points 
and below resulted in a negative classification. The compiled AUC for this combinatorial group 
of eight is shown in Figure S and final assay statistics in Table I (below).    
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Figure 10: The combined assay. A combined assay, based on the number of miRNAs with in 
each individual sample to reach an empirically defined threshold value, produced an AUC of 
0.900, demonstrating a diagnostic potential remarkably superior to the PSA blood test (AUC = 
0.678103). 
 
Table 9: Final Assay Statistics 
Number of Cases 28 
Number Correctly 
Classified 23 
Accuracy 82.10% 
Sensitivity 93.30% 
Specificity 69.20% 
Positive Cases Missed 1 
Negative Cases Missed 4 
Fitted ROC AUC 0.900 
Empiric ROC AUC 0.885 
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 It can be seen here in this final combined assay that the specificity and the sensitivity of 
miRNAs biomarkers is additive and superior to that of PSA. This demonstrates that miRNAs, 
which have been repeatedly demonstrated to be more powerfully correlated to the cell state than 
any other biological molecule, are the perfect candidates to make up for PSA’s poor 
characteristic as a biomarker. 
 
Discussion 
 
The Assay 
There is no question that overall, PSA screening has had a positive effect on public 
health. However, considering the effects of over-diagnosis, the high risk of false positives, the 
potential for over treatment of indolent disease, and the crucial age dependence of PSA 
screening’s harm/benefit ratio, screening has the potential to do more harm than good for certain 
cadres of patients. This negative harm/benefit ratio is a direct result of the weak diagnostic power 
of the PSA test itself and the fact that almost all prostate cancers are aggressively treated once 
diagnosed, no matter the co-morbidities that might be present in its carrier.67  
Here, we have presented a urinary diagnostic test that is superior in terms of specificity 
and sensitivity to the PSA blood test. The novel approach utilized in this study was the use of an 
additive threshold model based on the expression of multiple miRNAs. Since this test only 
incorporates a handful of miRNAs and there are 2588 miRNAs currently included in miRBase 
v21, this concept has an almost endless potential for sophistication. In the future, it is anticipated 
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that expanding the diagnostic panel with more appropriate miRNAs will allow us to differentiate 
between different strata of patients as well as other genitourinary pathologies.  
The truly amazing thing about this additive risk model is that on their own, only two of 
these eight miRNAs would show a diagnostic potential comparable to PSA, but cumulatively, 
they are in fact superior. This final result demonstrates two things: that whole miRNA profiles 
are powerfully correlated with the cell state and that the urine is especially enriched for miRNAs 
from the prostate.  
Contemporary Attempts at a Urinary Test for pCa 
 Although many urine biomarkers have been proposed and investigated, very few have 
ever made it to the clinic. The three most promising biomarkers currently in development are 
urinary PC3, urinary detection of LOH, urinary TMPRSS2:ERG fusion proteins, and 
combinations thereof. In the clinical study submitted for approval to the FDA for the use of 
PCA3 urinary mRNA based prediction of prostate cancer, urinary PCA3 had an AUC of 0.68 
compared to serum PSA’s AUC of only 0.52. Moreover, a different researcher reported that 
urinary PCA3 has no ability to differentiate aggressive from indolent disease.37 A study assessing 
the sensitivity of LOH detection in the urine of prostate cancer produced a sensitivity of 87% 
between patients and non-patients. However, it did not fare so well in terms of specificity 
resulting in no report of an AUC. The most common genomic alteration in prostate cancer, 
occurring in up to 50% of tumors, is a fusion between the ERG proto-oncogene and the prostate 
specific, androgen related gene TMPRSS2.8 Of all contemporary assays being investigated, a 
TMPRSS2:ERG PCA3 combination urine test is the most likely to become clinically relevant in 
the near future and it boasts diagnostic potential comparable to the PSA blood test and an AUC 
of 0.66.37  
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As our results demonstrate, our miRNA assay has superior attributes in all categories to 
contemporary assays. However, I also believe that miRNA panels have the most potential for 
improvement. Utilizing a panel of body fluid biomarkers in combination with other diagnostic 
factors is the most likely approach to become clinically relevant, as no single biomarker 
candidate has been identified with acceptable qualities for use a single factor biomarker for any 
disease.19, 20 A multivariate approach is the only way that a circulating biomarker will ever have 
the specificity to differentiate between the different prostate pathologies, different stages of 
prostate cancer, cancers of different origins, and account for outliers. The advantage to exploring 
miRNAs as relevant biomarkers comes from their large numbers and superior association with 
the cell state. 
The Urinary Panel  
 The follow is a summary of the possible roles that the members of the urinary panel 
might play in prostate cancer. Information on the expression of these miRNAs in the prostate 
cancer cell line progression model and the tumor versus match normal epithelium (TGCA) 
analysis as described in chapter two have been incorporated for the sake of interpretation. 
 
Hsa-miR-204-5p 
 The analysis of NGS sequencing data demonstrated that this miRNA was downregulated 
in the urine of patients as opposed to controls by -2.29 fold with a P value of 0.017. This 
expression trend was validated by qRT PCR analysis and was found to be the most powerful, 
individual diagnostic factor identified in this study. This miRNA was also found to be 
downregulated in tumors as opposed to matched “normal” stroma by -0.82 fold with a P value of 
0.00093 in the TGCA analysis. However, this miRNA was not found to be significantly different 
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in the comparative P69 vs. M12 sequencing analysis described in Chapter 2. Microarray 
profiling of gastric tumors and surrounding stroma identified miR-204-5p to be the most 
powerfully under-expressed of all the miRNAs tested. Its absence was demonstrated to support 
anti-apoptotic pathways by allowing the overexpression of bcl-2, one of its direct targets. Ectopic 
expression of  miR-204-5p inhibited colony forming ability, migration, and tumorigenicity of 
gastric cancer cells as well as making them more susceptible to the effects of apoptosis inducing 
chemicals.106 Another study demonstrated that miR-204-5p had a tumor suppressor effect on four 
prostate tumor cell lines, LNCaP, PC3, VCaP, and NCI H660 via its ability to target the classical 
oncogene c-MYC.105   
 
Hsa-miR-205-5p 
 The analysis of the NGS data demonstrated that this miRNA was upregulated in the urine 
of patients as compared to controls by 2.80 fold with a P value of 0.011. However, this miRNA 
was found to be downregulated in tumors as opposed to matched normal stroma by -1.93 fold 
with a P value of 1.87E-15 in the TGCA analysis. In the cell progression model, the expression 
of miR-205-5p mirrors that of the miR-200 family, supporting the many existing reports that 
these miRNAs directly coordinate their effects on the EMT transition and the expansion of tissue 
stem cell populations via the suppression of N-cadherin, and the SNAI1/2 and ZEB1/2 
transcription factors.9 This miRNA’s well established role as a tumor suppressor suggests that its 
increased presence in the urine could be a result of an effort of tumor cells to suppress miR-205-
5p by dumping it into the surrounding extracellular matrix with eventual exclusion into the urine. 
Some of its other validated targets include, C-epsilon, MED1, and SHIP2, the last of which plays 
a critical role in Akt mediated survival, a pathway central to prostate cancer progression.97   
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Hsa-miR-223-3p and hsa-miR-223-5p  
 The expression of miR-223 was originally discovered as part of the myeloid 
differentiation pathway where its expression was found to be activated by the myeloid 
transcription factors NFIA, PU.1, and C/EBPalpha.98 The overexpression of miR-223 has been 
observed in blood as well as the T-lymphocytes of people suffering from pathological immune 
disorders such as systemic lupus and rheumatoid arthritis.104 miR-223 overexpression has been 
demonstrated to play a role in multiple solid tumors and leukemias including hepatocellular 
carcinoma, ovarian cancer, prostate cancer, CLL, ALL, and AML, although its roles in solid 
tumors and leukemias are likely to be different.  
 The tumorigenic effects of inflammation have long been recognized.4 Due to its critical 
role in hematopoiesis, the overexpression of this miRNA in solid tumors is likely to reflect a 
recruitment of immune cells to the pro-tumorigenic microenvironment. The analysis of the NGS 
data demonstrated that miR-223-3p was upregulated in the urine of patients as opposed to 
controls by 5.94 fold with a P value of 5.58E-05 and that miR-223-5p was upregulated in the 
urine of patient as opposed to controls by 5.96 fold with a P value of 0.000245. However, neither 
arm of this miRNA was found to be significantly different in the TGCA analysis or in our cancer 
cell line progression model. This suggests that the presence of this miRNA has something to do 
with the presence of tumor associated immune cells, in  agreement with the studies reported 
above. 
 Some specific targets of miR-223-5p includes mRNA transcripts that contain AU-rich 
elements such as those encoding RhoB and the FBXW7 protein, which normally represses cyclin 
E activity.98 Also, before invading other tissues, prostate cancer almost always metastasizes to 
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bone, and when it does so, it adopts an osteomimetic phenotype. It is worth noting that miR-223-
5p expression represses the differentiation of osteoclast precursors and is thought to be a 
potential systemic target for bone metastatic disorders.98 One study has found that miR-223-3p 
was significantly overexpressed in other prostate cancer cell lines where it was found to support 
anti-apoptotic pathways, migration, and invasion by targeting the tumor suppressor SEPT6.104  
 
Hsa-miR-199a-3p 
 The analysis of the NGS sequencing data demonstrated that this miRNA was upregulated 
in the urine of patients as opposed to controls by 4.88 fold with a P value of 0.00063. This 
miRNA was also found to be significantly upregulated by a fold change of 3.08 with a p-value of 
0.00281 in the M12 cells compared to the P69 cells, despite the fact that one of its two loci lies 
on the short arm of chromosome 19, a chromosomal area lost in the M12 cell line. It is also 
upregulated 6.24 fold in the miR array screen of M12s compared to p69s. Perhaps this 
upregulation is the result of the loss of some trans regulation between the two copies of miR-
199a and other members of its cluster. miRNA microarray expression profiling has shown miR-
199a-3p to be one of the most significantly overexpressed miRNAs in invasive squamous cell 
carcinomas and cervical cancer cell lines, along with 199a-5p, 199b-3p, and 199b-5p.99 miR-
199a-3p is of particular interest to prostate cancer due to prostate cancer’s propensity for 
invading bone tissue. This miRNA is specifically expressed in the skeletal system where it is 
known to inhibit chondrogenesis in response to activation by Twist-1 by targeting Smad1, a 
central regulator of bone and cartilage formation.99 NKX3.1, one of the central proteins 
governing prostate differentiation and growth, acts as a haplo-insufficient tumor suppressor 
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targeting twist and is seen to be down-regulated early in prostate cancer progression.28 It’s loss 
could result in increased levels of Twist, which leads to the increased activation of this locus.  
 
Hsa-miR-126-3p 
 The potential targets of this miRNA were discussed previously. However, it is worth 
noting that miR-126-3p was found to be upregulated in the metastatic M12 cell line by 1.792786 
fold with a p-value of 0.0065. Similarly, another group recorded the over expression of this 
miRNA in another metastatic cell line, but not in the non-metastatic cell lines that it 
investigated.104 In the future, this miRNA could help investigators differentiate between 
metastatic and localized prostate cancer. However, this miRNA was not found to be significantly 
dysregulated in the TGCA sequencing analyses. 
 
Hsa-miR-143-3p 
 The analysis of the NGS sequencing data demonstrated that this miRNA was upregulated 
in the urine of patients as opposed to controls by 3.96 fold with a P value of 0.0036. It has been 
established that miR-143 originating from normal prostate epithelia actively inhibits nearby 
prostate cancer cell proliferation.11 However, differences in expression of this miRNA were not 
found to be significant in the TGCA analysis or in our cell line progression model. Although its 
tumor suppressor effects remain a mystery, miR-143-3p is known to be a central player in the 
determination of cardiac progenitor cells and smooth muscle cells through the targeting of 
various transcription factors including nkx2-5, klf4, and elk-1. Perhaps underexpression of miR-
143-3p functions to facilitate dedifferentiation. 
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Hsa-miR-184-5p 
 The analysis of the NGS sequencing data demonstrated that this miRNA was upregulated 
in the urine of patients as opposed to controls by 5.86 with a P value of 0.005. It was similarly 
upregulated in the M12 cells by 3.09 fold with a p-value of 0.0014 and 3.077-fold in the miR 
array screens, but interestingly was not found to be significantly different in the TGCA analysis. 
Several targets of miR-184-5p have been validated including the regulators of neurological 
development and apoptosis, perhaps explaining its tumor suppressor-like behavior in ectopic 
expression experiments involving cell lines. One of miR-184-5p’s targets of particular interest to 
prostate cancer is Akt2, a central effector of the PI3K pathway. Since this pathway is critical to 
prostate cancer progression, it would make more sense to see this miRNA suppressed rather than 
upregulated in our cell lines and urine analysis. Perhaps its presence in the urine reflects an effort 
of tumor cells to actively pump this miRNA out of their cytoplasm or an attempt by the 
surrounding normal prostate tissue to maintain tissue architecture. It’s over expression in the 
M12 cell line, our most aggressive and fastest growing cell line, can be explained by the fact that 
this miRNA’s locus is directly activated by the classic oncogene cMYC.102 Given the established 
tumor suppressive activity of miR-184-3p, it is likely that its presence is the unintended result of 
activation of this oncogenic pathway in the M12 cell line. 
 
The Question of Normalization for a Clinical Assay 
The problem of proper normalization across various urine samples extends to any 
potential clinical biomarker assay that may arise from this type of work. This could make 
developing an inexpensive and quick assay difficult. One way in which this hurdle could be 
overcome is with the concept of in situ normalization as developed by Stahlberg et al. In this 
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method, in place of a classical endogenous control, a gene is chosen that is known to be either 
correlated or anti-correlated with the gene of interest for normalization. While this does not 
really allow for the comparison between samples, it is a powerful method for the detection of 
diseases where the ratio between multiple factors is a significant marker.41 This technique is 
perfect for the application of microRNA expression data. One such relationship has already been 
reported in a previous study: the inverse relationship of miR-141-5p and 21-5p. Due to our use of 
endogenous controls, we have inadvertently demonstrated that the ratio between the members of 
the biomarker panel that we have identified and the endogenous controls used for normalization 
correlates very powerfully with the presence of prostate cancer. A modified version of our 
normalization protocol may serve as a quick and effective normalization method for a usable 
clinical assay.  
  
How miRNAs might get into the Urine and the Potential for Outliers. 
 In developing a highly specific and sensitive assay, all possible sources of miRNAs, 
prostate derived or otherwise, need to be thoroughly considered in order to accurately interpret 
the urinary miRNA profile and to account for possible patient outliers.  
 Firstly, it has been established that there is a natural level of leakage from the healthy 
prostate into the urine via the ducts of the prostatic urethra. Prostate epithelium and cellular 
materials are constantly being shed into this compartment, especially in response to physical 
manipulation by the physician.37 Under pathological conditions, this contribution might be 
increased. For instance, the distensible nature of the glandular system of the prostate is what 
allows for it to store seminal fluid for later ejaculation.5 The growth of a solid tumor within the 
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confines of the prostate could compromise the tissue’s ability to store seminal fluid and could 
result in an enhanced leakage of prostatic materials into the urethra, which is then swept away by 
the urine as it passes. In the later stages of disease, as the tumor becomes more advanced, it may 
deteriorate the integrity of the glandular structure entirely. Different levels of structural integrity 
between advanced and early stage patients could stratify patients into different overall strata of 
profiles. 
Secondly, It has been established that circulating miRNAs bound to proteins or 
sequestered within exosomes can be delivered to the kidneys and excreted via the urine, although 
the portion of these present in the urine of either healthy or diseased persons has yet to be 
analyzed.31 It also has yet to be investigated whether some miRNAs are transported more easily 
than others, either based on sequence or type of packaging. One source of outliers could be a 
decrease in kidney function related with age. Since there is a high concentration of miRNAs in 
the blood, it is possible that age related leakage of miRNAs into the urine from the blood could 
confound a urinary assay if not properly considered. Thirdly, if a patient’s tumor has invaded the 
bladder or urethra through the smooth muscle of the urethral sphincter, his miRNA profile will 
be drastically different from a localized cancer that is restrained to the prostate. Although this is 
rare and requires a tumor to be advanced, it has been observed clinically.5 Small penetrations of 
carcinoma through the adipose and fibrous tissue and into the capsule of the neurovascular 
bundle of the prostate are more common however.  
Lastly, the largest source of miRNAs present in the healthy urine is from dying renal and 
urethral cells.31 One potential source of outliers could be the existence of urinary tract infections, 
more common to catheterized men. This could affect the miRNA profile through the activation 
of an immune response or through an alteration of desquamation in urinary tract cells. It is also 
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hypothesized that the presence of a catheter itself could alter the normal microflora of the distal 
urethra or that some men are just naturally predisposed to the presence or absence of specific 
bacterial species that cause different immune phenomena, like what is seen in the gastrointestinal 
tract. Both of these could affect the standing equilibrium of the mucosal immune response, which 
could in turn affect the miRNA content of the urine. The decision by our group to analyze the 
cell free compartment of the urine should, in theory, reduce the extremity of any outliers 
produced in this way by removing a large portion of miRNAs contributed by activated whole 
cells. 
 
Thoughts for the Future  
 Indolent vs. Aggressive forms of Disease 
Most often, prostate cancer is present in aged men in an indolent, latent form. Due to the 
slow growing nature of these tumors, they are not usually the cause of death for these patients. 
Because almost all positive diagnoses are followed by aggressive treatment, the inability to 
distinguish latent and aggressive disease has led to over diagnosis and over treatment of non-
threatening prostate cancers.12 Over-diagnosis is defined by many studies as the detection of a 
cancer that would otherwise go undetected throughout the lifetime of the patient. One of these 
studies estimated that over-diagnosis could be as high as 66% in the United States.67 Identifying 
a microRNA signature that could help differentiate between these forms of the disease could help 
identify cancers that are likely to stay slow growing and localized and cancers that are likely to 
become a threat to life. An advancement in this area could help improve quality of life for 
patients who receive a positive diagnosis in their 70s or later. 
 
71 
 
As a primitive example, it has been previously described that in the serum of early 
prostate cancer patients, levels of circulating miR-21 are elevated while levels of circulating 
miR-141 are comparable to those of controls. In advanced stage disease the situation is the 
opposite, where levels of circulating miR-21 are comparable to controls and levels of miR-141 
are high. Although this model has too low of a sensitivity to be adopted in the clinic, it gives us a 
good concept to aim for when considering the diagnostic value of microRNA expression 
patterns.18  
Metastasis  
Prostate cancer may metastasize to the lungs, liver, and pleura but if it becomes 
metastatic, it will most certainly form osteoblastic lesions in the bone.8 Hormone ablation 
therapy, radiation, and surgery are effective treatments for localized prostate cancer, but the 
options for metastatic disease are essentially limited to chemotherapy.2 However, due to the 
occult nature of the micro-metastases associated with advanced disease, techniques such as MRI 
and radionucleotide bone scans have a high false negative rate.12 Because of this, the decision to 
move forward with chemotherapy is often made liberally, the thinking being that it is better to err 
on the side of safety. However, considering its side effects, being able to spare an elderly man 
the pain and cost of chemotherapy would be a significant clinical advancement. 
Many studies have demonstrated differential miRNA signatures for metastases and 
primary tumors. The bulk of these characteristic metastases signatures are unique to each cancer 
type but some miRNAs do seem to overlap, such as miR-21-5p and miR-10b-5p.17Also, as 
opposed to primary prostate tumors which are multifocal and frustratingly heterogeneous, 
metastases are almost always monoclonal.8 The emergence of a sharp profile from a more diffuse 
and general dysregulation may be a sign of an expansion of metastatic tissue. However when 
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accomplished, an accurate and sensitive miRNA assay for metastasis would make a huge 
difference in the lives of patients with advanced disease. 
 The Androgen receptor and CRPC   
Androgens play an important role in early tumorigenesis, interacting with aberrant or 
over expressed forms of the androgen receptor to stimulate growth.2 Even when the androgen 
pathway is not aberrant, tumor growth is still androgen dependent as evidenced by the fact that 
androgen starvation is an effective strategy for de-bulking tumors. This is because, in prostate 
tissue, many central cellular processes such as proliferation and growth are directly or indirectly 
under the control of the androgen pathway’s effectors. One interesting example is the hTERT 
gene which is, in fact, directly controlled by androgens in the human prostate.16 Also, P68, 
described in Chapter 1 for its ability to influence the interaction between large groups or pri-
miRNAs and the Drosha/DGCR8 complex, has been demonstrated to interact with the androgen 
receptor, suggesting that it may be involved in propagating an AR driven miRNA profile.66  
Androgen starvation is an effective way to de-bulk large tumors and is usually a part of 
combined therapeutics. However, androgen starvation will eventually result in the emergence of 
castrate resistant prostate cancer (CRPC) for which treatment options are very limited. When 
pCa overcomes androgen starvation, it isn’t because the tumor tissue has abandoned its reliance 
on the androgen pathway for proliferation, but instead because it has found a way to circumvent 
the need for exogenous androgen stimulation. This is demonstrated by the observation that 
castration resistant cells often demonstrate AR over expression, AR gene mutations, AR 
corepressor or coactivator mutations, and amplification of the AR locus.6 Of specific importance 
to those hunting for miRNA biomarkers, it has also been demonstrated that an increase in AR 
mRNA is all that is required to make the transition between androgen sensitivity to androgen 
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independence.52 Being able to monitor the expression of a group of miRNAs associated with the 
AR in the urine could provide clinicians with an alternative method to circulating tumor cell 
count for the emergence of CRPC and relapse which would allow patients and their physicians 
more time to make decisions about treatment.  
 As treatment options for advanced disease expand in the coming years, late staging and 
prognosis will only become more relevant. This is especially true for one category of patient in 
particular, the post failure of androgen deprivation therapy CRPC patients. However, for this 
stage of disease, the only prognostic marker sanctioned by the US FDA is the circulating tumor 
cell count which is expensive, technically challenging, and of limited and complicated prognostic 
value to patients who fall into certain categories.22 As a proof of concept, miR-32-5p and miR-
148a-5p were demonstrated by one group to be downstream of AR binding sites and to be 
overexpressed in CRPC tissue samples compared to PC.79 Another researcher in our laboratory 
has demonstrated that an upregulation of miR-32 is detectable in the blood of prostate cancer 
patients compared to controls (unpublished results). After androgen deprivation therapy, a return 
to pretreatment miR-32 levels or above might be good evidence of androgen independence. 
 The Big Data Problem  
There is a lot of profiling information out there with no consensus as to how to interpret 
it. The variability and complexity inherent to miRNA profiling may seem overwhelming to the 
point of uselessness, but if the past few years of advancements in the fields of computational 
factoring and machine learning are any indication of the future, our ability to process vast 
quantities of data is poised to jump exponentially. 20 It could be that the vast amount of 
information provided by circulating miRNA profiles could be the source of the most 
sophisticated diagnostic information available to future diagnosticians.  
 
74 
 
Prostate Cancer Subgroups  
 At the genetic and histological level, prostate cancers from different patients have yet to 
be classified into distinguishable subgroups that correlate with patient outcomes.8 This is in 
contrast to breast cancers which are grouped into subtypes based on expression of the estrogen, 
progesterone, and epidermal growth factor receptors. One contributing factor is that prostate 
cancer is highly multifocal. That is, it is often made up of genetically distinct, histological foci of 
cancer.8  In breast cancers, miRNA profiling has been demonstrated to correlate with tumor 
subtype.19 This observation lends itself to the idea that miRNA profiling of tissues could be used 
to help distinguish prostate cancers into similar subtypes with specific prognoses. As a proof of 
concept, miRNA profiles have already proved useful in the prediction of response to 
chemotherapy3 and there is some convincing evidence that members of the miR-200 family 
correlate to the established breast cancer subgroups.84  
 Tissue Specific miRNA Modifications  
There are many different interesting post-transcriptional modifications (excellently 
reviewed in reference 66) including uridylation, 5’-methylation, favoring of isomiRs,35 arm 
switching and many more.66 Many of these demonstrate tissue specificity and could affect the 
profiles of body fluids in such a way as to yield diagnostic information. As an example, RNA 
specific adenosine deaminases also act on pre-miRNA transcripts (ADARs) to change either 
their expression or their specificity by changing an adenosine to an inosine within the seed 
sequence.7 In one striking example, an ADAR acts on pre-miR-151 which then proceeds to block 
targets involved in Dicer processing of other pre-miRs leading to their accumulation in the 
cytoplasm.1 This demonstrates that ADARs have some important implications for cancer 
development, in their own right. Since ADARs are tissue specific, quantitating the amount of 
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circulating miRNAs with tell-tale signs that they have been processed by specific ADARs could 
give clues as to where a pathology is located in the body. 
 
Detecting the expansion of specific miRNA profiles. 
Most miRNA expression profiles that have been established are extremely specific to cell 
type and differentiation status.13 Detecting the expansion of a miRNA profile associated with a 
specific type of cell known to be associated with aggressive or indolent disease may help 
differentiate aggressive from indolent disease. The first cell type to be investigated for this 
purpose was the putative prostate tissue stem cell and there are many active studies pursuing this 
exact concept.13 However, two hypothetical candidate cell types include the basal cells and 
neuroendocrine cells of the prostate. 
The epithelium is mostly made up of simple cuboidal or columnar epithelial “luminal” 
cells. Luminal cells are terminally differentiated, have a low proliferative index, contain 
secretory granules, express cytokeratins 8 and 18, and stain positive for PSA, acid phosphatase, 
and the androgen receptor. They are anchored to the basement membrane by integrins. Wedged 
between the epithelium and the basement membrane is a ring of flat “basal” cells with a high 
nucleus to cytoplasm ratio that express cytokeratins 4, 14, and 15 and stain negative for PSA and 
the androgen receptor. They make up less than 10% of the glandular epithelium in the healthy 
prostate.5 The basal cell population is thought to be the originator of the luminal epithelium and 
is also thought to contain the proposed prostate stem cells, defined as single cells that have the 
ability to reconstitute the entire gland. These are also the cells most predicted to be the origin of 
prostate cancer stem cells and prostate cancer in general.5 PIN is widely regarded as a precursor 
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to prostate cancer and so differentiating it from true malignancy could be a challenge. One key 
difference between them is that in PIN, basal cells are reduced in number compared to normal 
prostate while in the case of cancer, the reverse is true.8 Characterization of the miRNA profile 
associated with the basal phenotype may be a good place to start looking for a way to distinguish 
between these two conditions. 
Scattered among the epithelial cells of the prostate are neuroendocrine (NE) cells that 
stain positive for chromogranin A, neuron-specific enolase, and synaptophysin, as well as other 
neuronal markers. They have a paracrine function on the growth, differentiation, and secretory 
effect of the epithelium.5 While tumors derived from NE cells are rare, mouse experiments have 
demonstrated that NE cells themselves do have an effect on alveolar carcinoma growth and 
aggressiveness. This effect is still appreciable when NE cells are transplanted to parts of the body 
distant from the prostate, indicating that they could act in an autocrine manner.16 A tumor’s 
microenvironment is critical to its survival. It is possible that as a prostate tumor develops, it 
recruits resident NE cells and causes them to proliferate. If this were the case, then an expansion 
of the miRNA expression profile of NE cells could correlate with tumor aggressiveness.  
Delivery to the Vagina  
The prostate is first and foremost, an exocrine organ. It secrets a thick alkaline fluid 
composed of materials designed to increase the viability of spermatozoa inside the hostile 
environment of the vagina. This fluid is ejected with the spermatozoa and contributes 50-70% of 
the seminal fluid. I propose that the epithelial tissue of the prostate packages miRNAs for 
extracellular delivery to the vagina for the purpose of mitigating its hostile environment.  The 
following is an original example for a proposal for how this might be accomplished. In 2013, a 
team of researchers established that norepinephrine potentiates the pro-inflammatory response of 
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human vaginal epithelial cells (HVEC) and that this response is dependent upon HVEC 
expression of the B-adrenergic receptor.63 One miRNA that we found to be one of our most 
powerful biomarkers, 205-5p, was found to potentially target ADRB2, the gene that encodes the 
B-adrenergic receptor. I think that it is possible that the presence of this miRNA in the urine is 
derived directly from the prostate and that one of its natural functions there is as an intended 
component of the seminal fluid. Repeated exposures to seminal fluid may increase fertility by 
lowering the expression of the beta adrenergic receptor in the HVECs lining the vagina, which 
would in turn lower HVECs’ responsiveness to NE, which would reduce the production of IFN-
gamma by these cells, which would mitigate the spermatocidal, pro-inflammatory environment 
of the vagina. Being more fertile in a situation where sex is a more frequent event might have 
made our female ancestors more likely to conceive a child with an established partner as opposed 
to as the result of a chance encounter. This would have made her more likely to conceive while 
she could make use of social advantages such as a long term partner, a familial community, or 
some primitive equivalent. This would have been important since caring for an infant demands 
resources and attention that would be difficult for an individual parent to provide in ancient 
times. 
More in depth small RNA analyses of semen of different men could give us information 
regarding which, if any, miRNAs originate in the prostate with the direct intention of delivery 
into the vagina along with the sperm. 
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Chapter 2- miRNA NGS of the Cancer Cell Line Progression Model 
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Specific Aims 
The P69 cell line and its derivatives are a unique prostate cancer progression model. They 
were derived from normal prostate epithelium, immortalized with SV40 large T antigen, and 
allowed to become tumorigenic via multiple rounds of in vivo selection in nude mice.30 From 
this approach, a family of related cell lines was produced, each representing a different stage of 
tumor progression. The P69 parental cell line is poorly tumorigenic, non-metastatic, and has a 
lower chromosomal modal number than other more established prostate cancer cell lines. Three 
rounds of subcutaneous injections produced the M12 daughter cell line which is highly 
tumorigenic and metastatic and harbors a chromosome 16:19 translocation resulting in the 
deletion of one copy of chromosome 19p-q13.1. Restoration of chromosome 19 to the M12’s 
produced the F6 cell line which is less tumorigenic and not metastatic.30 It has long been known 
that chromosome 19 contains one of the highest concentrations of miRNAs32 leading to the 
hypothesis that an alteration in miRNA expression might be responsible for the M12 cell line’s 
powerful metastatic character.  To investigate this, deep sequencing was performed on RNA 
extracted from each of the cell lines. Recent genome wide association studies have established an 
association between a risk for prostate cancer and a panel of inheritable mutations. A single 
nucleotide polymorphism (SNP) analysis was performed on all participating cell lines, partly to 
investigate the mystery of P69 cell line’s tumorigenicity and partly to establish that none of these 
SNPs were acquired by the M12 cell line during in vivo passaging, thereby explaining its 
character.  
History and Character of the Cell Lines   
The P69 cell line was derived from prostate epithelial cells isolated from the tissue 
obtained from a 63 year old African American man during a transurethral resection and 
 
80 
 
transfected with SV40 large T antigen via the pcc5 plasmid. It is important to point out that these 
cells are immortalized but not transformed by ectopic expression of any other oncogenic factor 
such as cMYC. Most cell lines immortalized by SV40 large T antigen are not tumorigenic and 
therefore, are not considered to be cancer cell lines. In contrast, the P69 cell line is weakly 
tumorigenic in athymic nude mice which allowed for serial passaging to move forward without 
any other unnatural modifications.39 Histologically, P69 cells demonstrate a homogeneous flat, 
cobblestone appearance consistent with their epithelial character. These cells demonstrated acini-
like morphology complete with basement membrane and basal polarity of alpha 6 and beta 1 
integrin expression, when grown in embedded in lamimin rich extracellular matrix (lrECM) gel 
(3D) cultures.49 Co-expression of keratin 5/6, keratin 8, and p63 suggest that the p69 cell line 
was derived from a prostate basal cell.49 Although these cells have a number of characteristic 
translocations, none result in chromosomal loss and these cells retain both X and Y 
chromosomes. The most prominent cytogenetic event present in this cell line is a t(5;7) 
translocation that is retained in all of its derivative cell lines. P69 cells were injected 
subcutaneously and produced tumors in 2/18 athymic nude mice after 180 days. Cells from these 
two tumors were immediately injected subcutaneously and after 25 days, the tumors that were 
isolated from these mice produced the daughter cell lines M2182 and M2055.  
The morphology of M2182 cells, differs markedly from that of the P69 parent. While the 
P69 cells show consistent epithelial character, these cells are extremely heterogeneous. 
Histological analysis of the tumor from which these cells were derived showed a poorly 
differentiated tissue.39 Interestingly, the modal chromosome number for these cells was 46, 
demonstrating consistent pseudodiploidy after 2 rounds of in vivo selection. This pseudodiploid 
character is a characteristic unique to this prostate cancer cell model as it demonstrates that, in 
 
81 
 
this case, tumorigenesis precedes chromosomal instability. This sets this family of cell lines apart 
from the PC-3, DU-145, LNCap, and PC-82 cell lines which are all characterized by high 
chromosome numbers. The M2182 cell line was passaged via subcutaneous injection one 
additional time, producing tumors in 2/3 athymic nude mice, one of which resulted in the M12 
cell line. 
The M12 cells metastasized aggressively to the diaphragm and lung and were highly 
tumorigenic, producing tumors in 13/13 mice after 9-15 days. In contrast to its grandparent 
parent cell line, p69, the M12 subline demonstrated an unstructured spheroid morphology with 
no polarity when grown in lrECM 3D cultures.49 It was also observed that early on the M12 cells 
quickly migrate out of these spheroid balls and penetrate the entire lrECM gel. In addition they 
have lost the Y chromosome and chromosome 19p-q13.1 as a result of an unbalanced 
translocation with chromosome 16.40 The loss of chromosome Y is one of the most common 
cytogenetic phenomena detected in prostate cancers alongside aberrations involving 
chromosomes 7, 8, 10, and 16. Loss of chromosome 19 is less common, but is often lost in 
prostate tumors that have reached an advanced stage.40 These regions harbor few known classical 
tumor suppressor genes relevant to prostate cancer. In order to investigate the role that this 
deletion has on the aggressiveness of the M12 cell line, a new copy of chromosome 19 was 
introduced via microcell mediated chromosome transfer (MMCT) using A9neo19 donor cells.  
The resulting cell line (F6) demonstrated significantly reduced in vitro doubling time, 
anchorage independent growth, and tumorigenicity compared to the M12 cell lines.40 It was also 
observed that these cells revert back to the acini-like morphology of the p69 cells, complete with 
basement membrane and basal polarity, when grown in lrECM 3D cultures.49 F6 cells have an 
additional chromosomal aberration resulting in the acquisition of an additional copy of both the 
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long arms of chromosome 22 (from q13 on) and the X chromosome (also from q13 on).  These 
hybrid cells created microscopic tumors in 6/15 athymic nude mice after 120 days with no 
metastases. Analysis of tumors formed by subcutaneous injection of the F6 cells revealed new 
chromosomal aberrations in all cells including an additional loss of chromosome 19 in 40% of 
the cells. Within the same MMCT experiment that produced the F6 cell line, another daughter 
cell line was produced that failed to obtain a new copy of chromosome 19, but did acquire other 
chromosomal aberrations and demonstrated comparable tumorigenicity to the M12 parent, 
demonstrating that the MMCT method does not itself drastically inhibit tumorigenesis.40  
 
Materials and Methods 
 
Cell Line RNA Extraction and Sequencing  
Small RNA was extracted from duplicate P69 samples and one M2182, one M12, and 
one F6 sample using the miRVana microRNA extraction kit. The protocol was followed 
according to the manufacturer’s specifications for the extraction of small RNA and RNA eluted 
in 200 ul. Sample concentration was normalized according to the miRNA concentration reported 
by the Agilent Bioanalyzer’s small chip and samples were sent to the Nucleic Acids Research 
Facility at Virginia Commonwealth University for paired end sequencing on the Illumina 
platform. Normalization, trimming, and analysis was performed exactly as described in Chapter 
1 and results are reported as comparisons between duplicate  P69 samples and each of the M12, 
M2182, and F6 samples individually. Sequencing quality, trimmed reads, alignment, etc. are 
reported in Figure Y.   
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TCGA pCa tumor samples  
Level 3 Illumina data from The Cancer Genome Atlas from 50 tumor samples and 
matched samples of normal tissue from the same patients was selected for analysis. Since the 
P69 cell line is immortalized epithelium, this comparison was thought to be especially 
appropriate. Normalization, trimming, and analysis was again performed exactly as described in 
Chapter 1. 
SNP Analysis 
The SNP analysis utilized in this study makes use of Ion Torrent DNA sequencing and 
emulsion PCR (emPCR). DNA was extracted from P69, M2182, M12, and F6 cell lines with the 
QIAamp DNA Mini Kit. Input DNA (10 ng) from each sample was used to generate DNA 
libraries using the Ion AmpliSeq Library Kit 2.0 and the Ion AmpliSeq Cancer Hotspot Panel v2.  
The Cancer Hotspot Panel is a pool of primers that specifies the amplification of 207 different 
amplicons covering over 2,800 different common mutations within the Catalogue of Somatic 
Mutations in Cancer (COSMIC) database, representing 50 different oncogenes and tumor 
suppressors important to prostate cancer. The COSMIC database catalogs more than two million 
coding sequence point mutations identified in different cancers. Individual samples were 
barcoded and ligated with the Ion Xpress Barcode Adapters 1-16 Kit and then attached to 
Agencourt AMPure XP magnetic beads. Sample libraries were then quantitated with a Qubit 2.0 
Fluorometer and normalized to a concentration of 100 pM. emPCR was performed on the Ion 
OneTouch 2 Instrument. Samples enriched on the Ion OneTouch ES using the Ion PGM 
Template OT2 200 Kit and DynaBeads MyOne streptavidin C1 beads according to the 
manufacturer's protocols. The enriched ISPs were eluted off the MyOne streptavidin C1 beads 
using a sodium hydroxide and tween melt solution and then sequenced with an Ion Torrent Ion 
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318™ Chip. The Ion Torrent PGM was run with standardized Ion Torrent 200 Kit v2 
modifications for 500 nucleotide flows, and the output was aligned to the HG19 as a reference. 
This sequencing was outsourced to American International Biotechnology, Richmond VA, and 
generously done by Katherine O’Hanlon overseen by Dr. William Budd. 
 
Results 
 
SNP Analysis  
A next generation sequencing analysis was undertaken to identify potential nucleotide 
variations in genes associated with cancer progression. Over 200,000 reads were obtained for 
each cell subline with a mean read length of ~110 nts in length (Table 1). Although F6 is not 
shown in the table below, it produced similar results, demonstrating good coverage for all cell 
lines. 
Table 10: SNP NGS Summary 
Cell Line Reads Mean Length Total Bases 
P69 562,713 110 61,626,082 
M2182 206,177 114 23,518,988 
M12 448,016 114 50,956,206 
 
There were three COSMIC hotspot gene mutations identified in all sublines (STK11-
COSM29005, PGFRA- COSM22413 and APC-COSM19099 (Table 11).  All of the COSMIC 
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hotspot mutations plus the other 11 novel mutations were consistent across all cell lines of the 
progression model (P69, M2182, M12, and F6), which implies that none of them are responsible 
for the aggressiveness demonstrated by the M12s.  However, there was a single transition from a 
cytosine to a thymidine in the STK11* gene on chromosome 19 which is present in the P69 and 
M2182 cell lines but disappears in the M12 cell line, concomitant with the loss of one 
chromosome 19.   
Table 11: SNP Summary  
Gene 
Symbol 
Chromosome Position Reference 
Nucleotide 
Alternate 
Nucleotide 
Cosmic ID 
PIK3CA chr3 178917005 A G --- 
MET chr7 116340269 C T --- 
NOTCH1 chr9 139390853 C T --- 
RET chr10 43613843 G T --- 
TP53 chr17 7579472 G C --- 
STK11* chr19 1220321 T C --- 
STK11 chr19 1221293 C T COSM29005 
PIK3CA chr3 178927410 A G --- 
FGFR3 chr4 1807894 G A --- 
PDGFRA chr4 55141055 A G --- 
PDGFRA chr4 55152040 C T COSM22413 
KDR chr4 55955139 A T --- 
APC chr5 112175240 G C COSM19099 
APC chr5 112175770 G A --- 
CSF1R chr5 149433596 TG GA --- 
*Not present in M12 cell line. 
By looking at each SNP analysis individually we can see an interesting timeline emerge. 
In the P69 and M2182 cell lines, there are two SNPs within different parts of the STK11 gene. 
They are one novel mutation and one cancer hotspot and they are each consistently expressed at 
an allelic ratio of about 50% in both parent and daughter cell lines.  In the M12 cell line 
however, only the hotspot mutation is present and it enjoys an allelic ratio of 100%. Since the 
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M12s have lost a copy of the portion of chr19 where STK11 resides, the most obvious 
explanation for this is that the novel mutation was originally on the now missing copy of STK11. 
It is unclear whether or not this remaining mutation which does not produce a change in the 
amino acid sequence of the protein (Y272Y), has an effect on its activity. It is still likely that the 
mutation that we retain is fully functional. We can also see here that the allelic ratios in the F6 
cell line deviate significantly from the previous norms of either 50% or 100%, possibly reflecting 
the increase in cytogenetic heterogeneity that we see in these cells. 
Table 12: SNP Allelic Frequencies in the P69 Cell Line 
Gene 
Symbol 
Chromosome Position Reference 
Nucleotide 
Alternate 
Nucleotide 
Allele 
Ratio 
Cosmic ID 
PIK3CA chr3 178917005 A G 49.5 --- 
MET chr7 116340269 C T 51.4 --- 
NOTCH1 chr9 139390853 C T 37.5 --- 
RET chr10 43613843 G T 100 --- 
TP53 chr17 7579472 G C 44.8 --- 
STK11 chr19 1220321 T C 49.1 --- 
STK11 chr19 1221293 C T 49.1 COSM29005 
PIK3CA chr3 178927410 A G 55.2 --- 
FGFR3 chr4 1807894 G A 100 --- 
PDGFRA chr4 55141055 A G 100 --- 
PDGFRA chr4 55152040 C T 50.1 COSM22413 
KDR chr4 55955139 A T 48.2 --- 
APC chr5 112175240 G C 64.8 COSM19099 
APC chr5 112175770 G A 100 --- 
CSF1R chr5 149433596 TG GA 100 --- 
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Table 13: SNP Allelic Frequencies in the M2182 Cell Line 
 
Gene 
Symbol 
Chromosome Position Reference 
Nucleotide 
Alternate 
Nucleotide 
Allele 
Ratio 
Cosmic ID 
PIK3CA chr3 178917005 A G 48.4 --- 
MET chr7 116340269 C T 54.3 --- 
NOTCH1 chr9 139390853 C T 34.7 --- 
RET chr10 43613843 G T 100 --- 
TP53 chr17 7579472 G C 62.1 --- 
STK11 chr19 1220321 T C 53.1 --- 
STK11 chr19 1221293 C T 47.6 COSM29005 
PIK3CA chr3 178927410 A G 50.8 --- 
FGFR3 chr4 1807894 G A 99.2 --- 
PDGFRA chr4 55141055 A G 100 --- 
PDGFRA chr4 55152040 C T 47.7 COSM22413 
KDR chr4 55955139 A T 44.6 --- 
APC chr5 112175240 G C 32.9 COSM19099 
APC chr5 112175770 G A 100 --- 
CSF1R chr5 149433596 TG GA 100 --- 
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Table 14: SNP Allelic Frequencies in the M12 Cell Line 
 
Gene 
Symbol 
Chromosome Position Reference 
Nucleotide 
Alternate 
Nucleotide 
Allele 
Ratio 
Cosmic ID 
PIK3CA chr3 178917005 A G 62.4 --- 
MET chr7 116340269 C T 50.8 --- 
NOTCH1 chr9 139390853 C T 28.6 --- 
RET chr10 43613843 G T 100 --- 
TP53 chr17 7579472 G C 49 --- 
STK11 chr19 1221293 C T 100 COSM29005 
PIK3CA chr3 178927410 A G 65.9 --- 
FGFR3 chr4 1807894 G A 100 --- 
PDGFRA chr4 55141055 A G 100 --- 
PDGFRA chr4 55152040 C T 51.5 COSM22413 
KDR chr4 55955139 A T 44.6 --- 
APC chr5 112175240 G C 49.3 COSM19099 
APC chr5 112175770 G A 100 --- 
CSF1R chr5 149433596 TG GA 100 --- 
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Table 15: SNP Allelic Frequencies in the F6 Cell Line 
 
Gene 
Symbol 
Chromosome Position Reference 
Nucleotide 
Alternate 
Nucleotide 
Allele 
Ratio 
Cosmic ID 
PIK3CA chr3 178917005 A G 49.5 --- 
MET chr7 116340269 C T 90.3 --- 
SMO chr7 128846355 C T 10.1 --- 
NOTCH1 chr9 139390853 C T 34.1 --- 
RET chr10 43613843 G T 100 --- 
TP53 chr17 7579472 G C 52.7 --- 
STK11 chr19 1220321 T C 52.9 --- 
STK11 chr19 1221293 C T 49.1 COSM29005 
PIK3CA chr3 178927410 A G 51.8 --- 
FGFR3 chr4 1807894 G A 100 --- 
PDGFRA chr4 55141055 A G 100 --- 
PDGFRA chr4 55152040 C T 47.3 COSM22413 
KDR chr4 55955139 A T 49.3 --- 
APC chr5 112175240 G C 50 COSM19099 
APC chr5 112175770 G A 100 --- 
CSF1R chr5 149433596 TG GA 100 --- 
 
RNA Sequencing    
Since SNP analysis could not define any known cancer genes that could account for the 
phenotypic differences between the p69, M2182, M12 and F6 cell lines, we initiated NGS to 
search for miRs whose dysregulation could contribute to the different tumorigenic and metastatic 
properties of this progression model. Previously, miR array screens were conducted in duplicate 
on the parental p69 cell and its M12 variant.  Eventually, results from this previous analysis will 
be compared to NGS results in an effort to pin point relevant miRs driving tumor progression.  
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Table 16: miRNA NGS P69 vs M2182 
Gene Name Chromosome logFC logCPM LR PValue FDR 
hsa-miR-340-5p chr5 -8.672291 10.063148 58.54637 1.99E-14 1.31E-11 
hsa-miR-381-3p chr14 -12.54818 9.7167823 55.34134 1.01E-13 3.35E-11 
hsa-miR-429 chr14 -7.945767 10.869757 35.94044 2.03E-09 3.56E-07 
hsa-miR-146a-5p chr5 5.6748522 5.9314763 35.83435 2.15E-09 3.56E-07 
hsa-miR-205-5p chr1 -9.40322 12.729872 34.01031 5.48E-09 6.78E-07 
hsa-miR-200c-3p chr12 -8.976546 13.379708 33.78686 6.15E-09 6.78E-07 
hsa-miR-370-3p chr14 -11.43019 8.6030225 31.87443 1.64E-08 1.56E-06 
hsa-miR-200a-3p chr1 -8.931423 9.4067572 29.11996 6.80E-08 5.63E-06 
hsa-miR-379-5p chr14 -10.57524 7.7600633 27.68123 1.43E-07 9.65E-06 
hsa-miR-411-5p chr14 -10.5446 7.7298956 27.64473 1.46E-07 9.65E-06 
hsa-miR-654-3p chr14 -10.17118 7.3631675 27.41589 1.64E-07 9.87E-06 
hsa-miR-409-3p chr14 -10.06848 7.2616111 26.51293 2.62E-07 1.44E-05 
hsa-miR-200b-3p chr1 -7.306893 9.6681274 26.33481 2.87E-07 1.46E-05 
hsa-miR-127-3p chr14 -7.854096 8.3292901 26.14608 3.17E-07 1.50E-05 
hsa-miR-934 chrX -9.904999 7.1250306 25.82157 3.74E-07 1.65E-05 
hsa-miR-543 chr14 -9.50421 6.7074089 23.09731 1.54E-06 6.37E-05 
hsa-miR-493-5p chr14 -9.767545 6.9630524 22.87422 1.73E-06 6.74E-05 
hsa-miR-493-3p chr14 -8.744402 5.989907 22.46514 2.14E-06 7.87E-05 
hsa-miR-141-3p chr12 -8.88349 6.1602202 19.94271 7.98E-06 0.000278 
hsa-miR-200a-5p chr1 -7.128074 8.5440246 18.79742 1.45E-05 0.000481 
hsa-miR-200b-5p chr1 -9.051804 6.3275499 17.10568 3.54E-05 0.001115 
hsa-miR-134-5p chr14 -5.291734 5.8575744 16.06363 6.12E-05 0.001843 
hsa-miR-598-3p chr8 -7.79695 5.130604 15.69745 7.43E-05 0.002074 
hsa-miR-136-3p chr14 -7.862185 5.1749528 15.66054 7.58E-05 0.002074 
hsa-miR-382-5p chr14 -8.001095 5.2856901 15.5985 7.83E-05 0.002074 
hsa-miR-651-5p chrX -5.132838 5.7292055 15.49069 8.29E-05 0.002111 
hsa-miR-129-5p chr7, chr11 3.2518363 5.6992039 15.17975 9.77E-05 0.002397 
hsa-miR-125b-2-3p chr21 5.2439076 4.0085396 14.79464 0.0001199 0.002834 
hsa-miR-708-3p chr11 3.1357166 6.2904811 14.68159 0.0001273 0.002906 
hsa-miR-758-3p chr14 -7.722852 5.0327932 13.41604 0.0002495 0.005505 
hsa-miR-9-5p 
chr1, chr5, 
chr15 -7.625341 5.0040919 13.15851 0.0002862 0.006112 
hsa-miR-1185-1-3p chr14 -7.626848 4.9491223 13.0495 0.0003034 0.006276 
hsa-miR-323a-3p chr14 -7.706867 5.0110519 12.82824 0.0003414 0.006849 
hsa-miR-889-3p chr14 -7.657582 4.9656434 12.29348 0.0004545 0.00885 
hsa-miR-30a-5p chr6 2.0908475 11.791584 11.99622 0.0005331 0.010083 
hsa-miR-935 chr19 -7.221246 4.6260864 11.91707 0.0005562 0.010228 
hsa-miR-335-3p chr7 -2.401886 10.534727 11.65372 0.0006407 0.011464 
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hsa-miR-708-5p chr11 2.8279161 7.9699047 11.01502 0.0009038 0.015745 
hsa-miR-582-5p chr5 -4.663765 5.3218581 10.87422 0.0009751 0.016552 
hsa-miR-654-5p chr14 -7.078403 4.480912 10.64118 0.001106 0.018304 
hsa-miR-148a-3p chr7 -2.731018 11.115454 10.5735 0.0011472 0.018523 
hsa-miR-369-3p chr14 -7.087502 4.4846182 10.46925 0.0012138 0.019131 
hsa-miR-411-3p chr14 -7.069145 4.457903 9.893838 0.0016583 0.025531 
hsa-miR-323b-3p chr14 -6.990587 4.3909656 9.755046 0.0017883 0.026312 
hsa-miR-369-5p chr14 -6.783574 4.2410767 9.754758 0.0017886 0.026312 
hsa-miR-495-3p chr14 -6.931813 4.342174 9.656266 0.0018871 0.027157 
hsa-miR-944 chr3 -7.3065 4.7528396 9.220271 0.0023935 0.033713 
hsa-let-7g-3p chr3 5.1814771 2.4933962 8.805469 0.0030033 0.04142 
hsa-miR-629-5p chr15 -3.354367 8.0147785 8.766761 0.0030677 0.041445 
hsa-miR-299-3p chr14 -6.792964 4.2203811 8.727155 0.0031351 0.041508 
hsa-miR-744-5p chr17 -2.034339 11.254919 8.653361 0.0032646 0.042376 
hsa-miR-539-3p chr14 -6.453826 3.9675278 8.123694 0.004369 0.054924 
hsa-miR-1910-5p chr16 -6.40306 3.9506157 8.112041 0.0043972 0.054924 
hsa-miR-6501-5p chr21 3.7145808 2.9815034 7.93164 0.0048578 0.059553 
hsa-miR-129-1-3p chr7 3.7147703 2.9815034 7.892704 0.0049635 0.059742 
hsa-let-7d-5p chr9 -2.117487 12.677702 7.697619 0.0055294 0.065365 
hsa-miR-1294 chr5 -6.183616 3.785751 7.424735 0.0064333 0.073435 
hsa-miR-141-5p chr12 -4.338616 5.0556808 7.424577 0.0064339 0.073435 
hsa-miR-221-5p chrX 2.0848437 6.391886 7.267509 0.0070213 0.078408 
hsa-miR-375 chr2 -3.484342 5.1221568 7.245865 0.0071064 0.078408 
hsa-let-7i-5p chr12 2.2957013 16.715867 7.15418 0.0074789 0.081165 
hsa-miR-136-5p chr14 -5.973259 3.6134911 7.000483 0.0081488 0.087008 
hsa-miR-3664-5p chr11 4.7796309 2.3392565 6.891529 0.0086605 0.088204 
hsa-miR-4659a-3p chr8 4.7796309 2.3392565 6.891529 0.0086605 0.088204 
hsa-miR-4474-3p chr9 4.7796309 2.3392565 6.891529 0.0086605 0.088204 
hsa-miR-433-3p chr14 -6.379645 3.8789678 6.847639 0.0088758 0.089027 
hsa-miR-27b-5p chr9 2.1553767 7.4831288 6.703051 0.0096248 0.095099 
hsa-miR-4497 chr12 3.4964478 2.8726121 6.635261 0.009998 0.097044 
hsa-miR-377-3p chr14 -6.022918 3.6271826 6.614553 0.0101149 0.097044 
hsa-miR-656-3p chr14 -5.81706 3.486217 6.44361 0.0111352 0.105307 
hsa-miR-148a-5p chr7 -2.68988 6.2201689 6.34921 0.0117434 0.109494 
hsa-miR-485-3p chr14 -5.942797 3.5629937 6.262382 0.0123328 0.113393 
hsa-miR-376c-3p chr14 -5.580185 3.3305671 6.153677 0.0131139 0.118923 
hsa-miR-409-5p chr14 -5.599274 3.335382 6.021738 0.0141307 0.124565 
hsa-miR-618 chr12 -5.713739 3.4582101 6.000672 0.0143004 0.124565 
hsa-let-7i-3p chr12 2.0009366 7.1859608 6.000656 0.0143006 0.124565 
hsa-miR-329-3p chr14 -5.529089 3.3161719 5.974179 0.0145168 0.124807 
hsa-miR-556-3p chr1 -5.287797 3.1518639 5.703965 0.0169266 0.14201 
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hsa-miR-23a-5p chr19 -3.097498 4.7759874 5.701871 0.0169468 0.14201 
hsa-miR-487b-3p chr14 -5.395773 3.2316274 5.629107 0.0176646 0.146175 
hsa-miR-582-3p chr5 -2.54518 7.1206987 5.599272 0.0179679 0.146723 
hsa-miR-16-5p chr13 1.4235721 11.038119 5.579287 0.0181741 0.146723 
hsa-miR-23b-3p chr9 1.9573244 8.1018797 5.502409 0.0189903 0.151465 
hsa-miR-3614-5p chr17 2.531968 4.3894983 5.402201 0.0201114 0.158497 
hsa-miR-410-3p chr14 -5.90353 3.5050319 5.272944 0.0216594 0.168688 
hsa-miR-203a-3p chr14 -3.172983 7.09839 5.211115 0.0224429 0.172758 
hsa-miR-382-3p chr14 -5.184408 3.0717108 5.080347 0.0241985 0.184131 
hsa-miR-193a-5p chr17 1.740287 8.660351 5.042799 0.0247285 0.186026 
hsa-miR-296-3p chr20 -2.306024 7.6343258 4.976608 0.0256923 0.191105 
hsa-miR-4521 chr17 -5.209988 3.0767387 4.881817 0.027141 0.199637 
hsa-miR-4683 chr10 -5.222587 3.1371223 4.794656 0.0285482 0.202498 
hsa-miR-181c-5p chr19 2.4671956 3.9411375 4.747547 0.0293401 0.202498 
hsa-miR-3127-3p chr2 -4.989542 2.9651669 4.739435 0.0294787 0.202498 
hsa-miR-17-3p chr13 1.6773977 6.7237412 4.731572 0.0296138 0.202498 
hsa-miR-1268b chr17 4.2206945 2.1671304 4.720934 0.0297975 0.202498 
hsa-miR-204-5p chr9 4.2206945 2.1671304 4.720934 0.0297975 0.202498 
hsa-let-7c-3p chr9, chr22 4.2206945 2.1671304 4.720934 0.0297975 0.202498 
hsa-miR-337-3p chr14 -5.00872 2.9702526 4.698453 0.0301898 0.202498 
hsa-miR-338-5p chr17 -4.972073 2.9600919 4.691358 0.0303147 0.202498 
hsa-miR-3929 chr18 -5.733861 3.5123903 4.675896 0.0305888 0.202498 
 
 
 
 
93 
 
 
 
0
5
10
15
20
25
30
35
40
45
C
h
ro
m
o
so
m
e
 1
4
C
h
ro
m
o
so
m
e
 1
2
C
h
ro
m
o
so
m
e
 1
C
h
ro
m
o
so
m
e
 5
C
h
ro
m
o
so
m
e
 9
C
h
ro
m
o
so
m
e
 1
7
C
h
ro
m
o
so
m
e
 7
C
h
ro
m
o
so
m
e
 1
1
C
h
ro
m
o
so
m
e
 1
9
C
h
ro
m
o
so
m
e
 X
C
h
ro
m
o
so
m
e
 2
1
C
h
ro
m
o
so
m
e
 1
5
C
h
ro
m
o
so
m
e
 1
3
C
h
ro
m
o
so
m
e
 8
C
h
ro
m
o
so
m
e
 3
C
h
ro
m
o
so
m
e
 2
C
h
ro
m
o
so
m
e
 2
2
C
h
ro
m
o
so
m
e
 2
0
C
h
ro
m
o
so
m
e
 1
8
C
h
ro
m
o
so
m
e
 1
6
C
h
ro
m
o
so
m
e
 1
0
C
h
ro
m
o
so
m
e
 6
C
h
ro
m
o
so
m
e
 2
3
C
h
ro
m
o
so
m
e
 Y
C
h
ro
m
o
so
m
e
 4
Differential Expression M2182 vs P69 (100)
N
u
m
b
er
o
f 
m
iR
s
A)
Chromosome 
14
51%
Chromosome 1
9%
Chromosome 5
7%
Chromosome 12
5%
Others
28%
DOWNREGULATED MIRNAS M2182 VS P69 
(74)
B)
 
94 
 
 
Figure 11: The chromosomal representation of dysregulated miRNAs between the P69 and 
M2182 cell lines. A) A bar graph representing the total numbers of dysregulated miRNAs (both 
upregulated and downregulated) between the P69 and M2182 cell lines segregated by the 
chromosomal location. It can immediately be seen that the vast majority of dysregulated 
miRNAs lie on chromosome 14. B) A pie graph of only downregulated miRNAs demonstrates 
that a majority lie on chromosome 14 (51%). C) A pie graph of only upregulated miRNAs 
demonstrates a much more even distribution of dysregulated miRNAs between chromosomes. 
Considering both B and C, we can see that overall there are almost 3 times as many 
downregulated miRNAs (74) as there are upregulated miRNAs (26).   
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By far the largest number of dysregulated miRNAs come from chromosome 14 (39) and it 
should be pointed out that not a single one of these is upregulated. This phenomenon persisted in 
all of the other cell lines. 
 
Table 17: Sequencing Results M12 
Gene Name Chromosome logFC logCPM LR PValue FDR 
hsa-miR-675-5p chr11 10.48098 6.3352868 56.85745 4.69E-14 3.10E-11 
hsa-miR-34a-5p chr1 5.888364 8.7589316 46.10263 1.12E-11 3.71E-09 
hsa-miR-370-3p chr14 -9.48895 8.659433 35.48923 2.56E-09 5.66E-07 
hsa-miR-493-3p chr14 -9.3606 5.9076875 32.8014 1.02E-08 1.35E-06 
hsa-miR-127-3p chr14 -8.33681 8.377626 32.79676 1.02E-08 1.35E-06 
hsa-miR-493-5p chr14 -10.3842 6.955522 32.16034 1.42E-08 1.57E-06 
hsa-miR-598-3p chr8 -8.4122 4.9548096 24.67561 6.78E-07 5.75E-05 
hsa-miR-136-3p chr14 -8.47713 5.0025315 24.63068 6.94E-07 5.75E-05 
hsa-miR-654-3p chr14 -5.64906 7.3934053 22.61502 1.98E-06 0.000146 
hsa-miR-375 chr2 3.875028 8.0789744 20.23177 6.86E-06 0.000454 
hsa-miR-1250-5p chr17 5.621295 4.6057246 19.64089 9.34E-06 0.000562 
hsa-miR-409-3p chr14 -5.04411 7.2955072 18.90595 1.37E-05 0.000758 
hsa-miR-654-5p chr14 -7.69118 4.2170658 17.79949 2.45E-05 0.00125 
hsa-miR-134-5p chr14 -4.28 5.7937288 17.55702 2.79E-05 0.00126 
hsa-miR-1257 chr20 4.664937 4.5637498 17.51255 2.85E-05 0.00126 
hsa-miR-1269a chr4 4.749274 4.630331 17.24964 3.28E-05 0.001356 
hsa-miR-147b chr15 3.55611 5.7494634 16.33096 5.32E-05 0.002071 
hsa-miR-381-3p chr14 -3.89591 9.838635 15.70913 7.39E-05 0.002717 
hsa-miR-590-5p chr7 7.001886 3.4677385 14.50294 0.00014 0.004876 
hsa-miR-411-5p chr14 -4.10567 7.8055164 14.29948 0.000156 0.005161 
hsa-miR-95-3p chr4 2.77126 6.3715901 14.09168 0.000174 0.005489 
hsa-miR-9-5p 
chr1, chr5, 
chr15 3.017321 7.3062746 13.10485 0.000295 0.008658 
hsa-miR-136-5p chr14 -6.58187 3.2398911 13.06526 0.000301 0.008658 
hsa-miR-16-2-3p chr3 -2.9334 11.075447 12.89995 0.000329 0.009064 
hsa-miR-548ar-3p chr13 6.476366 3.09203 12.52451 0.000402 0.010393 
hsa-miR-4421 chr1 6.476366 3.09203 12.48961 0.000409 0.010393 
hsa-miR-424-3p chrX -3.18094 10.243336 12.42388 0.000424 0.010393 
hsa-miR-191-3p chr3 -3.46682 5.4169411 12.23556 0.000469 0.011086 
hsa-let-7f-1-3p chr9 -3.99859 4.5650288 11.95661 0.000545 0.012308 
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hsa-miR-196a-5p chr17 2.820411 8.1780643 11.91188 0.000558 0.012308 
hsa-miR-656-3p chr14 -6.42394 3.0954587 11.7599 0.000605 0.012604 
hsa-miR-411-3p chr14 -5.12293 4.2162943 11.74745 0.000609 0.012604 
hsa-miR-433-3p chr14 -6.9885 3.5322098 11.61041 0.000656 0.013156 
hsa-miR-382-5p chr14 -3.94655 5.1898311 11.36491 0.000748 0.014573 
hsa-miR-485-3p chr14 -6.54944 3.1794872 11.16467 0.000834 0.015769 
hsa-miR-379-5p chr14 -3.37206 7.8662884 11.08155 0.000872 0.016033 
hsa-miR-301b-3p chr22 3.474327 4.8391433 10.97718 0.000922 0.016504 
hsa-miR-3065-5p chr17 4.631569 3.6242743 10.86462 0.00098 0.017076 
hsa-miR-487b-3p chr14 -6.00228 2.8186083 10.75552 0.00104 0.017406 
hsa-miR-369-3p chr14 -4.26928 4.2734684 10.68631 0.001079 0.017406 
hsa-miR-10a-5p chr17 2.304609 13.258105 10.6622 0.001093 0.017406 
hsa-miR-548ah-3p chr4 3.349915 4.6115115 10.64398 0.001104 0.017406 
hsa-miR-323b-3p chr14 -4.83247 4.1473728 10.54316 0.001166 0.017954 
hsa-miR-3664-5p chr11 6.013099 2.7836886 10.37589 0.001277 0.019209 
hsa-miR-184 chr15 3.087705 4.8152331 10.24206 0.001373 0.020195 
hsa-miR-944 chr3 -5.36328 4.555844 10.04392 0.001529 0.021997 
hsa-miR-152-3p chr17 2.315802 9.1330732 9.628353 0.001916 0.02691 
hsa-miR-382-3p chr14 -5.78871 2.6370488 9.594902 0.001951 0.02691 
hsa-miR-337-3p chr14 -5.61139 2.5264609 9.041296 0.002639 0.03566 
hsa-miR-576-3p chr4 2.469907 5.29373 8.997121 0.002704 0.035779 
hsa-miR-338-3p chr17 -5.42373 2.4247609 8.958831 0.002761 0.035779 
hsa-miR-199a-3p chr19 3.081538 4.3007655 8.926641 0.00281 0.035779 
hsa-miR-323a-3p chr14 -3.70565 4.8942093 8.778075 0.003049 0.03808 
hsa-miR-98-3p chr8 -5.41038 2.4082323 8.648416 0.003273 0.04013 
hsa-miR-2682-5p chr1 2.407057 7.2944211 8.566853 0.003423 0.041205 
hsa-let-7d-3p chr9 -3.43439 7.5190379 8.393942 0.003765 0.044505 
hsa-miR-122-5p chr18 -4.44091 3.0241506 8.331172 0.003897 0.04526 
hsa-miR-328-3p chr16 -3.14837 5.5455648 8.291738 0.003983 0.045456 
hsa-miR-597-3p chr8 3.893616 3.3102441 8.251362 0.004072 0.045691 
hsa-miR-548ao-3p chr8 5.492478 2.4685463 8.212879 0.004159 0.045863 
hsa-miR-372-3p chr19 3.865788 3.2594223 8.175138 0.004247 0.045863 
hsa-miR-4659a-3p chr8 5.492478 2.4685463 8.154538 0.004295 0.045863 
hsa-miR-3691-5p chr16 5.492478 2.4685463 8.097273 0.004433 0.046177 
hsa-miR-485-5p chr14 -5.43541 2.4123409 8.084636 0.004464 0.046177 
hsa-miR-369-5p chr14 -3.42558 4.0415502 7.964503 0.00477 0.047314 
hsa-miR-196a-3p chr12 3.483345 3.6823701 7.958197 0.004787 0.047314 
hsa-miR-187-3p chr18 3.824204 3.2629259 7.957606 0.004789 0.047314 
hsa-miR-548u chr6 2.136299 6.0780429 7.863472 0.005044 0.048622 
hsa-miR-548o-3p chr7 2.632128 4.7902015 7.855073 0.005068 0.048622 
hsa-miR-377-3p chr14 -4.07126 3.3063933 7.670454 0.005613 0.052389 
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hsa-miR-573 chr4 2.533832 4.8411543 7.662799 0.005637 0.052389 
hsa-miR-3127-5p chr2 3.327382 3.5737832 7.643444 0.005698 0.052389 
hsa-miR-490-3p chr7 -5.16585 2.2770809 7.567163 0.005944 0.053257 
hsa-miR-579-3p chr5 3.715198 3.1590142 7.480956 0.006235 0.053257 
hsa-miR-495-3p chr14 -3.57425 4.1461033 7.430418 0.006413 0.053257 
hsa-miR-543 chr14 -2.77738 6.8061615 7.419707 0.006451 0.053257 
hsa-miR-126-3p chr9 1.792786 12.074767 7.415971 0.006465 0.053257 
hsa-miR-125b-5p chr11, chr21 -2.11366 12.478931 7.412455 0.006477 0.053257 
hsa-miR-127-5p chr14 -5.20605 2.2852835 7.392657 0.006549 0.053257 
hsa-miR-539-3p chr14 -3.63397 3.7168493 7.387283 0.006569 0.053257 
hsa-miR-23a-5p chr19 -3.00936 4.6082631 7.385263 0.006576 0.053257 
hsa-miR-10a-3p chr17 2.230213 7.2016388 7.379602 0.006597 0.053257 
hsa-let-7b-3p chr9 -2.58209 5.2834221 7.30702 0.006869 0.054319 
hsa-miR-296-3p chr20 -2.67863 7.6420561 7.300799 0.006892 0.054319 
hsa-miR-450b-5p chrX 2.147228 7.6617199 7.251046 0.007086 0.055187 
hsa-let-7f-2-3p chrX -2.46118 5.4015447 7.197493 0.007301 0.056197 
hsa-miR-128-3p chr2, chr3 -2.03285 11.215315 7.111267 0.00766 0.057844 
hsa-miR-148b-3p chr12 1.784121 10.907865 7.104476 0.007689 0.057844 
hsa-miR-329-3p chr14 -3.57835 2.979897 7.02224 0.00805 0.059505 
hsa-miR-125b-2-3p chr21 3.593308 3.1091984 7.013499 0.00809 0.059505 
hsa-let-7a-3p chr9, chr22 -2.21176 6.9095419 6.878635 0.008723 0.063459 
hsa-miR-181a-2-3p chr9 -2.13046 10.342785 6.852166 0.008853 0.063706 
hsa-miR-2682-3p chr1 3.336262 3.6144046 6.758249 0.009332 0.066424 
hsa-miR-3129-3p chr2 -4.93673 2.1479022 6.696228 0.009662 0.066532 
hsa-miR-15b-5p chr3 1.825168 10.230745 6.669626 0.009807 0.066532 
hsa-miR-92a-1-5p chr13 -2.438 8.2641077 6.654721 0.009889 0.066532 
hsa-miR-758-3p chr14 -2.84456 4.9815014 6.647138 0.009932 0.066532 
hsa-miR-6866-5p chr17 5.139035 2.2762212 6.646976 0.009932 0.066532 
hsa-miR-642a-5p chr19 5.139035 2.2762212 6.643882 0.00995 0.066532 
hsa-miR-512-3p chr19 5.139035 2.2762212 6.613384 0.010122 0.067004 
hsa-miR-3116 chr1 5.139035 2.2762212 6.579103 0.010318 0.067631 
hsa-miR-3200-3p chr22 3.353912 2.9303525 6.443731 0.011134 0.072265 
hsa-miR-33a-3p chr22 2.766316 3.9288706 6.364888 0.01164 0.074813 
hsa-miR-148a-3p chr7 1.935925 12.639621 6.345345 0.011769 0.074914 
hsa-miR-1185-1-3p chr14 -2.74844 4.8972821 6.264789 0.012316 0.07765 
hsa-miR-431-3p chr14 -4.96702 2.1520145 6.236076 0.012517 0.078174 
hsa-miR-548e-3p chr10 1.857489 5.7167086 6.206615 0.012727 0.078743 
hsa-miR-339-3p chr7 -2.11746 9.259144 6.137829 0.013232 0.081107 
hsa-miR-1910-5p chr16 -3.04462 3.7401283 6.048531 0.013918 0.084529 
hsa-miR-3940-5p chr19 -5.52255 2.4205882 5.964598 0.014596 0.087295 
hsa-miR-3139 chr4 4.923451 2.1681413 5.959638 0.014637 0.087295 
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hsa-miR-570-3p chr3 4.923451 2.1681413 5.886894 0.015254 0.090162 
hsa-miR-3170 chr13 4.923451 2.1681413 5.866616 0.015431 0.090399 
hsa-miR-548k chr11 1.894143 8.2768119 5.796123 0.016062 0.09327 
hsa-miR-3677-3p chr16 2.475676 4.2133491 5.723648 0.016738 0.096149 
hsa-miR-889-3p chr14 -2.7791 4.9132735 5.712154 0.016848 0.096149 
hsa-miR-7-1-3p chr9 1.764288 6.1247875 5.606257 0.017896 0.10126 
hsa-miR-618 chr12 2.138383 4.9344568 5.476391 0.019275 0.107284 
hsa-miR-224-5p chrX -1.94772 6.9168376 5.475387 0.019286 0.107284 
hsa-miR-556-3p chr1 2.211928 4.6062099 5.460845 0.019447 0.107284 
hsa-miR-7-5p 
chr9, chr15, 
chr19 1.743322 9.0592988 5.406258 0.020065 0.109775 
hsa-miR-365a-5p chr16 1.712045 6.8402291 5.371329 0.02047 0.110186 
hsa-miR-1185-2-3p chr14 -5.06289 2.1753721 5.371133 0.020473 0.110186 
hsa-miR-643 chr19 3.135802 2.7983221 5.334908 0.020902 0.111592 
hsa-miR-520g-3p chr19 4.669893 2.0502485 5.202568 0.022554 0.119373 
hsa-miR-3131 chr2 4.669893 2.0502485 5.166451 0.023027 0.119373 
hsa-miR-597-5p chr8 3.100262 2.8020182 5.16341 0.023068 0.119373 
hsa-miR-195-5p chr17 4.669893 2.0502485 5.159725 0.023117 0.119373 
hsa-miR-9-3p 
chr1, chr5, 
chr15 2.620518 3.5080849 5.148871 0.023261 0.119373 
hsa-miR-34c-5p chr11 -1.9367 5.545866 5.093011 0.024022 0.122091 
hsa-miR-363-3p chrX -1.79728 6.3615813 5.083104 0.02416 0.122091 
hsa-miR-374a-3p chrX 1.696491 8.7016884 4.976214 0.025698 0.12888 
hsa-miR-376c-3p chr14 -2.75651 3.0566237 4.842516 0.027766 0.138205 
hsa-miR-1303 chr5 2.000339 4.6920058 4.748333 0.029327 0.144883 
hsa-miR-449c-5p chr5 2.112273 4.3874344 4.731084 0.029622 0.145259 
hsa-miR-299-3p chr14 -2.73452 4.0777917 4.712507 0.029944 0.14528 
hsa-miR-503-3p chrX -2.59151 3.727045 4.705543 0.030066 0.14528 
hsa-miR-409-5p chr14 -2.77587 3.0606133 4.605431 0.031871 0.152078 
hsa-miR-30b-5p chr8 1.513539 10.100684 4.602152 0.031932 0.152078 
hsa-miR-1278 chr1 1.677183 7.1805861 4.587985 0.032197 0.152245 
hsa-miR-580-3p chr5 2.49057 3.4251131 4.5718 0.032502 0.1526 
hsa-miR-1293 chr12 -2.64721 3.4468847 4.517648 0.033547 0.156395 
hsa-miR-6511b-3p chr16 -4.24142 1.8420774 4.436395 0.03518 0.159676 
hsa-miR-148b-5p chr12 1.663716 7.2717588 4.431588 0.03528 0.159676 
hsa-miR-1268b chr17 4.362065 1.920639 4.422736 0.035463 0.159676 
hsa-miR-5000-3p chr2 4.362065 1.920639 4.422736 0.035463 0.159676 
hsa-miR-3136-5p chr3 4.362065 1.920639 4.422736 0.035463 0.159676 
hsa-miR-1294 chr5 -2.43317 3.6137166 4.411475 0.035698 0.159676 
hsa-miR-4517 chr16 -4.21201 1.8338735 4.3789 0.036386 0.161663 
hsa-miR-224-3p chrX -2.05186 4.832077 4.353778 0.036927 0.162147 
hsa-miR-146a-3p chr5 -4.19767 1.8297875 4.351093 0.036985 0.162147 
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hsa-miR-340-3p chr5 1.569211 5.7601478 4.330719 0.03743 0.163019 
hsa-miR-138-5p chr3, chr16 -2.13388 6.5033582 4.267339 0.038852 0.168104 
hsa-miR-26a-2-3p chr12 -2.21646 4.1429851 4.207465 0.040246 0.173007 
hsa-miR-590-3p chr7 1.563978 7.111982 4.189975 0.040664 0.173673 
hsa-miR-3935 chr16 -2.81498 2.4975099 4.151213 0.041605 0.176553 
hsa-miR-151a-3p chr8 1.430195 10.844449 4.116336 0.042471 0.178699 
hsa-miR-138-1-3p chr3 -2.79921 3.9424093 4.10921 0.04265 0.178699 
hsa-miR-1272 chr15 2.478951 3.0055759 4.038241 0.04448 0.185194 
hsa-miR-137 chr1 1.655684 6.9304506 3.971105 0.046287 0.191514 
hsa-miR-374b-3p chrX 1.506554 7.4790533 3.876637 0.048963 0.201324 
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Figure 12: The chromosomal representation of dysregulated miRNAs between the P69 and M12 
cell lines. A) A bar graph representing the total numbers of dysregulated miRNAs (both 
upregulated and downregulated) between the P69 and M12 cell lines segregated by the 
chromosomal location. The dysregulation of miRNAs on chromosome 14 can be seen to persist 
into this cell line from its immediate parent, the M2182 cell line. We can also see that the total 
number of dysregulated miRNAs in this cell line has increase by a 61% compared to its 
predecessor. B) A pie graph of only downregulated confirms that this trend. We can also see in B 
that the overall number of downregulated miRNAs in the M12 cell line is roughly the same as in 
the M2182 cell line (79 and 74 respectively). Despite losing a portion of chromosome 19, the 
number of dysregulated miRNAs encoded there is still comparable to M2182 levels. C) A pie 
graph of only upregulated miRNAs demonstrates that while distribution of dysregulated 
miRNAs between chromosomes is still relatively even, the overall number of upregulated 
miRNAs in the M12 (82) is more than 3 times the number of upregulated miRNAs in the M2182 
cell line (26). 
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Here in the M12 cells we can see the number of downregulated miRNAs is comparable to 
the M2182 cell line (79 vs 74 respectively), and yet a there is a three-fold increase in upregulated 
miRNAs (82 vs 26 respectively). This is concomitant with the loss of chromosomes Y and 19p 
and with the acquisition of aggressiveness and the ability to form metastases. 
It can be seen here that the downregulation of miRNAs on chromosome 14 persists into 
the M12 cells. Concomitant with the loss of chromosome 19p, the number of overall miRNAs on 
this chromosome has become slightly more significant, but there are as many upregulated as 
there are down regulated. This suggests that the loss of classical tumor suppressor genes encoded 
here may be of superior importance to prostate cancer progression than any putative tumor 
suppressor miRNAs. The number of miRNAs downregulated on chromosome Y is still zero, 
despite having lost this chromosome. This confirms that its established tumor suppressive effects 
on prostate cancer cell lines is not likely to have to do with any tumor suppressive miRNAs it 
might harbor.  
Table 18: P69 vs F6 
Gene Name Chromosome logFC logCPM LR PValue FDR 
hsa-miR-34a-5p chr1 5.28694 8.1245389 42.30434 7.81E-11 1.83E-08 
hsa-miR-1269a chr4 6.65214 6.1098223 42.19116 8.28E-11 1.83E-08 
hsa-miR-675-5p chr11 8.10835 4.4516836 23.98414 9.71E-07 4.59E-05 
hsa-miR-505-3p chrX 3.61660 6.2455042 19.62687 9.41E-06 0.000389 
hsa-miR-125b-2-3p chr21 5.33109 4.2350748 16.56261 4.71E-05 0.001558 
hsa-miR-10b-5p chr2 3.04822 11.270945 16.41801 5.08E-05 0.001601 
hsa-miR-199a-3p chr19 4.17014 4.969716 16.26473 5.51E-05 0.001657 
hsa-miR-196a-5p chr17 3.23062 8.4314117 16.07379 6.09E-05 0.001753 
hsa-miR-10a-5p chr17 2.41095 13.282397 14.04539 0.000178 0.004219 
hsa-let-7i-5p chr12 1.85346 16.45271 13.74265 0.00021 0.004786 
hsa-miR-361-3p chrX 2.80688 8.5085082 13.1887 0.000282 0.005826 
hsa-miR-1250-5p chr17 4.87268 3.8831863 12.97187 0.000316 0.006342 
hsa-miR-139-5p chr11 3.39115 5.1520331 12.91645 0.000326 0.006342 
hsa-miR-642a-5p chr19 6.08884 2.9559976 12.67369 0.000371 0.007014 
hsa-miR-195-5p chr17 6.08884 2.9559976 12.60353 0.000385 0.00708 
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hsa-miR-99a-5p chr21 2.54264 7.1774488 11.59852 0.00066 0.010162 
hsa-miR-664a-3p chr1 2.88991 5.7458885 11.40007 0.000734 0.01105 
hsa-miR-30a-5p chr6 2.07473 11.818727 10.46181 0.001219 0.016135 
hsa-miR-449c-5p chr5 3.11206 4.9415651 10.01221 0.001555 0.019797 
hsa-miR-221-5p chrX 2.32529 6.6357527 9.819883 0.001726 0.021563 
hsa-miR-1245a chr2 5.58332 2.6647987 9.411507 0.002156 0.025954 
hsa-miR-148a-3p chr7 2.07778 12.681966 8.136702 0.004338 0.045033 
hsa-miR-187-3p chr18 3.88489 3.203581 8.130102 0.004354 0.045033 
hsa-miR-181c-5p chr19 2.91202 4.3529279 7.824303 0.005155 0.04875 
hsa-miR-10a-3p chr17 2.14456 7.0650517 7.670906 0.005612 0.050891 
hsa-miR-130a-3p chr11 2.00606 7.6840626 7.53043 0.006067 0.05334 
hsa-miR-3200-3p chr22 3.66418 3.0439327 7.490012 0.006204 0.05334 
hsa-miR-152-3p chr17 2.07854 8.9084374 7.447926 0.006351 0.053346 
hsa-miR-590-5p chr7 5.10988 2.4297758 7.443662 0.006366 0.053346 
hsa-miR-548ao-3p chr8 5.10988 2.4297758 7.418374 0.006456 0.053424 
hsa-miR-509-3-5p chrX 5.10988 2.4297758 7.392172 0.006551 0.053539 
hsa-miR-4421 chr1 5.10988 2.4297758 7.344333 0.006727 0.054312 
hsa-miR-10b-3p chr2 3.07171 4.0258038 7.210032 0.00725 0.056463 
hsa-miR-224-5p chrX 1.97105 8.2978289 6.989162 0.0082 0.063125 
hsa-miR-2682-5p chr1 2.07079 6.9817644 6.873096 0.00875 0.065826 
hsa-miR-196a-3p chr12 3.26264 3.41058 6.851355 0.008857 0.065883 
hsa-miR-16-5p chr3, chr13 1.77086 11.285314 6.708965 0.009593 0.069786 
hsa-miR-184 chr15 2.58788 4.3264753 6.239362 0.012494 0.087064 
hsa-miR-195-3p chr17 2.65931 4.1834736 6.214046 0.012674 0.087072 
hsa-miR-2682-3p chr1 3.21916 3.4147977 6.202327 0.012758 0.087072 
hsa-miR-6500-3p chr1 3.31461 2.8733581 6.144557 0.013182 0.088263 
hsa-miR-597-3p chr8 3.31459 2.8733581 6.142171 0.0132 0.088263 
hsa-miR-3065-5p chr17 3.38240 2.7541336 5.814981 0.01589 0.101855 
hsa-miR-3127-5p chr2 2.91935 3.2066061 5.636264 0.017593 0.109871 
hsa-miR-452-5p chrX 1.59653 11.241521 5.557691 0.0184 0.113097 
hsa-miR-95-3p chr4 1.95871 5.7080952 5.542424 0.018561 0.113097 
hsa-miR-365a-5p chr16 1.71798 6.7675464 5.473446 0.019308 0.113111 
hsa-miR-374a-3p chrX 1.77063 8.6879929 5.339528 0.020847 0.116626 
hsa-miR-338-5p chr17 2.33324 4.2922706 5.324789 0.021024 0.116626 
hsa-miR-579-3p chr5 3.15774 2.7721097 5.240973 0.022061 0.116626 
hsa-miR-4691-3p chr11 4.40050 2.1466227 5.202834 0.02255 0.116626 
hsa-miR-3691-5p chr16 4.40050 2.1466227 5.202834 0.02255 0.116626 
hsa-miR-5000-3p chr2 4.40050 2.1466227 5.202834 0.02255 0.116626 
hsa-let-7g-3p chr3 4.40050 2.1466227 5.202834 0.02255 0.116626 
hsa-miR-943 chr4 4.40050 2.1466227 5.202834 0.02255 0.116626 
hsa-miR-96-3p chr7 4.40050 2.1466227 5.202834 0.02255 0.116626 
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hsa-miR-4474-3p chr9 4.40050 2.1466227 5.202834 0.02255 0.116626 
hsa-miR-1298-5p chrX 4.40050 2.1466227 5.202834 0.02255 0.116626 
hsa-miR-374c-5p chrX 1.73857 8.7752367 5.129653 0.02352 0.119773 
hsa-miR-548a-3p chr6, chr8 3.12410 2.7767159 5.109919 0.023789 0.120218 
hsa-miR-618 chr12 2.18522 4.8465448 4.956013 0.026 0.126295 
hsa-miR-15b-5p chr3 1.61895 10.047672 4.801022 0.028443 0.136443 
hsa-miR-664b-3p chrX 2.63479 3.0514968 4.765006 0.029044 0.138191 
hsa-miR-126-3p chr9 1.40233 11.787279 4.74413 0.029398 0.138191 
hsa-miR-1257 chr20 2.63470 3.0514968 4.742083 0.029433 0.138191 
hsa-let-7c-5p chr21 1.55967 9.2199826 4.572925 0.032481 0.149323 
hsa-miR-374a-5p chrX 1.60071 8.875408 4.493051 0.034033 0.155378 
hsa-let-7g-5p chr3 1.13731 15.427259 4.292813 0.038274 0.165603 
hsa-miR-454-3p chr17 1.75129 5.1928679 4.120601 0.042364 0.18211 
hsa-miR-4664-3p chr8 2.36334 4.2477801 4.095113 0.043007 0.183683 
hsa-miR-548ah-3p chr4 2.28859 3.7609821 4.058521 0.043949 0.184141 
hsa-miR-137 chr1 1.63693 6.8443564 3.993441 0.045678 0.188991 
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Figure 13: The chromosomal representation of dysregulated miRNAs between the P69 and F6 
cell lines. A) A bar graph representing the total numbers of dysregulated miRNAs (both 
upregulated and downregulated) between the P69 and F6 cell lines segregated by the 
chromosomal location. The dysregulation of miRNAs on chromosome 14 can be seen to persist 
into this cell line as is has in both the M2182 and M12 cell lines. We can also see that the total 
number of dysregulated miRNAs in this cell line is almost the same as its immediate predecessor 
the M12 cell line (162 and 161 respectively). B) A pie graph of only downregulated miRNAs 
confirms that the suppression of miRNAs on chromosome 14 persists. We can also see in B that 
the overall number of downregulated miRNAs in the F6 cell line has increase to 90 from the 79 
exhibited by the M12 cell line, despite the addition of a new chromosome 19. C) A pie graph of 
only upregulated miRNAs demonstrates that while distribution of dysregulated miRNAs between 
chromosomes is still relatively even, the overall number of upregulated miRNAs in the F6 (72) is 
slightly decreased compared to the M12 cell line (82). 
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Chromosome 19 harbors the largest cluster of miRNAs encoded in the human genome at 
19q13.41. The Chromosome 19 megacluster (C19MC) harbors 46 miRNA genes whose 
expression is largely restricted to the placenta. Eight of these miRNAs have been demonstrated 
to target p21, a positive regulator of the cell cycle. It was also demonstrated that ectopic 
expression of a handful of these miRs resulted in G1 accumulation.51 The portion of 
chromosome 19 that is lost in the M12 cell line does not include this area which therefore 
remains diploid. When a whole chromosome 19 is introduced to produce the F6 cell lines, this 
area becomes triploid. It is tempting to assume that the increased presence of this tumor 
suppressor encoding DNA accounts for the decreased tumorigenicity of the F6 compared to the 
M12 cell line, but the above F6 profile demonstrates that this is not the case as no large influx of 
expression on chromosome 19 is observed. It seems that in both this cell line and in the chr19 
donor cell line, this giant miRNA cluster is effectively permanently silenced. 
 
Table 19: Overall Sequencing Summary of miR expression in the parental p69 Cells 
compared to its subsequent variants 
Cell Line (vs P69) M2182 M12 F6 
Upregulated 26 82 72 
Downregulated -74 -79 -90 
Ratio 0.35 1.04 0.80 
Tumors formed in 
mice39.40 2/3 13/13 6/15 
 
 One long recognized maxim of tumor biology is that tumor suppressors are more 
important to lose than oncogenes are to gain. This table illustrates that in the first step of this 
tumor progression model, tumorigenesis begins with a lasting knockdown of a large number of 
miRNAs. One of the most inscrutable things about prostate cancer is that, where in other cancers, 
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Dicer1 is usually downregulated, in prostate cancer Dicer1 is upregulated and the degree of this 
upregulation correlates with Gleason score.80 In this case we detect a large number of miRs that 
are downregulated between M2182 and M12 compared to parental p69.  On the other hand, there 
is a tremendous increase in the number of miRNAs that are upreguated (82) in the M12 cell line 
and only 26 in its immediate precursor M2181 with a slight decrease of only 10 in the F6 cell 
line.  There results demonstrate that the acquisition of aggressiveness and metastasis in the late 
stage of a prostate cancer progression model is concomitant with massive upregulation of a select 
group of miRNAs that may function as oncomiRs. 
 
Discussion  
 
SNP Analysis  
Since most seminal mutations that lead to prostate cancer later in life are actually 
acquired during the rapid expansion of this tissue during puberty, it cannot be assumed with 
certainty that each of the above SNPs were with this patient from birth. However, these are the 
SNPs present in the “normal” prostate epithelium taken from the patient before immortalization. 
After an exhaustive search in the literature, it was determined that the specific base changes 
reported by the SNP analysis were not likely to have effected tumorigenesis in a meaningful 
way.  
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The Early Downregulated miRs  
The Chromosome 14 Cluster  
Upon investigation, it was discovered that all of the miRNAs from chromosome 14 that 
are suppressed in the M2182, M12, and F6 cell lines are all located within the same paternally 
imprinted region of chromosome 14 referred to in humans as the Dlk-Dio3 area.93 This area is a 
highly conserved region important to the development of mice and humans as demonstrated by 
the extreme phenotypes of altered gene dosages. This cluster also been dubbed the largest 
miRNA tumor suppressor cluster in mammals, the dysregulation of which plays an important 
role on the acquisition and maintenance of stemness, the EMT, and on metastasis to bone in 
prostate cancer.24 Other cancers in which this entire cluster has been demonstrated to be silenced 
include gastrointestinal tumors, gliomas, neuroblastomas, ovarian cancer, and melanomas.93 Our 
TGCA analysis confirms that on average, every single miRNA in this cluster is downregulated in 
tumors vs. normal epithelium. However the degree of this downregulation is variable between 
miRNAs, suggesting that some are suppressed more often than others. In fact, one miRNA, 
544b-5p, seems to be upregulated, but this effect does not reach significance. 
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Figure 14: Suppression of the Dlk-Dio3 megacluster in prostate cancer. A) Dlk-Dio3 
Megacluster Expression in Tumors vs Matched Normal Epithelium. B) Dlk-Dio3 Megacluster 
Expression in the P69 cell line vs the M2182 cell line. See tables 25 and 26 in the appendix for 
detailed legends. It should be noted that in the TGCA analysis (A), both arms of each miRNA 
are combined and reported as a single value while our sequencing data (B) reports on them 
separately. Light coloring implies a lack of statistical significance. 
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The regulation of imprinting for these genes is maintained by the maternal copy of an 
intergenic differentially methylated region (IG-DMR) centromeric to the cluster and to a lesser 
extent by a similar region telomeric to the cluster called MEG3-DMR. Uniparental disomy 
studies have demonstrated that these two regions alternatively control imprinting of the cluster in 
different parts to the body, with the IG-DMR being vastly dominant.93 Interestingly, deletion of 
the maternal copy of the IG-DMR resulted in a loss of gene expression from the maternal copy, 
resulting in a paternal-like expression pattern resulting in miRNA silencing. 
It has been demonstrated by previous studies involving small molecule inhibitors of 
histone acetylation and chromatin methylation that many of the members of the 14.32 
megacluster are independently regulated and exhibit different expression patterns in different 
tumor types.50 Many studies have also shown that a few of the miRNAs encoded here rise in 
expression in some cancers, ostensibly acting as oncogenes.93 One explanation for the 
suppression that we see is that the members of this large cluster are simply silenced by 
methylation, and the presence of only one functional gene under normal circumstances makes 
this effect much more impactful. However, this doesn’t explain why 100% of the members of 
this family that we do see are silenced and none of them seem capable of regaining expression at 
any stage of the cell line progression model. The apparent permanence and unanimous nature of 
the silencing of this cluster suggests that it is a result of a LOH event. Since the megacluster 
spans only 44.7 kbs, it is possible that a deletion of this area on the maternally inherited copy of 
the chromosome could have occurred without having been discovered by previous cytogenetic 
analyses. However, there are also other possibilities such as a classical somatic crossing over 
event4 or aberrant regulation of imprinting caused by mutation.93  
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P53 degradation is primarily degraded by the mouse double minute 2 homolog (MDM2). 
While in other cancers, p53 deletion or mutation is usually required for tumor progression, it is 
almost never lost in prostate cancers which prefer to attenuate its action by over expressing 
MDM2.2 Our SNP analysis demonstrates that there are two copies of p53 present in each of our 
cells lines and that neither of them harbor known inactivating mutations. Ectopic expression of 
Meg3, one of the genes expressed on the paternal allele opposite the active maternal miRNA 
megacluster, has been shown to increase the levels of p53 in a prostate cancer cell line by 
directly inhibiting MDM2.96 A classical LOH event derived from somatic crossing over that 
would result in silencing of the maternally expressed megacluster would also result in a doubling 
of expression for the paternally expressed genes including Meg3. This would antagonize the 
suppression of p53 via MDM2 overexpression. While it is still possible that this is the case, it 
would be more beneficial to the budding prostate cancer cell to knock out the maternally 
expressed miRNAs via the deletion of the locus that encodes them or by deletion of the maternal 
copy of the centromeric IG-DMR.  
The miR-200 Family 
 The miR-200 family is an evolutionarily conserved group of 8 miRNAs specific to 
epithelial tissues.23 Its members include 141-5p, 141-3p, 200a-5p, 200a-3p, 200b-5p, 200b-3p, 
200c-3p, 429-5p. Interestingly, although this family experiences coordinated expression, they are 
encoded on two separate transcripts: miR-200a, miR-200b, and miR-429 are generated from a 
single transcript on chromosome 1 while miR-200c and miR-141 are generated from a single 
transcript on chromosome 12.86 Expression of this family is one the most potent inducers of 
epithelial differentiation, known to target ZEB1/2 via highly conserved targets on their 3’ UTRs. 
The members of this conserved family are highly related in sequence and regulate many 
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processes related to cancer, including the EMT.86 The miR-200 family participates in a negative 
feedback look with the transcription factors ZEB1 and ZEB2 to enforce either an epithelial or a 
mesenchymal phenotype in a mutually exclusive manner.86 200b also targets SNAIL1/2, another 
EMT factor that also must be repressed before the acquisition of pluripotency in IPCs.86 All in 
all, the expression of this family is one the most potent inducers of epithelial differentiation that 
have been discovered. 
 miR-141 and miR-200c have been shown to attenuate Notch signaling in prostate cancer 
cells by directly targeting Jagged1, which led to impaired proliferation.88 Notch signaling is 
critical for the growth of various tissues, including the prostate, and is often aberrantly expressed 
in late stage tumors, correlating with their acquisition of stem cell characteristics. 
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Figure 15: The Expression of the miR-200 Family and associated miRNAs over the Cancer 
Progression Model. A) The Expression of the miR-200 Family over the Cancer Progression 
Model. Here we can see a clear suppression early in the M2182 cell line, a return to P69 
expression levels in the M12 cell line and a muted return of suppression in the F6 cell line. B) 
The expression of miR-205-5p, commonly reported to be correlated to the expression of the 
miR-200 family, mirrors their expression over the course of the progression model. C) The 
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expression of miR-22-5p in inversely correlated with miR-200 family expression in prostate 
tumor vs. matched normal epithelium. Light coloring implies a lack of statistical significance. 
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All eight members of this family display powerful suppression in the M2182 cell line. 
However, this repression disappears in the M12 cells where the expression of each one of these 
miRs is conspicuously similar to the P69 cell line. Then, in the F6 cell line, repression seem to 
resume for all of the members of the family, although only 3 of these reach statistical 
significance: miR-200b-3p, miR-200c-3p, and miR-429-5p. As described in the previous chapter, 
miR-205-5p shares multiple transcription factor targets with the miR-200 family and plays an 
equal part in the regulation of the EMT and MET as well as tissue stem cell proliferation. This 
miRNA shows the exact same expression pattern in our progression model as the miR-200 
family members. They are all powerfully suppressed in the M2182 cell line, return to P69 
expression levels in the M12 cell line, and then experience a muted return of suppression in the 
F6 cell line. This coordination of expression for multiple miRNAs transcribed on multiple 
transcripts suggests pathway activation/repression as opposed to a coincidence of random events 
such as an aberrant epigenetic mechanism or mutational promoter silencing.  
The data from mature tumors demonstrates that the members of this family may actually 
be upregulated once tumorigenesis is achieved. It is important to point out that as the expression 
of the miR-200 family increases, the expression of miR-22-5p decreases by a -0.32 fold with a p-
value of 1.25E-05. Collectively, these data suggest that a previously unidentified, transient 
suppression of the miR-200 family of miRNAs may play a role in prostate cancer progression. 
 It is known from studies on the rates of induction of pluripotency in adult somatic cells 
that a candidate cell’s general expression profile at the time of application of the Yamanaka 
factors is the crucial determinate of its chance of successfully undergoing dedifferentiation. The 
miR-200 family of miRNAs powerfully enforce differentiation to the epithelial phenotype. The 
fact that we see a return to P69 levels of expression in the M12 cells seems counter intuitive to 
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the maxim that as a cancer progresses, it becomes more stem cell like.4 Instead of thinking of the 
acquisition of stem cell characteristics as a general dedifferentiation process that extends to all of 
the cells of a tumor, we might try thinking of it as an expansion of the population of functional 
cancer stem cells present in the malignant tissue. In this case, the transient decrease in miR-200 
family members could represent an opportunity for the developing cancer to expand its 
population of cancer stem cells by allowing all of the cells in the population to adopt a more stem 
cell like expression pattern and increasing activity of the Notch signaling pathway. This would 
increase the perpetually slim chance that a handful of them would successfully undergo 
dedifferentiation to pluripotency. This is supported by the observation made by another 
researcher that the tumor from which this cell line was derived was poorly differentiated.39 The 
apparent return of expression in the M12 cells and in the mature tumors reported on in the TGCA 
analysis could represent a subsequent overall increase in the number of cells undergoing 
differentiation, which we could interpret as an expansion of transit amplification cause by the 
higher number of cancer stem cells. 
 One study demonstrated that an increase in miR-22 was partly responsible for expanding 
the mammary stem cell population by targeting the methylcytosine dioxygenase TET which is 
responsible for demethylating the miR-200 promoters.58 Although the difference in expression of 
miR-22 between the M2182 and P69 does not reach statistical significance, there is a two-fold 
decrease in expression between the M2182 and M12 cell lines concomitant with relief of 
suppression of the miR-200 family in the M12 cells. Previous work in our laboratory has 
demonstrated that this miRNA plays an active role in the phenotype of these cells lines.69 A high 
count per million (CPM) for miR-22-5p in both the M2182 and P69 cell lines suggest the reason 
that this miRNA does not change significantly is because it is already overexpressed in the P69 
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cell line. It could be that suppression of these promoters was made possible by overexpression of 
miR-22 (an absence of the on-switch TET) in the P69 cell line but that it took two rounds of in 
vivo selection for these genes to be silenced by other epigenetic phenomena (the off-switch). 
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The Late Upregulated miRNAs 
miR10a and miR-196a 
 
 
Figure 16: The Expression of miR-10a and miR196a (3p and 5p) in the Cancer Cell Line 
Progression Model. Strangely, it can be seen that the copy numbers of both the 3p and 5p arms of 
both miRNAs are roughly equal. Light coloring implies a lack of statistical significance. 
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miR-10 and miR-196 are both highly conserved miRNA families exclusive to vertebrates. 
They are both encoded in the intergenic regions between HOX genes and play important roles in 
developments. miR-10a is encoded on chromosome 17 in the region between HOXB4 and 
HOXB5, Two copies of 196a exist, one on chromosome 17 between HOXB9 and HOXB10 and 
one on chromosome 12 between HOXC9 and HOXC10.89 The presence of these miRNA in the 
M12 cell line could reflect a higher degree of permissive chromatin structures facilitated by the 
loss of one copy of BRG1, possibly explaining the acquisition of upregulated miRNAs.  
Important HOX gene targets of 196a include HOXB8, HOXC8, HOXD8, and HOXA7. 
196a also regulates the HMGA family members and HMGA2 especially. The high mobility 
group AT-hook (HMGA) family part of the non-histone chromosomal high-mobility group is 
comprised of 2 proteins, HMGA1 and HMGA2. While not specifically altering the expression of 
any genes in particular, these proteins are a critical part of maintaining permissive and repressive 
chromatin structures. After embryogenesis, transcription of these proteins is tightly repressed by 
conserved targeting by the let-7 family of miRNAs such that expression of these two groups is 
mutually exclusive. In adults, the expression of these genes outside of embryogenesis is 
indicative of tumor formation. In ovo experiments in zebrafish have demonstrated that miR-196 
regulates the axial skeleton through targeting components of the retinoic acid pathway, a 
pathway critical to prostate development.89  
miR-10a has been demonstrated to work together with HOXB4 to repress expression of 
HOXA1, HOXA3, and HOXD10. Decreased expression of HOXD10 results in an increase in the 
expression of RhoA, RhoC, and Rho kinase which all facilitate tumor cell invasion. Some of its 
other targets include Ran and Pbp1 genes as well as the USF1/2 transcription factors. miR-10a 
binds directly downstream of the oligopyrimidine tract on the 5’-UTR of mRNAs encoding 
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ribosomal proteins, augmenting their translation. miR-10a overexpression has been observed in 
multiple solid cancer types.90  
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miR-675 and lncRNA-H19 
 
 
Figure 17: The Expression of miR-675 in the Cancer Cell Line Progression Model. Not a single 
read was recorded from the M2182, reflecting the extremely tight regulation of cleavage from 
H19. Light coloring implies a lack of statistical significance. 
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miR-675 is a tumor suppressor miRNA derived from the multifunctional lncRNA H19. 
H19, including the miR-675 stem loop, is one of the most highly expressed and conserved RNA 
transcripts in mammalian development.94 In vivo, the liberation of 675 from H19 is tightly 
regulated, its only truly established role being the modulation of placental growth in the human 
embryo. 
 miR-675 
 miR-675 represses expression of p53 and pRB.95 Overexpression can be caused by LOH 
at the imprinted region, a loss of p53, or through Myc activity. This has been demonstrated to 
lead to the activation of genes promoting proliferation, survival, and angiogenesis and has been 
implicated in multiple solid tumor types, usually correlating with severity of tumor grade.92 This 
fits conceptually with its presence in the M12 cells as these would represent a very high tumor 
grade in our progression model. However it has been demonstrated to act as a tumor suppressor 
in multiple different cell line studies suggesting that it’s action is complex.94 Dual luciferase 
experiments have demonstrated that miR-675 targets the 3’-UTR of TGF-beta inducible protein, 
part of the TGF-beta pathway, which is well known to antagonize prostate cancer progression.95  
  Excision of miR-675 is regulated by the localization of the stress response RNA binding 
protein HuR from the nucleus to the cytoplasm. However it was also demonstrated through CHIP 
studies that 48 other proteins actively bound the H19 transcript in that area of the miR-675 stem 
loop. These included among others, Upfl, Zcchc11, and Luc71.94  
 H19 
 Although its expression is thought to be repressed in adult tissues, H19 itself has been 
reported to act as a both a tumor suppressor or an oncogene.95 The presence of miR-675 in the 
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M12 and F6 cells demonstrates the presence of H19, although considering the tight regulation of 
miR-675 processing, it is unclear if it is the expression of H19 that is increasing or if it is just the 
processing of miR-675 that is increasing. It has been demonstrated that in the placenta, H19 
functions as a vast reservoir of miR-675 precursor and that even at its peak miR-675 expression, 
only 1% of H19 is processed. However it has been demonstrated that ectopic expression of H19 
in p69 cells and PC3 cells resulted in an increase in miR-675 expression.95 Like miRNAs, 
lncRNAs have been well established contributors to the maintenance of the stem cell state, 
progenitor cell proliferation, mammalian development, differentiation, and cancer.92 H19 is 
mediates allelic imprinting of many genes including the IGN locus, and is itself paternally 
imprinted along with the rest of the Igf2 locus. In adults, its expression is restricted to skeletal 
tissues after embryogenesis. H19 exerts its tumor suppressor action by coordinating with the 
methyl-CpG-binding domain harboring protein MBD1 to repress multiple genes including 
mesoderm-specific transcript homolog protein (MEST) and Igf2, the agonist for the IGFRs.92 It 
is possible that H19 could have an oncogenic effect in the context of the M12 cells by acting as a 
molecular sponge for the let-7 miRNAs, which have been demonstrated to enforce the 
differentiated phenotype.95  
The 548 Family 
This extremely large and poorly conserved (only primates- like alu sequences) family of 
miRNAs is hypothesized to have expanded evolutionarily in connection to nearby transposable 
elements (TEs). In fact, a handful of these miRNAs have been demonstrated to be associated 
with active TEs in the body and it is possible that many more are as well. It has been proposed 
by others that the activation of TEs plays a part in aging and cancer progression. I propose that 
these miRNAs experience copy number increases as their nearby TEs become active. 
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miR-34a-5p 
 
 
Figure 18: The Expression of miR-34a in the Cancer Cell Line Progression Model. miR-34a, an 
effector of p53, is a potent tumor suppressor and yet can be seen to be upregulated in the late 
stages of the model. Light coloring implies a lack of statistical significance. 
 
 
 
 
 
 
  
-2
-1
0
1
2
3
4
5
6
7
miR-34a-5p
Lo
g 
Fo
ld
 C
h
an
ge
M2182 M12 F6
 
126 
 
Despite its well established tumor suppressor qualities, 34a is our second most 
significantly upregulated miRNA in the M12 cell line. 34a belongs to a family of evolutionarily 
conserved miRNA effectors of the tumor suppressor p53, augmenting apoptosis, senescence, and 
cell cycle arrest in many types of cancer.91 It has also been demonstrated that miR-34a targets the 
3-UTR of the AR receptor mRNA transcript in vivo.52 Due to its tumor suppressive properties, it 
is usually seen to be downregulated in cancer but here we see that its mature form is the second 
most significantly upregulated miRs observed in the M12 cell line. It is important to note that 
p53 is rarely dysregulated in all but extremely late stage prostate cancers and that our SNP screen 
of these cell lines did not detect a DNA aberration of p53. It is likely that expression of this 
miRNA is activated by the low levels of p53 still active in our cells lines in response to the 
aberrant progression of the cell cycle. If a miRNA is found by sequencing in its mature form, it is 
likely that it is effectively bound by the RISC complex ready to perform its duties. This is 
because free mature miRs floating in the cytoplasm are usually degraded so fast that they cannot 
be significantly appreciated, and especially not in the concentration that is observed here for 
miR-34a. Considering our observation that this mature potent tumor suppressor miRNA is 
present in a 6 fold concentration in the M12 compared to the P69 and yet does not appear to be 
effecting its intended cell cycle arrest, it may be possible that its action is attenuated by a late 
actor such as a miRNA sponge like H19, RNA-binding proteins, circular RNAs (circRNAs), 
competitive pseudogenes, or many other possibilities. 
The first anticancer miRNA mimic to reach phase 1 trials in April, 2013 was MRX34, a 
miR34a-5p mimic. The logic behind using miRNA mimics as cancer drugs is two-fold dependent 
on their large number of targets. It is thought that since miRNAs target entire pathways instead 
of just a single protein, their effect will be both more powerful and less susceptible to acquired 
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resistance by tumors. The fact that we see miR34a-5p specifically to be so powerfully 
upregulated in our most aggressive cell line, indicating an intact p53 pathway, suggests that this 
later point might not actually be the case. Apparently, there are more ways in which a cancerous 
cell can resist the effects of an ectopic miRNA rather than through somatic mutation of its targets 
binding sites. 
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The Rest 
miR-9  
 
 
Figure 19: The Expression of miR-9 in the Cancer Cell Line Progression Model. miR-9-5p was 
found to be powerfully downregulated in the M2182s but powerfully upregulated in the M12s. 
Light coloring implies a lack of statistical significance. 
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Among its other functions, miR-9 has been found to target the 3’-UTR of the AR mRNA 
transcript.52 However, previous work in our laboratory has demonstrated that miR-9 can also act 
as an oncomiR by repressing E-cadherin and SOCS5.65 It could be that miR-9’s biphasic 
expression is a result of its mixed effects on cancer progression, first being suppressed during the 
early, more androgen dependent stage of prostate cancer progression due to its targeting of the 
AR mRNA transcript, and then upregulated in the late, near-androgen independent stage of the 
progression model when AR expression is more robust.  
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miR146a-5p  
 
 
Figure 20: The Expression of miR-146a in the Cancer Cell Line Progression Model. The tumor 
suppressor miRNA 146a-5p demonstrates the exact opposite expression pattern as miR-9 above. 
Light coloring implies a lack of statistical significance. 
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One study found that miR-146a-5p was dramatically upregulated in an androgen 
dependent prostate cancer cells while it was dramatically down regulated in androgen 
independent prostate cancer cells.80 Similarly, miR-146a is the #1 most upregulated miRNA in 
our M2182 cell line where it is expressed at almost 6 fold the levels of the p69 cell line. Yet it is 
significantly downregulated in the M12 cell line. The M12 cells, while not totally androgen 
dependent, need very little androgen compared to truly androgen dependent prostate cancer cell 
lines. Forced expression of 146a in the PC3 prostate cancer cell line resulted in inhibition of 
migration, proliferation, invasion, and metastasis via silencing of the HA/ROCK1 pathway.80 It 
could be that miR-146a-5p is a tumor suppressor activated in early tumorigenesis as a response 
to the aberrant cell cycle progression and that this activation is eventually overcome. 
Literature Search- Tumor suppressors lost with chromosome 19p  
 In an experiment involving MMCT of variable fragments of chromosome 19 into another 
cell line, one investigator came to the conclusion that there must be a tumor suppressor in the 
region of chr19p13.1-13.2.39 Another study of 37 CRPC tumors demonstrated that a loss of 
chromosome 19 with a minimal overlap generally centered on 19p13.1 was the most common 
late stage chromosomal event.40 There has been much investigation into possible tumor 
suppressors that may lie on the short arm of chromosome 19 since the creation of these cell lines. 
A literature search produced two convincing candidate tumor suppressors, STK11 and BRG1, 
that both coincidentally happen to lie close together on 19p13.2. 
STK11 is a 433 amino acid serine-threonine kinase with a nuclear localization signal that 
functions in complex with the pseudokinase STE20-related adapter and the armadillo repeat 
scaffolding-like protein MO25.82 It’s most well studied activity is its regulation of the cellular 
energy checkpoint through the phosphorylation and activation of adenosine monophosphate 
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kinase (AMPK). When the ratio between AMP and ATP inside the cell reaches a critical 
threshold, this complex activates AMPK, which proceeds to modulate its downstream targets, 
arresting the cell cycle. It is postulated that deregulation of this checkpoint is important for 
tumorigenesis in that it allows for high energy processes such as DNA replication to proceed 
under conditions of energetic stress. Germline mutations in this gene cause the cancer prone 
disease Peutz-Jeghers syndrome in humans which, among other things, causes hamarrtomatous 
polyps of the gastrointestinal tract. Heterozygous mice survive to adulthood but also have 
gastrointestinal polyps similar to what happens in humans.82  
 It has been observed that STK11 mutations accumulate in less differentiated tumors of 
various  cell types.82 It has also been demonstrated that STK11 mutations occur in about half of 
all NSCLCs, by way of large deletions or nonsense mutations, and is the third most altered gene 
in lung adenocarcinomas after TP53 and KRAS.82 STK11 alterations are found most often to be 
concomitant with alterations in KRAS, TP53, P16, MYC, PIK3CA, and BRG1 but almost never 
with alterations in EGFR.82 Previous proteomic analysis in our lab  demonstrated that EGFR 
plays an active role in growth signaling in the P69, M2182, and M12 cell lines. Also, as is 
common in prostate cancer, proteomic analysis demonstrated an upregulation of the PI3K 
pathway in M12’s compared to parental p69 cells, which together with the loss of STK11 may 
further promote tumorigenesis in vivo.   
 STK11 has also been linked to the regulation of cell polarity. One study reported that 
STK11 expression induces complete polarization in intestinal epithelial cell cells in a cell-
autonomous fashion. This is important because previous work in our laboratory has 
demonstrated that the loss of the ability of M12 cells to form acini in lrECM 3D cultures, as 
compared to their parental cell line, was concomitant with the loss of the polarization of alpha-
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6/beta-1 integrins. This polarization and acini forming ability was restored by the return of 
chromosome 19 in the F6 cells. STK11 deficient mice have reduced TGF-Beta activity in 
endothelial cells which allows for a permissive environment for epithelial expansion. That the 
TGF-Beta pathway antagonizes prostate cancer progression is well documented. This may be 
exemplified by the fact that tissue specific knockout of STK11 has been demonstrated to lead to 
prostate intraepithelial neoplasia in mice, a condition thought to precede prostate cancer.82  
STK11 also regulates the levels of cyclooxygenase-2 and the transcription factor Ets 
Variant 4 (ETV4).82 ETV4 is a member of the winged helix-turn-helix superfamily associated 
with transcriptional misregulation and the upregulated expression of matrix metalloproteinases 
and other genes associated with invasion and metastasis.83 This specific TF has been 
demonstrated to be commonly upregulated by a translocation that results in a fusion with 
TMPRSS2 (TMPRSS2:ETS fusion), the single most prominent molecular hallmark of prostate 
cancer. It is activated by sumoylation in response to MAPK/ERK pathway activity downstream 
of the ERbB2/ERbB3 heterodimer. Previous proteomic data in our laboratory has demonstrated 
the significant upregulation of both ErbB2/ErbB3 and the downstream MAPK/ERK pathway in 
M12 cells compared to P69 cells (See Table 20 below). Interacting proteins, as predicted by 
STRING UniProtKB I2D with a STRING value of 1 and reported in ETV4’s genecard, includes 
HOX4D, possibly coordinating with the action of miR-10a-5p in the M12 cell line as described 
in the discussion section.83  
 
Brahma/SWI2-related gene 1 (BRG1) is a critical component of the SWI/SNF chromatin 
remodeling complex. It features a bromodomain and Helicase/ATPase activity and can regulate 
transcriptional activation or repression by remodeling chromatin structure. This gene is also seen 
 
134 
 
to experience inhibiting point mutations and deletions in prostate cancer cell lines and in lung 
cancers that undergo LOH. BRG1 is also located at 19p13.2, only 10 Mb from STK11. One 
study demonstrated that inactivating mutations in this gene are common to one third of all 
NSCLC cell lines.82 Although it is true that the protein Brahma (BRM) can partially substitute 
for BRG1 in the SWI/SNF complex, it has been observed that mice heterozygous for Brg1 are 
prone to developing epithelial tumors, despite full activity of BRM.82 This may be due to the loss 
of BRG1 SWI/SNF’s activity downstream of the retinoblastoma protein. It was also established 
that a tissue specific homozygous knockout of BRG1 in mice produced fewer tumors than their 
heterozygous littermates suggesting that retention of a single BRG1 allele (as is the case in the 
M12 cell line) may provide some anti-apoptotic protection. The auxiliary functions of the BRG1 
containing SWI/SNF complex include regulation of cell growth, differentiation, and general 
DNA repair. It has also been demonstrated to interact with BRCA1 directly during homologous 
recombination after DNA damage.82  
The SWI/SNF complex containing BRG1 is also involved in transcriptional modulation 
of hormone responsive promoters in response to hormone receptor activation, including the AR, 
through direct binding of hormone receptors and their target promoters.82 One study reported that 
BRG1 and not BRM was required along with the rest of the SWI/SNF complex and the tumor 
suppressor Prohibitin to silence AR responsive genes during hormone ablation therapy of 
prostate cancer.81 It could be that the loss of one copy of this gene in the M12s could facilitate 
their partial androgen independence. 
Surprisingly, one study discovered that STK11 and BRG1 interact in the cell. That study 
demonstrated that STK11 had the capability to bind and regulate the chromatin remodeling 
activity of the BRG1 containing SWI/SNF in vivo and that the ATPase activity of BRG1 is 
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enhanced in its presence. The independent inactivation of these two genes often occurs 
concomitantly in many different types of cancers, including prostate cancer, through somatic 
mutation. This suggests that the effects of their simultaneous loss may cooperate in cancer 
progression.82 Mouse studies have demonstrated that heterozygosity for either of these genes 
alone results in a tumor susceptibility syndrome making both of these haplo-insufficient tumor 
suppressors. Interestingly, our SNP analysis uncovered two STK11 mutations described below. 
 
Low vs. High copy numbers 
Due to the heterogeneous nature of microRNA function, it is difficult to draw conclusions 
about the relative impact of differential expression in high versus low copy number microRNAs. 
It is a good idea to evaluate differential expression in these two categories separately. Previous 
NGS studies have demonstrated that a handful of microRNAs (less than 20) represent the 
majority of cellular microRNA expression (more than 80%) in tissues.57 In the case of neurons, 
the highest messenger RNA (mRNA) levels seen are below 2500 copies per cell with the vast 
majority of cells having a peak mRNA copy number for any particular gene being far below that. 
In the same cells, a high copy number miRNA, of which there are just a handful, could be 
present at 25,000 or more copy numbers.60 A 10% increase in expression of one of these 
microRNAs might result in a 2500 copy number change, where as a 1000% increase in a low 
copy number microRNA originally expressed at 20 copies per cell would result in a an increase 
of only 180 copies. It seems logical to assume that changes in high copy number miRNAs will 
have a more physiological effect on the cell and this opinion is highly expressed in the current 
literature. However, it is this author’s opinion that so little is known about the mechanisms of 
miRNA action that it is dangerous to discount them. Low expression miRNAs could easily be 
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part of amplification cascades, positive and negative loops with other miRNAs and transcription 
factors, or they could even be localized at more appreciable concentrations in a specific part of 
the cell where they act. That means that the concentration of one of these miRNAs could very 
well have a large impact on the cell state. It is for these reasons that particular attention was 
given to miRNA abundancy, as it directly informs any possible downstream hypotheses or 
conclusions about the roles of miRNAs described in our results. 
Oncomirs and Tumor Suppressors miRs: The Reductionist’s Approach  
Since the expression of a particular miRNA and that of its target are inversely related, a 
miRNA that is upregulated in cancer, is assumed to target a classic tumor suppressor gene and is 
referred to as an oncomiR. Accordingly, a miRNA that is downregulated in cancer is assumed to 
target a classic oncogene and is known as a tumor suppressor miR. This classification is 
supported by the observation made by many that a number of miRNAs experience the same kind 
of selection pressures and genomic alterations as classical oncogenes and tumor suppressors such 
as amplifications, deletions, point mutations, translocations, and loss of heterozygosity. In fact, 
although miRNA’s only represent less than 3% of the human genome7,10, more than half of them 
are located in commonly amplified or deleted regions.32 Certain human miRNAs have even been 
co-opted by cancer causing viruses, reminiscent of the very first oncogenes ever to be 
discovered, ras, myc and sarc.4 A 2009 study determined that miR-127-5p was a central player in 
the development of Epstein Barr Virus positive Burkitt’s Lymphoma possibly through its effect 
on the expression of the master regulators of B-cell differentiation, BLIMP-1 and XBP-1.48 
These and other examples demonstrate that miRNA expression is still powerfully selected for or 
against in a way that suggests oncogenic or tumor suppressive power. However, this concept is 
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complicated by the fact that miRNAs demonstrate both oncomiR and tumor suppressive activity 
in different tumor tissues. 
Considering that miRNA expression profiles correlate with cell type and differentiation 
state better than any other type of biological molecule, it may be that there is more to the role of 
miRNAs in the biology of the cancer than can be adequately expressed with the “oncomiR” and 
“tumor suppressor miR” terminology. It may be more helpful to think of miRNAs in terms of 
their association with different cell states or modular programs. miRNAs commonly target 
hundreds of mRNAs at once and thinking of them only in terms of the specific tumor suppressors 
or oncogenes that they inhibit in a 1:1 ratio is unnecessarily laborious. For instance, members of 
the Let-7 family have been shown to negatively regulate the Myc, Ras, and HGMA2 proto-
oncogenes,21 leading to their initial classification as tumor suppressor miRs. However, something 
that is far more valuable to understand is the fact that the double negative nature of the 
relationship between the let7 family and the LIN28 RNA binding protein (RBP), which is 
activated by Myc,66 creates a mutually exclusive expression pattern governing the exit of the 
stem cell state and entry into the differentiation program. It has been demonstrated that this shift 
in expression musts be reversed during the reprogramming of induced pluripotent stem cells 
(IPCs).68 This could mean that let7 family expression must be reversed in order for the 
acquisition of stem cell characteristics by would be cancer cells.  
 Understanding how a particular miRNA or miRNA family affects the biology of the cell 
naturally involves the genes that they target, but adopting a reductionist’s approach may lead us 
to miss the forest for the trees. I think that it is more important, at this point in our understanding 
of ncRNA biology, to focus on how and why miRNAs are associated with particular cell states 
and work backward from there. 
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Thoughts for the Future- Considering Proteomic Data  
The most promising application of miRNA profiling information is its integration with 
corresponding genomic, proteomic, and metabolomic data. From this approach it may finally be 
possible to get a whole picture of the living cell. Below are a few examples of promising areas of 
investigation that come to light when considering the transcriptomic data presented in this study 
and proteomic data conducted on these cell lines previously.  
Table 20: RPMA Analysis Shows Increased Protein Expression from the PI3K/RAS 
pathways in M12 versus p69 Cell Lines (original title).  
Protein Fold change 
ErbB2 1.8 
ErbB3 2.0 
PI3K 1.4 
p-BAD 1.7 
MET  1.3 
pERK 4.0 
Table adapted from reference 69. 
 
EGFR has been demonstrated to play a surprising role in miRNA biogenesis. As just one 
example of many, under hypoxic conditions, such as those which occur in the center of tumors 
pre-angiogenesis4, EGFR is internalized in cells in association with late stage endosomes, where 
it phosphorylates human AGO2 at Y393, causing AGO2 to dissociate from Dicer1.61 Through a 
poorly described mechanism, this leads to a decrease in activity for a specific set of tumor 
suppressor miRNAs with a characteristic long loop structure in their pri-miRNA.66 This has been 
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demonstrated to increase cell survival and invasion in HeLa and MDA-MB-231 cell lines. It has 
been established that prostate epithelial cells require EGF in culture and that EGF is abundant in 
the prostate as a normal part of its growth and function. However, our cell lines exhibit 
interesting EGFR phenomena. As evidenced by previous research performed in our laboratory, 
both ErbB2 and ErbB3 are upregulated by two fold in the M12 cell line compared to the P6969 
cell line while the expression of EGFR itself was demonstrated to be downregulated 6 fold over 
all with a specific 4 fold decrease on the surface of the M2182 and M12 cells. This was all 
concomitant with a 3 fold increase in TGF-alpha expression, an EGF-like peptide, demonstrating 
a possible autocrine loop adopted by these cells.39 In support of this, addition of a TGF-alpha 
neutralizing antibody arrested growth in this cell line. It could be that the observed decrease in 
EGFR expression is in response to the overexpression of TGF-alpha which is a common feature 
of autocrine loops of this kind.4 However, why this does not lead to the decrease in ErbB2 and 
ErbB3 remains to be investigated. One explanation may be dysregulation of growth inhibitory 
miRNAs that usually play a large part in the negative feedback mechanism governing expression 
of these receptors. For instance, it was demonstrated previously in our lab that the 3’-UTR for 
ErbB2 contains two perfect match binding sites for miR-125b-5p, a miRNA that iscommonly 
reported to be downregulated in prostate cancer and lost in our M2182 and M12 cell lines. 
A handful of let7 family miRNAs are significantly downregulated in the M12 cell line 
compared to the P69 cell line while others seem to be upregulated. A previous researcher in our 
laboratory identified an activation of the Ser/Thr kinase ERK (MAPK) in connection to an 
increase in miR-22-5p and a decrease in miR-125b-5p. ERK activation results in the inhibition of 
KSRB, an RBP that promotes the let7 family processing exactly antagonistic to LIN28 by 
binding to the same terminal loop in the pre-miRNA transcripts that produce them. ERK 
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activation also results in phosphorylation of TRBP at four different serine residues which leads 
to an increase in Drosha/DGCR8 stability and activity in the nucleus. However, while increasing 
the activity of a majority of mature miRNAs in this way, phosphorylation of TRBP 
simultaneously directly downregulates the let7 family of miRNAs through a separate but 
unidentified mechanism.66 Apart from the those mentioned above, it is likely that there could be 
anywhere between tens to hundreds of analogous RBPs that effect the production of specific let-
7 family members over others under different conditions. More research incorporating large 
proteomic data with high throughput RNA sequencing is needed to illuminate these subtle 
mechanisms. 
Apo-AGO proteins and apo-Dicer are usually marked by polyubiquitination and 
degradation via autophagy involving the selective autophagy receptor NDP52.66 A common 
hallmark of prostate cancer is a deficiency of autophagic processes through loss of beclin1 and 
overexpression of mTOR via PI3K/AKT activation.8,16 This phenomenon could help explain why 
in prostate cancer, miRNA expression is generally downregulated, but Dicer1 expression is 
commonly seen to be upregulated. While previous work in our laboratory has centered on the 
increase in PI3K activity and expression mentioned above, we have yet to focus on how the 
activation of this pathway might affect miRNA processing in general. 
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Appendix 
 
 
 
Table 21: Extended NGS Analysis for Urine 
Gene Name logFC locCPM LR PValue PAdjusted 
hsa-miR-223-3p 5.940734 10.614319 16.24019 5.58E-05 0.013335658 
hsa-miR-223-5p 5.95683 7.6441786 13.45336 0.000245 0.029225904 
hsa-miR-142-3p 6.801603 9.4414229 12.68913 0.000368 0.029300375 
hsa-miR-199a-3p 4.884872 8.3158747 11.69224 0.000628 0.037499873 
hsa-miR-363-3p -2.4222 11.602927 11.15461 0.000838 0.040067362 
hsa-miR-199b-5p 4.974522 7.5241254 10.1309 0.001458 0.058078823 
hsa-miR-199b-3p 4.59329 7.3669649 9.558437 0.00199 0.067955399 
hsa-miR-143-3p 3.957342 10.998673 8.453135 0.003644 0.108868889 
hsa-miR-184 5.863426 12.214555 7.873185 0.005017 0.133237726 
hsa-miR-629-5p 2.227044 9.2003383 7.185232 0.007351 0.175679457 
hsa-miR-941 2.812312 10.376636 6.913948 0.008553 0.185824598 
hsa-miR-205-5p 2.799235 11.093862 6.44201 0.011145 0.221976188 
hsa-miR-146a-5p 2.617289 11.905298 6.268341 0.012291 0.224995801 
hsa-miR-185-5p 1.792165 10.981644 6.009805 0.014227 0.224995801 
hsa-miR-204-5p -2.28501 11.863405 5.651272 0.017443 0.224995801 
hsa-miR-221-3p 2.323762 11.741003 5.607212 0.017887 0.224995801 
hsa-miR-34c-5p 4.915895 9.5787856 5.939451 0.014806 0.224995801 
hsa-miR-375 -2.25697 15.598242 5.837234 0.01569 0.224995801 
hsa-miR-618 4.634886 8.8283879 5.737391 0.016607 0.224995801 
hsa-miR-145-5p 4.683413 7.6031015 5.48455 0.019185 0.229263865 
hsa-miR-135a-5p -2.25086 9.7143463 5.31853 0.0211 0.240001966 
hsa-miR-3613-5p 2.656422 8.6492001 5.238507 0.022092 0.240001966 
hsa-miR-224-5p 4.2514 7.5193947 4.93534 0.026313 0.24582941 
hsa-miR-30b-5p -1.86501 9.0509587 5.032267 0.024879 0.24582941 
hsa-miR-338-5p 2.660272 8.1421914 4.90733 0.026743 0.24582941 
hsa-miR-378a-3p 2.340643 14.428333 5.045535 0.024689 0.24582941 
hsa-miR-106b-3p 1.754481 9.994472 4.798615 0.028483 0.252123979 
hsa-miR-142-5p 2.641637 7.5290462 4.502165 0.033852 0.259292108 
hsa-miR-194-5p -2.04975 10.826673 4.524387 0.033415 0.259292108 
hsa-miR-335-3p -2.42317 7.0238824 4.677256 0.030565 0.259292108 
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hsa-miR-378c 2.163248 11.654233 4.459043 0.034717 0.259292108 
hsa-miR-7706 2.934246 7.0007226 4.460831 0.034681 0.259292108 
hsa-miR-20b-5p -2.88384 7.4043395 4.21983 0.039954 0.289364984 
hsa-miR-18a-3p 2.27682 7.2060772 3.981565 0.046001 0.323358661 
hsa-miR-181a-5p 1.588965 12.463507 3.798065 0.051312 0.349502663 
hsa-miR-210-3p 2.308042 8.6079003 3.709392 0.054107 0.349502663 
hsa-miR-382-5p 3.957323 7.591024 3.751917 0.052747 0.349502663 
hsa-miR-203a-3p 1.8338 14.43704 3.347386 0.067312 0.407257978 
hsa-miR-3529-3p 1.612157 11.583631 3.326777 0.06816 0.407257978 
hsa-miR-500a-3p 2.410842 7.3620295 3.384309 0.06582 0.407257978 
hsa-miR-22-3p 1.662862 15.848046 3.218368 0.072816 0.422801075 
hsa-miR-29a-3p -1.31887 10.858349 3.159242 0.075498 0.422801075 
hsa-miR-99a-5p -1.28535 14.669096 3.146955 0.076069 0.422801075 
hsa-miR-135b-5p 2.544828 7.711581 3.03227 0.081624 0.42408849 
hsa-miR-23a-3p 1.845069 11.166412 3.05629 0.080425 0.42408849 
hsa-miR-361-3p 1.325939 10.239265 3.0998 0.078302 0.42408849 
hsa-miR-15b-5p 1.779465 7.9188845 2.900423 0.088556 0.450318343 
hsa-miR-574-3p -1.7858 8.9486664 2.812291 0.093545 0.465774519 
hsa-miR-10b-5p -1.57388 15.415848 2.724711 0.098806 0.475890367 
hsa-miR-185-3p 2.117409 7.4792644 2.681074 0.101547 0.475890367 
hsa-miR-34a-5p 2.174507 7.8564769 2.636348 0.104443 0.475890367 
hsa-miR-3615 1.935132 8.2198082 2.59025 0.107523 0.475890367 
hsa-miR-452-5p 2.417074 8.5605751 2.633221 0.104649 0.475890367 
hsa-miR-576-3p 1.97834 6.8467383 2.618304 0.105637 0.475890367 
hsa-miR-615-3p -1.8157 8.4008804 2.420809 0.119733 0.520294811 
hsa-miR-508-3p 2.40192 6.988689 2.365041 0.124081 0.529558413 
hsa-let-7i-5p 1.174783 13.456275 2.214528 0.136717 0.545840497 
hsa-miR-1301-3p 1.533529 7.5259215 2.194434 0.13851 0.545840497 
hsa-miR-150-5p 1.391047 8.4929822 2.268832 0.131999 0.545840497 
hsa-miR-17-5p -1.45356 8.3589481 2.225052 0.135788 0.545840497 
hsa-miR-934 2.007721 8.8790982 2.18551 0.139315 0.545840497 
hsa-miR-10a-5p -1.40733 15.075426 1.937447 0.163946 0.55187454 
hsa-miR-16-5p 1.028633 9.5983274 2.064657 0.150749 0.55187454 
hsa-miR-222-3p 1.260597 9.1522395 2.08909 0.148354 0.55187454 
hsa-miR-30a-5p -1.09524 14.020108 2.025666 0.154661 0.55187454 
hsa-miR-30c-5p -1.08 11.508867 2.047487 0.152458 0.55187454 
hsa-miR-31-5p 2.059023 7.4618987 1.966738 0.160795 0.55187454 
hsa-miR-339-5p -1.63516 7.646961 2.123894 0.145017 0.55187454 
hsa-miR-425-5p 1.165469 9.7911464 1.948502 0.162748 0.55187454 
hsa-miR-769-5p 1.445804 9.3599063 1.947235 0.162885 0.55187454 
hsa-miR-93-5p 1.158637 10.704653 2.007314 0.156542 0.55187454 
 
154 
 
hsa-let-7f-2-3p -1.83447 6.9021967 1.884003 0.16988 0.556182113 
hsa-miR-4516 2.535969 7.0990241 1.889215 0.169291 0.556182113 
hsa-miR-192-5p -1.13134 12.636514 1.82492 0.176729 0.556388654 
hsa-miR-24-3p 1.228274 12.316643 1.860406 0.172578 0.556388654 
hsa-miR-509-3p 2.234188 7.6173777 1.82325 0.176927 0.556388654 
hsa-miR-10a-3p -1.52778 8.2616514 1.787996 0.181171 0.558102418 
hsa-miR-125b-5p -0.99019 12.159405 1.691233 0.193439 0.558102418 
hsa-miR-1287-5p 1.831372 7.4062168 1.745971 0.186384 0.558102418 
hsa-miR-181b-5p 1.179 10.596126 1.685387 0.19421 0.558102418 
hsa-miR-197-3p 1.519523 9.8423829 1.736972 0.187523 0.558102418 
hsa-miR-224-3p 2.018405 6.7094447 1.716731 0.190114 0.558102418 
hsa-miR-29c-3p -1.55311 9.5344584 1.695269 0.192908 0.558102418 
hsa-miR-582-3p 1.295381 7.2272314 1.670787 0.196153 0.558102418 
hsa-miR-127-3p 2.104886 7.0465542 1.55704 0.212099 0.589438236 
hsa-miR-25-3p 0.876096 12.732683 1.562199 0.211343 0.589438236 
hsa-miR-125a-3p 1.094682 7.2026524 1.509864 0.21916 0.602059593 
hsa-miR-141-3p -1.29889 10.741446 1.405796 0.235755 0.604689108 
hsa-miR-181a-3p 1.433398 6.9958551 1.363756 0.242888 0.604689108 
hsa-miR-374b-5p -1.05493 7.6279577 1.37916 0.240244 0.604689108 
hsa-miR-374c-3p -1.05514 7.6279577 1.374266 0.24108 0.604689108 
hsa-miR-425-3p 1.481974 7.512011 1.372764 0.241338 0.604689108 
hsa-miR-484 1.051318 10.572526 1.431092 0.231586 0.604689108 
hsa-miR-542-3p 1.075885 7.6999108 1.38348 0.239509 0.604689108 
hsa-miR-660-5p -1.43373 7.5509697 1.442304 0.229767 0.604689108 
hsa-miR-99b-5p -0.9183 12.268869 1.421832 0.233102 0.604689108 
hsa-miR-128-3p -0.79693 10.230627 1.332768 0.248313 0.611823645 
hsa-let-7c-5p -1.12959 12.216749 1.317865 0.250976 0.612073166 
hsa-miR-155-5p -1.13839 8.6408106 1.284241 0.257112 0.618381929 
hsa-miR-196a-5p -1.17834 9.5608818 1.273414 0.259127 0.618381929 
hsa-miR-584-5p 1.185308 9.4131734 1.261726 0.261325 0.618381929 
hsa-miR-221-5p 1.439904 7.0291555 1.220318 0.269298 0.624876689 
hsa-miR-499a-5p -1.31607 7.3947201 1.22459 0.268462 0.624876689 
hsa-miR-129-5p 1.244769 7.1954452 1.176863 0.277996 0.638855328 
hsa-let-7g-5p 0.946926 14.97011 1.145196 0.284557 0.647706186 
hsa-miR-30d-3p -1.31195 7.1178337 1.131943 0.287361 0.647918217 
hsa-miR-149-5p -1.14834 9.8564527 1.102254 0.293772 0.656182052 
hsa-miR-103a-3p 0.76367 10.992585 1.031106 0.309899 0.666971637 
hsa-miR-103b 0.763898 10.992585 1.036608 0.308612 0.666971637 
hsa-miR-140-3p 0.753401 9.4584128 1.019845 0.312556 0.666971637 
hsa-miR-23b-3p -1.2533 8.4086539 1.020777 0.312335 0.666971637 
hsa-miR-30a-3p -0.88467 12.506809 1.023248 0.31175 0.666971637 
 
155 
 
hsa-miR-450a-5p 1.071002 8.3415863 0.995493 0.318404 0.673437632 
hsa-miR-514a-3p 1.12481 8.6371099 0.926653 0.335734 0.703863979 
hsa-let-7b-3p -0.91672 7.5056897 0.886563 0.346411 0.719931446 
hsa-let-7e-5p -0.87016 9.363299 0.859982 0.353744 0.7213812 
hsa-miR-151a-3p 0.739576 11.726425 0.851377 0.356163 0.7213812 
hsa-miR-181a-2-3p -0.87729 7.5396238 0.856033 0.354851 0.7213812 
hsa-miR-125a-5p -0.66648 12.794758 0.812233 0.367461 0.738009517 
hsa-miR-26a-5p -0.75643 14.605994 0.80039 0.370977 0.738862208 
hsa-miR-486-5p 0.730327 16.244364 0.784264 0.37584 0.742362281 
hsa-miR-200b-3p 0.932365 13.749107 0.77115 0.379861 0.744154701 
hsa-miR-1180-3p 0.864256 10.187516 0.748352 0.386998 0.74583312 
hsa-miR-378a-5p 1.018679 7.2739192 0.755861 0.384627 0.74583312 
hsa-miR-421 -0.82075 7.4961372 0.738692 0.39008 0.74583312 
hsa-miR-1307-3p 0.736694 9.8132621 0.726515 0.394015 0.747378241 
hsa-miR-140-5p 0.801628 8.0546998 0.679131 0.409886 0.752859232 
hsa-miR-28-5p -0.83576 8.5648107 0.671138 0.412655 0.752859232 
hsa-miR-30d-5p -0.59802 12.318839 0.678252 0.410189 0.752859232 
hsa-miR-449c-5p 1.216989 6.7866859 0.683502 0.408384 0.752859232 
hsa-miR-6087 -1.26265 6.9454955 0.69931 0.403016 0.752859232 
hsa-miR-10b-3p -0.7495 8.417257 0.644384 0.422128 0.758560528 
hsa-miR-30e-3p 0.65092 10.213295 0.64554 0.421712 0.758560528 
hsa-miR-146b-5p 0.772095 8.9693704 0.581008 0.445917 0.786460081 
hsa-miR-152-3p 0.757186 9.464975 0.557559 0.455246 0.786460081 
hsa-miR-28-3p 0.580208 10.408234 0.587205 0.443502 0.786460081 
hsa-miR-30c-2-3p 0.651444 9.4977678 0.552256 0.457397 0.786460081 
hsa-miR-374a-5p -0.84624 7.765129 0.573262 0.448965 0.786460081 
hsa-miR-582-5p 1.014564 6.7948591 0.555297 0.456161 0.786460081 
hsa-miR-126-3p -0.54452 8.4566623 0.517901 0.471738 0.788429661 
hsa-miR-181d-5p 1.218029 7.5618856 0.518671 0.471409 0.788429661 
hsa-miR-203b-5p 0.881604 9.8042724 0.535991 0.464099 0.788429661 
hsa-miR-96-5p -0.74472 7.8129823 0.522664 0.469707 0.788429661 
hsa-miR-32-5p -0.76836 7.8389839 0.493167 0.482518 0.799299487 
hsa-miR-708-5p 0.912175 7.3963661 0.487755 0.484931 0.799299487 
hsa-miR-132-3p 0.866036 7.130833 0.464477 0.495539 0.803367374 
hsa-miR-23c -0.7005 8.3158521 0.446074 0.504205 0.803367374 
hsa-miR-3184-3p 0.448782 11.459004 0.454393 0.500256 0.803367374 
hsa-miR-423-5p 0.448814 11.459004 0.452919 0.500952 0.803367374 
hsa-miR-652-3p 0.628272 8.6999016 0.46131 0.497012 0.803367374 
hsa-miR-148a-3p -0.56148 15.457351 0.423959 0.514968 0.80534939 
hsa-miR-27b-3p -0.68293 12.96632 0.420665 0.516605 0.80534939 
hsa-miR-423-3p 0.450973 14.069983 0.420907 0.516485 0.80534939 
 
156 
 
hsa-miR-92a-3p 0.464458 14.618178 0.416023 0.518928 0.80534939 
hsa-let-7b-5p -0.41652 12.815815 0.28883 0.590971 0.815541785 
hsa-miR-106a-5p 0.667345 9.5701581 0.334483 0.563031 0.815541785 
hsa-miR-106b-5p 0.619592 7.2591352 0.376208 0.53964 0.815541785 
hsa-miR-1290 0.827504 7.0878356 0.314267 0.575074 0.815541785 
hsa-miR-148a-5p -0.43351 8.7009787 0.272519 0.601647 0.815541785 
hsa-miR-151a-5p 0.578661 6.9543925 0.267522 0.604999 0.815541785 
hsa-miR-15a-5p 0.567429 6.8846508 0.387827 0.533444 0.815541785 
hsa-miR-186-5p 0.418498 10.862124 0.377459 0.538966 0.815541785 
hsa-miR-23b-5p 0.811317 6.8660568 0.338481 0.560707 0.815541785 
hsa-miR-26b-5p -0.55522 11.507932 0.318765 0.572351 0.815541785 
hsa-miR-27b-5p 0.597064 7.4734448 0.321358 0.570793 0.815541785 
hsa-miR-29b-3p -0.63324 7.7126068 0.266382 0.605769 0.815541785 
hsa-miR-320b -0.63986 11.309314 0.259007 0.610803 0.815541785 
hsa-miR-339-3p 0.436579 7.580464 0.263409 0.607788 0.815541785 
hsa-miR-362-5p -0.68801 6.8831844 0.290659 0.589799 0.815541785 
hsa-miR-374a-3p -0.70429 6.903374 0.277316 0.598466 0.815541785 
hsa-miR-449a 0.707319 7.1738906 0.26791 0.604737 0.815541785 
hsa-miR-450b-5p 0.597008 6.9648557 0.274462 0.600354 0.815541785 
hsa-miR-532-5p -0.42383 11.679605 0.327338 0.567231 0.815541785 
hsa-miR-598-3p 0.620447 7.1412008 0.308179 0.5788 0.815541785 
hsa-miR-664a-5p 0.583614 8.3986854 0.349184 0.554575 0.815541785 
hsa-miR-744-5p -0.43236 10.564927 0.324956 0.568645 0.815541785 
hsa-miR-92b-3p 0.459972 8.0969897 0.302407 0.582377 0.815541785 
hsa-miR-98-5p 0.656272 11.543766 0.313011 0.575838 0.815541785 
hsa-miR-99b-3p 0.617464 7.7242429 0.354147 0.551775 0.815541785 
hsa-miR-148b-3p 0.411804 11.6944 0.24427 0.621139 0.820976005 
hsa-miR-20a-5p -0.46117 9.7100253 0.238656 0.625178 0.820976005 
hsa-miR-429 -0.49702 12.148174 0.241064 0.623438 0.820976005 
hsa-miR-200b-5p -0.5376 9.8354871 0.229757 0.631704 0.823063935 
hsa-miR-30e-5p -0.41913 9.8912822 0.227136 0.633656 0.823063935 
hsa-miR-193a-5p 0.412648 11.408706 0.219856 0.639149 0.825711901 
hsa-miR-107 0.399244 8.6348749 0.186616 0.665748 0.846349796 
hsa-miR-21-5p 0.424921 15.605387 0.192542 0.660809 0.846349796 
hsa-miR-29c-5p -0.43363 7.9730302 0.189158 0.663618 0.846349796 
hsa-miR-3184-5p -0.35109 9.5390259 0.182246 0.66945 0.846553651 
hsa-miR-22-5p 0.371383 9.1984617 0.175799 0.675009 0.8490897 
hsa-miR-451a 0.324515 16.397745 0.157973 0.69103 0.86469193 
hsa-miR-191-5p 0.260682 13.440101 0.147479 0.700956 0.872544106 
hsa-let-7a-5p -0.32923 16.345996 0.115813 0.73362 0.872846438 
hsa-miR-1-3p -0.48282 7.6747278 0.132573 0.715779 0.872846438 
 
157 
 
hsa-miR-100-5p 0.323166 14.368302 0.127479 0.72106 0.872846438 
hsa-miR-200a-5p -0.40083 8.8829552 0.130879 0.717523 0.872846438 
hsa-miR-2110 0.409964 8.1529223 0.139777 0.708503 0.872846438 
hsa-miR-424-3p 0.323625 7.9585278 0.123483 0.725287 0.872846438 
hsa-miR-4488 -0.44849 7.782507 0.128613 0.719874 0.872846438 
hsa-miR-504-5p -0.44546 7.2183624 0.11541 0.734068 0.872846438 
hsa-miR-874-3p 0.391261 6.7963615 0.120287 0.728723 0.872846438 
hsa-miR-196b-5p -0.40703 9.5067384 0.107008 0.743577 0.879776542 
hsa-miR-19a-3p 0.398072 6.9502228 0.084633 0.771114 0.907862993 
hsa-let-7d-3p -0.27558 10.195543 0.079932 0.777389 0.909917347 
hsa-miR-200a-3p 0.291708 13.614122 0.077675 0.780473 0.909917347 
hsa-miR-101-3p -0.19888 10.967683 0.058803 0.808398 0.922240334 
hsa-miR-200c-3p -0.25903 15.331867 0.061801 0.803672 0.922240334 
hsa-miR-204-3p 0.388138 8.7170939 0.062346 0.802826 0.922240334 
hsa-miR-320a -0.28819 15.036824 0.066632 0.796305 0.922240334 
hsa-miR-424-5p 0.329176 7.6192269 0.057596 0.810337 0.922240334 
hsa-miR-182-5p 0.161408 10.623732 0.050619 0.821989 0.931068234 
hsa-miR-324-5p 0.242013 6.9771132 0.04712 0.828152 0.932447136 
hsa-miR-335-5p -0.18641 7.3765432 0.039372 0.842714 0.932447136 
hsa-miR-502-3p -0.1876 8.3272378 0.039712 0.842045 0.932447136 
hsa-miR-532-3p 0.182299 7.8862883 0.04048 0.840545 0.932447136 
hsa-miR-7704 -0.2011 9.1348154 0.04143 0.83871 0.932447136 
hsa-let-7d-5p -0.1593 10.553354 0.026416 0.870888 0.954781328 
hsa-miR-218-5p -0.17003 7.1465665 0.026974 0.869543 0.954781328 
hsa-miR-9-5p 0.143642 8.8394647 0.021938 0.882253 0.962824372 
hsa-miR-144-3p -0.13792 7.278947 0.013572 0.907258 0.96801203 
hsa-miR-183-5p -0.09587 9.9540567 0.013607 0.907137 0.96801203 
hsa-miR-345-5p -0.10947 7.291081 0.015997 0.899351 0.96801203 
hsa-miR-455-5p -0.18113 7.2724557 0.018401 0.892099 0.96801203 
hsa-miR-501-3p 0.092629 8.202342 0.014765 0.903285 0.96801203 
hsa-miR-27a-3p -0.08653 11.99531 0.008104 0.928271 0.976368263 
hsa-miR-328-3p 0.087142 9.3043696 0.009527 0.922245 0.976368263 
hsa-miR-342-3p -0.06731 7.3940077 0.00765 0.930304 0.976368263 
hsa-miR-361-5p -0.07828 8.5256917 0.007404 0.931431 0.976368263 
hsa-miR-21-3p 0.08556 6.8639263 0.005286 0.942042 0.983178981 
hsa-miR-193b-3p 0.084254 8.3841002 0.004494 0.946553 0.983591596 
hsa-miR-19b-3p -0.03645 8.5633183 0.002498 0.960142 0.989111909 
hsa-miR-4497 0.063175 7.4202507 0.002777 0.957976 0.989111909 
hsa-let-7f-5p 0.013499 13.614829 0.000133 0.990814 0.995958467 
hsa-miR-125b-2-3p 0.01143 6.7902867 0.000962 0.975259 0.995958467 
hsa-miR-1307-5p 0.015023 8.1094631 0.000159 0.989929 0.995958467 
 
158 
 
hsa-miR-193b-5p 0.014656 7.5314755 0.000195 0.988848 0.995958467 
hsa-miR-320c 0.01255 8.7207467 9.49E-05 0.992229 0.995958467 
hsa-miR-340-5p 0.004386 10.301802 2.57E-05 0.995958 0.995958467 
hsa-miR-95-3p -0.03531 9.1361922 0.001293 0.971311 0.995958467 
 
Table 22: NGS Results Reanalyzed without the Outlier 10242013 G6 (significant values 
only) 
Gene Name logFC logCPM LR PValue FDR 
hsa-miR-223-3p 6.058034 10.920572 18.6917 1.54E-05 0.003672 
hsa-miR-135a-5p -3.74411 9.7413361 16.13384 5.90E-05 0.007053 
hsa-miR-142-3p 6.838292 9.8458739 14.13144 0.00017 0.011801 
hsa-miR-223-5p 5.654684 8.0163204 13.85467 0.000198 0.011801 
hsa-miR-363-3p -2.50551 11.791686 11.73019 0.000615 0.029394 
hsa-miR-199b-3p 4.541513 7.8019737 10.65301 0.001099 0.039301 
hsa-miR-199a-3p 4.606071 8.1449676 10.46955 0.001214 0.039301 
hsa-miR-20b-5p -5.2 7.6765883 10.27568 0.001348 0.039301 
hsa-miR-199b-5p 4.873913 7.8268478 10.10341 0.00148 0.039301 
hsa-miR-335-3p -4.20383 7.4143649 9.32286 0.002263 0.053027 
hsa-miR-148a-3p -1.96908 15.022611 8.767695 0.003066 0.053027 
hsa-miR-141-3p -2.93239 10.480757 8.766494 0.003068 0.053027 
hsa-miR-18a-3p 2.63595 7.72636 8.657284 0.003258 0.053027 
hsa-miR-143-3p 4.044592 11.182106 8.64716 0.003276 0.053027 
hsa-miR-26b-5p -2.25021 11.007079 8.567721 0.003422 0.053027 
hsa-miR-200c-3p -2.28666 14.64529 8.420047 0.003711 0.053027 
hsa-miR-184 6.013703 12.486412 8.390545 0.003772 0.053027 
hsa-miR-941 2.960932 10.667177 8.191066 0.00421 0.055896 
hsa-miR-30d-3p -3.8984 7.3098222 7.785788 0.005266 0.066239 
hsa-miR-429 -2.2439 11.655725 7.65768 0.005653 0.066846 
hsa-miR-618 4.717046 9.2540133 7.588716 0.005873 0.066846 
hsa-miR-145-5p 4.678684 8.1148049 7.452943 0.006333 0.068802 
hsa-miR-629-5p 2.18884 9.0952823 6.969643 0.00829 0.086148 
hsa-miR-28-5p -2.44446 8.2959277 6.719835 0.009535 0.094949 
hsa-miR-29c-3p -3.00686 9.4359788 6.599694 0.0102 0.097508 
hsa-miR-375 -2.39585 15.732764 6.25059 0.012415 0.114124 
hsa-miR-185-5p 1.766215 10.97283 5.932252 0.014866 0.131594 
hsa-miR-338-5p 2.789545 8.5425559 5.815708 0.015884 0.135578 
hsa-miR-205-5p 2.621553 10.832302 5.696611 0.016998 0.140085 
hsa-miR-3613-5p 2.736128 8.9034732 5.53656 0.018623 0.142586 
hsa-miR-362-5p -3.20117 7.0637951 5.501983 0.018995 0.142586 
hsa-miR-7706 3.062136 7.440193 5.493157 0.019091 0.142586 
hsa-miR-106b-3p 1.855044 10.197222 5.426127 0.019838 0.143673 
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hsa-let-7c-5p -2.10493 12.03373 5.342758 0.020809 0.146272 
hsa-miR-374a-3p -3.20561 7.0625966 5.230147 0.022199 0.151585 
hsa-miR-142-5p 2.750075 7.958257 5.098495 0.023947 0.156714 
hsa-miR-378a-3p 2.34489 14.462887 5.075865 0.024261 0.156714 
hsa-miR-499a-5p -2.90046 7.5751569 4.968956 0.025806 0.157202 
hsa-miR-200a-3p -1.7102 12.746068 4.943868 0.026183 0.157202 
hsa-miR-204-5p -2.13617 12.09691 4.922713 0.026506 0.157202 
hsa-miR-374a-5p -2.48276 7.731995 4.892872 0.026968 0.157202 
hsa-miR-196b-5p -2.50038 8.8013411 4.662995 0.030819 0.175314 
hsa-miR-3615 2.145313 8.6951132 4.594493 0.032075 0.175314 
hsa-miR-221-3p 1.99 11.403436 4.583806 0.032275 0.175314 
hsa-miR-29a-3p -1.56991 10.950711 4.538318 0.033144 0.176032 
hsa-miR-194-5p -2.08035 11.035454 4.338388 0.037262 0.193601 
hsa-miR-26a-5p -1.56089 14.407557 4.299118 0.038132 0.193906 
hsa-miR-378c 2.117121 11.50856 4.262065 0.038973 0.194051 
hsa-miR-382-5p 4.079753 8.1052867 4.178959 0.040929 0.194612 
hsa-miR-30b-5p -1.78232 9.361434 4.169492 0.041158 0.194612 
hsa-miR-200a-5p -2.0379 8.4756649 4.131579 0.04209 0.194612 
hsa-miR-146a-5p 1.879016 11.066714 4.121463 0.042342 0.194612 
hsa-miR-210-3p 2.441074 8.8114332 4.0693 0.043669 0.196839 
hsa-miR-27b-3p -1.91852 12.638123 4.038468 0.044474 0.196839 
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Table 23: The Cancer Genome Atlas NGS Analysis  
Gene Name logFC logCPM LR PValue FDR 
hsa-mir-153-2 2.375872 4.2179218 134.3074 4.68E-31 4.90E-28 
hsa-mir-93 1.189148 10.550639 119.7268 7.26E-28 3.80E-25 
hsa-mir-3074 1.814727 1.568247 108.3875 2.21E-25 7.71E-23 
hsa-mir-92a-1 1.564023 8.3213546 107.1198 4.19E-25 1.10E-22 
hsa-mir-20a 1.132973 6.8277576 90.2482 2.10E-21 4.39E-19 
hsa-mir-891a -4.69622 5.7882076 82.21717 1.22E-19 2.13E-17 
hsa-mir-148a 1.108021 14.993064 68.8513 1.06E-16 1.39E-14 
hsa-mir-221 -1.2587 8.3836717 68.56983 1.22E-16 1.39E-14 
hsa-mir-19b-2 1.065629 6.4343874 68.52597 1.25E-16 1.39E-14 
hsa-mir-27b -0.80095 11.045283 68.40606 1.33E-16 1.39E-14 
hsa-mir-200c 1.159767 12.559697 67.30591 2.32E-16 2.21E-14 
hsa-mir-3648 2.114903 1.752852 66.47013 3.55E-16 3.10E-14 
hsa-mir-92a-2 0.880161 12.000063 64.57169 9.31E-16 7.49E-14 
hsa-mir-204 -1.92817 5.272123 63.19781 1.87E-15 1.40E-13 
hsa-mir-96 1.521856 3.6452804 61.95647 3.51E-15 2.45E-13 
hsa-mir-17 0.852782 8.3718011 61.82654 3.75E-15 2.45E-13 
hsa-mir-3653 1.376266 2.1313151 60.26718 8.28E-15 5.10E-13 
hsa-mir-153-1 1.911868 1.04943 59.08511 1.51E-14 8.77E-13 
hsa-mir-3651 2.366102 -0.051638 58.82416 1.72E-14 9.49E-13 
hsa-mir-708 1.081198 3.9738929 58.62231 1.91E-14 9.99E-13 
hsa-mir-143 -0.95183 19.164957 57.06874 4.21E-14 2.10E-12 
hsa-mir-130b 1.021477 3.1036429 55.8414 7.86E-14 3.74E-12 
hsa-mir-187 -2.39347 4.4546513 55.31364 1.03E-13 4.67E-12 
hsa-mir-222 -0.93211 6.1568708 51.57749 6.88E-13 3.00E-11 
hsa-mir-133b -1.31753 5.379416 51.33117 7.80E-13 3.26E-11 
hsa-mir-19b-1 0.949312 1.8721361 50.60346 1.13E-12 4.55E-11 
hsa-mir-141 1.022551 9.7097178 50.44562 1.23E-12 4.75E-11 
hsa-mir-23c -1.83966 2.5130641 50.11969 1.45E-12 5.40E-11 
hsa-mir-629 0.704272 5.7138313 49.96907 1.56E-12 5.63E-11 
hsa-mir-19a 1.161695 3.7454592 49.89754 1.62E-12 5.65E-11 
hsa-mir-1224 -4.30229 1.2200315 49.05925 2.48E-12 8.38E-11 
hsa-mir-133a-2 -1.35028 3.4053011 48.93359 2.65E-12 8.65E-11 
hsa-mir-10a -1.81014 12.372823 48.84375 2.77E-12 8.79E-11 
hsa-mir-126 0.734171 9.9003198 48.05625 4.14E-12 1.24E-10 
hsa-mir-889 -1.04511 4.1637969 48.04553 4.16E-12 1.24E-10 
hsa-mir-375 1.60362 15.632796 46.46021 9.35E-12 2.72E-10 
 
161 
 
hsa-mir-378c -1.02956 3.3046928 44.90335 2.07E-11 5.70E-10 
hsa-mir-7-1 0.896851 3.6806218 44.90242 2.07E-11 5.70E-10 
hsa-mir-381 -0.82828 5.6754016 44.56851 2.46E-11 6.59E-10 
hsa-mir-196b 0.792775 9.0507603 44.21714 2.94E-11 7.69E-10 
hsa-mir-20b 1.143666 6.8579937 42.27071 7.95E-11 2.03E-09 
hsa-mir-1275 2.361612 -0.028257 41.71947 1.05E-10 2.62E-09 
hsa-mir-184 -2.50435 2.5996989 41.10668 1.44E-10 3.51E-09 
hsa-mir-873 -2.2561 -0.088651 40.82375 1.67E-10 3.96E-09 
hsa-mir-892a -4.87136 0.9964634 40.47178 1.99E-10 4.64E-09 
hsa-mir-452 -0.758 5.5046358 39.81024 2.80E-10 6.36E-09 
hsa-mir-25 0.800304 11.867799 39.03831 4.16E-10 9.25E-09 
hsa-mir-615 2.180022 -0.057721 35.88002 2.10E-09 4.57E-08 
hsa-mir-182 1.245345 12.93727 34.69345 3.86E-09 8.24E-08 
hsa-mir-888 -5.66614 0.3677875 33.31146 7.85E-09 1.64E-07 
hsa-mir-3189 2.62196 -0.982561 32.66443 1.10E-08 2.23E-07 
hsa-mir-379 -0.7396 9.1201181 32.63807 1.11E-08 2.23E-07 
hsa-mir-3687 1.707156 0.4725616 32.59746 1.13E-08 2.24E-07 
hsa-mir-3170 1.591742 -0.616192 32.44443 1.23E-08 2.38E-07 
hsa-mir-425 0.76313 5.7920194 32.30154 1.32E-08 2.51E-07 
hsa-mir-1-2 -0.87472 7.9576222 31.13993 2.40E-08 4.47E-07 
hsa-mir-3607 1.184976 4.5866887 31.11324 2.43E-08 4.47E-07 
hsa-mir-542 -0.96701 6.8026582 30.8819 2.74E-08 4.95E-07 
hsa-mir-106a 0.919663 5.5517447 30.81021 2.85E-08 5.04E-07 
hsa-mir-1258 -1.34897 1.1020469 30.15134 4.00E-08 6.97E-07 
hsa-mir-1251 -2.29768 2.8075032 29.50735 5.57E-08 9.55E-07 
hsa-mir-135b -1.52791 0.8813382 29.47205 5.67E-08 9.57E-07 
hsa-mir-561 1.133266 0.2380957 29.02588 7.14E-08 1.19E-06 
hsa-mir-490 -2.74685 2.1406113 28.72398 8.35E-08 1.36E-06 
hsa-mir-106b 0.526667 7.8125021 28.46152 9.56E-08 1.54E-06 
hsa-mir-32 0.773088 4.8223119 27.83285 1.32E-07 2.10E-06 
hsa-mir-218-2 -0.46608 5.7003667 27.66883 1.44E-07 2.25E-06 
hsa-mir-23b -0.55774 10.960628 27.41853 1.64E-07 2.52E-06 
hsa-mir-323b -1.82248 1.326315 27.38474 1.67E-07 2.53E-06 
hsa-mir-654 -0.60883 4.3471905 26.81406 2.24E-07 3.35E-06 
hsa-mir-24-2 -0.52602 10.48834 26.46609 2.68E-07 3.95E-06 
hsa-mir-191 0.631971 7.8381464 26.06139 3.31E-07 4.80E-06 
hsa-mir-423 0.493807 5.7133823 25.73824 3.91E-07 5.60E-06 
hsa-mir-299 -0.69771 1.5389282 25.64819 4.10E-07 5.79E-06 
hsa-mir-934 -1.2634 0.6017654 25.09668 5.45E-07 7.60E-06 
hsa-mir-616 0.998361 0.1730767 24.92321 5.97E-07 8.21E-06 
hsa-mir-30d 0.403105 12.398191 24.43917 7.67E-07 1.04E-05 
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hsa-mir-487b -0.73082 2.2862904 24.35392 8.02E-07 1.07E-05 
hsa-mir-342 0.482584 5.5961014 24.34723 8.04E-07 1.07E-05 
hsa-mir-27a -0.47366 9.3506832 24.27636 8.35E-07 1.09E-05 
hsa-mir-133a-1 -0.8883 7.1426282 24.2585 8.42E-07 1.09E-05 
hsa-mir-1269 3.5489 4.4194509 24.14436 8.94E-07 1.14E-05 
hsa-mir-18a 0.70535 1.7441356 23.90582 1.01E-06 1.26E-05 
hsa-mir-576 0.597962 2.2538887 23.90079 1.01E-06 1.26E-05 
hsa-mir-449a 2.819635 -0.159285 23.69269 1.13E-06 1.39E-05 
hsa-mir-99b -0.35597 13.823526 23.62524 1.17E-06 1.42E-05 
hsa-mir-378 -0.6635 8.9037056 23.35121 1.35E-06 1.62E-05 
hsa-mir-363 0.699295 6.4066321 23.3231 1.37E-06 1.63E-05 
hsa-mir-891b -5.14585 -0.130729 23.2777 1.40E-06 1.65E-05 
hsa-mir-183 1.103625 11.367074 23.25485 1.42E-06 1.65E-05 
hsa-mir-500a 0.523525 6.2745502 23.13477 1.51E-06 1.74E-05 
hsa-mir-330 -0.57455 3.5008487 22.70964 1.88E-06 2.14E-05 
hsa-mir-134 -0.52931 7.0027908 22.57249 2.02E-06 2.28E-05 
hsa-mir-152 -0.60935 8.3401442 22.49824 2.10E-06 2.34E-05 
hsa-mir-21 0.471152 16.196297 21.92 2.84E-06 3.13E-05 
hsa-mir-652 -0.96209 3.8734763 21.75394 3.10E-06 3.38E-05 
hsa-mir-3664 1.680061 -0.776448 21.6186 3.33E-06 3.59E-05 
hsa-mir-196a-1 -0.87573 2.1546557 21.15967 4.23E-06 4.51E-05 
hsa-mir-541 -1.51921 -0.580814 21.14076 4.27E-06 4.51E-05 
hsa-mir-24-1 -0.44331 4.439857 21.07526 4.42E-06 4.62E-05 
hsa-mir-618 1.694674 -0.772066 20.94669 4.72E-06 4.89E-05 
hsa-mir-496 -0.69917 1.1432969 20.75066 5.23E-06 5.36E-05 
hsa-mir-411 -0.6642 2.8882369 20.44708 6.13E-06 6.23E-05 
hsa-mir-1291 1.237728 -0.494637 20.42559 6.20E-06 6.24E-05 
hsa-mir-127 -0.51892 9.0653456 20.24933 6.80E-06 6.77E-05 
hsa-mir-142 0.798764 8.9525854 19.92059 8.07E-06 7.97E-05 
hsa-mir-210 1.111234 5.8703593 19.81764 8.52E-06 8.33E-05 
hsa-mir-491 0.627844 1.3230771 19.75425 8.81E-06 8.53E-05 
hsa-mir-1304 1.606437 -0.445973 19.15283 1.21E-05 0.000116 
hsa-mir-769 0.391005 4.0479618 19.10706 1.24E-05 0.000118 
hsa-mir-22 -0.31887 15.574185 19.08515 1.25E-05 0.000118 
hsa-mir-3614 1.144672 -0.428612 18.82959 1.43E-05 0.000133 
hsa-mir-760 -1.00978 0.023289 18.72802 1.51E-05 0.00014 
hsa-mir-451 -1.02134 7.0260939 18.61829 1.60E-05 0.000147 
hsa-mir-744 0.527733 4.487698 18.52389 1.68E-05 0.000153 
hsa-mir-410 -0.55338 3.5086681 18.49244 1.71E-05 0.000154 
hsa-mir-892b -4.02234 -0.677826 18.3868 1.80E-05 0.000161 
hsa-mir-146b 0.757807 7.2233514 18.36164 1.83E-05 0.000162 
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hsa-mir-944 -1.04098 1.3734933 18.15102 2.04E-05 0.000179 
hsa-mir-100 -0.46524 13.170244 18.02096 2.18E-05 0.00019 
hsa-mir-514-3 -1.45621 0.1594851 17.59132 2.74E-05 0.000237 
hsa-mir-3612 -1.62059 -1.267406 17.51498 2.85E-05 0.000244 
hsa-mir-450b -0.87174 3.0927677 17.30202 3.19E-05 0.000271 
hsa-mir-758 -0.49704 3.4817026 17.2797 3.23E-05 0.000272 
hsa-mir-26a-2 -0.45882 11.094345 17.09713 3.55E-05 0.000297 
hsa-mir-1248 0.846675 0.9442437 17.05347 3.63E-05 0.000302 
hsa-mir-1976 0.533807 1.8627077 17.00728 3.72E-05 0.000307 
hsa-mir-514-2 -1.50625 0.1951512 16.66533 4.46E-05 0.000364 
hsa-mir-190b 1.259403 -0.35248 16.25653 5.53E-05 0.000447 
hsa-mir-432 -0.62185 2.325647 16.24684 5.56E-05 0.000447 
hsa-mir-651 0.612704 0.7319562 16.22105 5.64E-05 0.00045 
hsa-mir-224 -0.54797 3.1618562 16.09485 6.02E-05 0.000477 
hsa-mir-370 -0.57781 2.4921079 15.97631 6.41E-05 0.000504 
hsa-mir-876 -1.54566 -1.034093 15.80843 7.01E-05 0.000547 
hsa-mir-514-1 -1.42358 0.1829902 15.51246 8.20E-05 0.000635 
hsa-mir-590 0.420038 3.1638283 14.76732 0.000122 0.000935 
hsa-mir-424 -0.64829 4.7932847 14.75247 0.000123 0.000936 
hsa-mir-219-2 -1.59514 -0.297982 14.53728 0.000137 0.001042 
hsa-mir-493 -0.5778 2.7048661 14.45822 0.000143 0.001078 
hsa-mir-212 -0.50694 2.8662911 14.37463 0.00015 0.001119 
hsa-mir-376c -0.61721 2.200399 14.08588 0.000175 0.001296 
hsa-mir-559 1.600928 -1.160333 14.01829 0.000181 0.001334 
hsa-mir-671 0.446058 1.5714286 13.8932 0.000193 0.001415 
hsa-mir-197 0.417267 6.6372194 13.87261 0.000196 0.001421 
hsa-mir-501 0.440567 3.2742846 13.67462 0.000217 0.001568 
hsa-mir-29a -0.35551 12.707552 13.54894 0.000232 0.001665 
hsa-mir-3676 1.017736 2.2830318 13.28862 0.000267 0.0019 
hsa-mir-660 0.404794 5.012233 13.1476 0.000288 0.002035 
hsa-mir-508 -1.2397 2.3448322 13.07565 0.000299 0.0021 
hsa-mir-338 -0.61435 7.8877981 13.05297 0.000303 0.002112 
hsa-mir-548t 1.280678 -0.799869 13.01175 0.00031 0.002144 
hsa-mir-145 -0.45408 12.363643 12.74921 0.000356 0.002443 
hsa-mir-675 -1.20006 2.5301579 12.74318 0.000357 0.002443 
hsa-mir-107 -0.26893 5.1128204 12.43036 0.000422 0.002869 
hsa-mir-592 1.112876 0.0786445 12.40798 0.000428 0.002885 
hsa-mir-505 -0.48984 4.355685 12.29427 0.000454 0.003046 
hsa-mir-144 -0.84323 5.0465558 12.21289 0.000475 0.003151 
hsa-mir-890 -2.26721 -1.19492 12.20763 0.000476 0.003151 
hsa-mir-431 -0.6881 2.2115542 11.98578 0.000536 0.003527 
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hsa-mir-154 -0.42403 2.2543405 11.9715 0.00054 0.003532 
hsa-mir-3152 1.547579 -0.676012 11.93548 0.000551 0.003578 
hsa-mir-382 -0.44196 3.1450414 11.75463 0.000607 0.003915 
hsa-mir-98 -0.32418 4.7639758 11.74473 0.00061 0.003915 
hsa-mir-663 1.363497 -0.765854 11.7246 0.000617 0.003934 
hsa-mir-488 -1.27539 -0.10305 11.32988 0.000763 0.004833 
hsa-mir-377 -0.47003 1.4469292 11.31949 0.000767 0.004833 
hsa-mir-129-1 -0.88255 1.202866 11.02947 0.000897 0.005617 
hsa-mir-205 -0.81572 10.109087 10.95431 0.000934 0.005814 
hsa-mir-2114 -1.13975 -0.0336 10.77982 0.001026 0.006341 
hsa-mir-383 -0.90911 1.6392219 10.77182 0.001031 0.006341 
hsa-mir-627 0.625524 0.2908571 10.67323 0.001087 0.006649 
hsa-mir-676 -0.68021 0.3620714 10.59113 0.001136 0.00691 
hsa-mir-188 0.477346 1.2396901 10.56898 0.00115 0.006943 
hsa-mir-376a-1 -0.66012 0.1372532 10.56094 0.001155 0.006943 
hsa-mir-509-3 -1.54933 -0.272854 10.43443 0.001237 0.007393 
hsa-mir-552 -1.15865 -0.980088 10.34536 0.001298 0.007714 
hsa-mir-486 -0.77592 5.3991957 10.19518 0.001408 0.008321 
hsa-mir-450a-2 -0.61022 0.9699993 10.10317 0.00148 0.008698 
hsa-mir-412 -1.00977 1.5010153 9.905115 0.001648 0.009631 
hsa-mir-543 -0.55986 0.4045636 9.750433 0.001793 0.010418 
hsa-mir-3658 1.085486 -1.307106 9.629619 0.001915 0.011065 
hsa-mir-376a-2 -0.7518 -0.5099 9.54603 0.002004 0.011516 
hsa-mir-129-2 -0.8246 1.2402839 9.437361 0.002126 0.012152 
hsa-mir-1296 0.46015 2.391548 9.250943 0.002354 0.013381 
hsa-mir-3923 -1.12384 -1.307406 8.928845 0.002807 0.015871 
hsa-mir-1-1 -0.67784 -0.080493 8.900593 0.002851 0.016032 
hsa-mir-484 0.421845 4.4109294 8.867331 0.002903 0.016239 
hsa-mir-532 0.349094 9.2625446 8.829194 0.002964 0.016494 
hsa-mir-323 -0.77066 0.8079309 8.803072 0.003007 0.016643 
hsa-mir-485 -0.49873 0.7664848 8.732438 0.003126 0.017209 
hsa-mir-454 0.33438 2.0117732 8.523015 0.003507 0.019205 
hsa-mir-15a 0.270969 6.1167716 8.418911 0.003713 0.02023 
hsa-mir-147b 1.213297 -0.653303 8.332971 0.003893 0.021039 
hsa-mir-181d -0.34867 3.7627408 8.328802 0.003902 0.021039 
hsa-mir-3622b -1.37434 -1.293387 8.282237 0.004003 0.021475 
hsa-mir-200b 0.512001 9.1454824 8.216699 0.004151 0.022151 
hsa-mir-369 -0.43261 3.0787675 8.119267 0.00438 0.023255 
hsa-mir-449b 1.970322 -1.08281 7.964609 0.00477 0.0252 
hsa-let-7c -0.30802 12.656205 7.902721 0.004936 0.025945 
hsa-mir-3193 -0.9805 -0.78771 7.829555 0.00514 0.026882 
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hsa-mir-3195 -1.26913 -1.124426 7.775057 0.005297 0.027567 
hsa-mir-214 -0.28483 3.8830032 7.716223 0.005473 0.02828 
hsa-mir-628 -0.34764 2.988739 7.711054 0.005488 0.02828 
hsa-mir-103-2 0.343933 1.71964 7.687482 0.005561 0.028511 
hsa-mir-494 -0.62473 0.2759539 7.639594 0.00571 0.029135 
hsa-mir-513c -1.20781 -1.255094 7.57005 0.005935 0.030134 
hsa-mir-589 0.233194 4.8469167 7.450223 0.006343 0.031996 
hsa-mir-3154 -1.19174 -1.06453 7.444645 0.006363 0.031996 
hsa-mir-653 0.459498 0.87323 7.419811 0.006451 0.032286 
hsa-mir-376b -0.55901 0.1533243 7.20836 0.007256 0.036144 
hsa-mir-539 -0.54821 1.7863857 7.150319 0.007495 0.037156 
hsa-mir-23a -0.28687 10.739657 7.093859 0.007735 0.038163 
hsa-mir-1255a 0.610042 -0.35008 7.022879 0.008047 0.03952 
hsa-mir-30b 0.402195 8.5344667 6.958267 0.008343 0.040781 
hsa-mir-219-1 0.399761 0.8042959 6.814108 0.009044 0.043945 
hsa-mir-509-1 -1.00122 -0.45673 6.799211 0.00912 0.043945 
hsa-mir-2278 1.070325 -1.286556 6.793383 0.00915 0.043945 
hsa-mir-136 -0.46398 5.5384516 6.786174 0.009187 0.043945 
hsa-mir-450a-1 -0.55158 0.9146509 6.783435 0.009201 0.043945 
hsa-mir-181a-2 -0.33465 7.713994 6.744644 0.009403 0.044707 
hsa-mir-3613 0.423838 2.8163195 6.728623 0.009488 0.044906 
hsa-mir-632 0.993626 -0.9512 6.703287 0.009624 0.045343 
hsa-mir-3622a -0.61936 -0.45416 6.609157 0.010146 0.047589 
hsa-mir-139 -0.36296 6.2422859 6.524153 0.010642 0.04969 
hsa-mir-495 -0.34241 2.2711025 6.516373 0.010689 0.04969 
hsa-mir-150 0.466193 7.9079427 6.506354 0.010749 0.04975 
hsa-mir-497 0.280251 4.9098755 6.369655 0.011609 0.053493 
hsa-mir-329-2 -0.60551 -0.410151 6.291365 0.012133 0.055662 
hsa-mir-3662 1.135779 -1.266248 6.168184 0.013007 0.059117 
hsa-mir-3943 -0.78855 -0.534875 6.163351 0.013042 0.059117 
hsa-mir-1225 -0.91101 -1.113035 6.161568 0.013056 0.059117 
hsa-mir-585 -0.88169 -0.49172 6.122093 0.01335 0.060191 
hsa-mir-550a-1 0.459876 0.2001389 6.068211 0.013764 0.061789 
hsa-mir-181b-1 -0.2924 6.1014706 6.029579 0.014068 0.062886 
hsa-mir-95 0.448455 0.6233907 5.96929 0.014557 0.064795 
hsa-mir-125a -0.25369 9.1056048 5.880956 0.015306 0.067837 
hsa-mir-4284 -0.96183 -1.294707 5.819267 0.015852 0.069961 
hsa-mir-206 -1.83627 6.7549515 5.693307 0.01703 0.074845 
hsa-mir-1274b 0.571288 2.2075754 5.685597 0.017105 0.07486 
hsa-mir-15b 0.313265 6.2310564 5.66825 0.017275 0.075289 
hsa-mir-31 -0.54201 2.0714663 5.63074 0.017648 0.076597 
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hsa-mir-103-1 0.246508 13.002564 5.464777 0.019404 0.083868 
hsa-mir-670 -0.78546 -1.32823 5.39122 0.020238 0.087116 
hsa-mir-935 0.695878 -0.388736 5.381551 0.020351 0.087241 
hsa-mir-668 -1.08927 -1.164109 5.37052 0.02048 0.087437 
hsa-mir-1237 -0.77066 -1.3284 5.34717 0.020756 0.088255 
hsa-mir-581 0.64162 -0.768555 5.329895 0.020963 0.088773 
hsa-mir-1179 -0.78141 -0.947104 5.304739 0.021267 0.089701 
hsa-mir-3180-4 -0.72341 -1.32902 5.195204 0.022649 0.095145 
hsa-mir-26a-1 0.416579 0.3972515 5.187801 0.022746 0.095169 
hsa-mir-105-1 1.207705 -0.331231 5.167196 0.023017 0.095921 
hsa-mir-655 -0.36388 0.6473016 5.13758 0.023413 0.097184 
hsa-mir-1539 0.714487 -1.329103 5.12272 0.023615 0.097632 
hsa-let-7a-2 0.22847 13.407557 5.096461 0.023975 0.09873 
hsa-mir-326 -0.30874 2.1257736 5.047497 0.024662 0.101161 
hsa-mir-498 0.685741 -1.329539 5.024415 0.024992 0.102117 
hsa-mir-3146 0.681822 -1.329602 5.010132 0.025199 0.102562 
hsa-mir-3647 0.486405 1.9821505 4.995338 0.025416 0.103042 
hsa-mir-555 0.672077 -1.329734 4.980918 0.025628 0.103503 
hsa-mir-612 1.369552 -1.110237 4.963316 0.025891 0.10416 
hsa-mir-345 0.266392 2.473808 4.913869 0.026642 0.10639 
hsa-mir-130a -0.27107 6.0258603 4.913443 0.026648 0.10639 
hsa-mir-3065 0.39577 4.9858477 4.895791 0.026922 0.107075 
hsa-mir-548e 0.702434 -0.861516 4.851402 0.027624 0.109448 
hsa-mir-362 0.301661 2.625225 4.792975 0.028576 0.112794 
hsa-let-7a-1 0.227778 12.407351 4.741326 0.029446 0.115793 
hsa-mir-105-2 1.248527 -0.21597 4.727204 0.029689 0.11631 
hsa-let-7a-3 0.225029 12.414 4.671376 0.030669 0.119702 
hsa-mir-3650 0.898982 -1.259267 4.604422 0.03189 0.124002 
hsa-mir-339 0.230297 3.8974532 4.594222 0.03208 0.12428 
hsa-mir-4286 0.803333 -1.032317 4.560788 0.032712 0.126261 
hsa-mir-599 -0.89787 -1.197875 4.525217 0.033399 0.128438 
hsa-mir-378b -0.83605 -1.174776 4.490212 0.034089 0.130614 
hsa-mir-556 0.710719 -0.62805 4.474166 0.034411 0.131365 
hsa-mir-2115 0.865139 -0.902961 4.448892 0.034924 0.132838 
hsa-mir-198 0.843868 -1.300827 4.365231 0.03668 0.13901 
hsa-mir-125b-2 -0.20212 5.9984506 4.299676 0.03812 0.143946 
hsa-mir-30e -0.1728 13.216998 4.263042 0.03895 0.146553 
hsa-mir-937 0.543025 -0.368983 4.243216 0.039407 0.147743 
hsa-mir-4326 0.487951 0.4040128 4.206982 0.040258 0.150392 
hsa-mir-574 0.237821 5.7688801 4.191981 0.040616 0.151188 
hsa-mir-3909 -0.55831 -0.789732 4.116423 0.042469 0.157526 
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hsa-mir-372 0.895694 -0.893316 4.097254 0.042953 0.158616 
hsa-mir-181c -0.21991 6.5870333 4.088872 0.043166 0.158616 
hsa-mir-3611 0.851846 -1.245825 4.086868 0.043218 0.158616 
hsa-mir-2110 0.393347 0.5408299 4.079816 0.043398 0.158723 
hsa-mir-335 0.274122 5.0125101 4.069488 0.043665 0.15914 
hsa-mir-3161 1.172215 -1.248226 4.050552 0.044157 0.160375 
hsa-mir-215 -0.37529 0.6691823 4.037941 0.044488 0.161019 
hsa-mir-1231 -0.5923 -1.335904 4.009117 0.045255 0.162738 
hsa-mir-3937 0.605495 -1.335697 4.0084 0.045274 0.162738 
hsa-mir-155 0.294701 6.2326402 3.997428 0.04557 0.16324 
hsa-mir-570 0.655976 -0.776421 3.978735 0.046078 0.164497 
hsa-mir-1285-1 0.582635 -1.335965 3.955972 0.046705 0.166169 
hsa-mir-622 0.571268 -1.336162 3.918812 0.047749 0.169305 
hsa-mir-3907 -0.55352 -1.336432 3.907852 0.048061 0.169837 
hsa-mir-3121 -0.55213 -1.33652 3.892043 0.048515 0.170713 
hsa-mir-3918 -0.79349 -1.287335 3.882747 0.048785 0.170713 
hsa-mir-200a 0.382774 8.57815 3.880845 0.04884 0.170713 
hsa-mir-943 -0.79195 -1.288203 3.876283 0.048973 0.170713 
hsa-let-7e -0.25991 9.3482691 3.871083 0.049125 0.170713 
hsa-mir-3927 -0.53496 -1.336734 3.85234 0.049677 0.171815 
hsa-mir-1277 0.556949 -0.301321 3.849172 0.049771 0.171815 
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Table 24: P69 vs M12 Microarray Analysis 
Gene Name 
Fold 
change Gene Name 
Fold 
change Gene Name 
Fold 
change 
hsa-miR-548m-5p -500 hsa-miR-135b-3p -6.84932 hsa-miR-500-5p -3.1348 
hsa-miR-127-3p -500 hsa-miR-132-3p -6.45161 hsa-miR-2113-5p -3.125 
hsa-miR-411-5p -200 hsa-miR-520a-5p -6.41026 hsa-miR-1227-5p -3.03951 
hsa-miR-138-1-3p -200 hsa-miR-29c-3p -6.32911 hsa-miR-425-3p -3.003 
hsa-miR-891b-5p -142.857 hsa-miR-514-5p -6.25 hsa-miR-146b-5p -2.99401 
hsa-miRPlus-C1089 -111.111 hsa-miR-489-5p -6.21118 hsa-miR-140-3p -2.95858 
hsa-miR-1248-5p -58.8235 hsa-miR-145-3p -6.17284 hsa-miR-127-5p -2.90698 
hsa-miR-299-5p -50 hsa-miR-342-5p -6.06061 hsa-miR-1181-5p -2.86533 
hsa-miR-379-5p -50 hsa-miR-23b-3p -5.91716 hsa-miR-587-5p -2.83286 
hsa-miR-889-5p -40 hsa-miR-556-3p -5.78035 hsa-miR-379-3p -2.7933 
hsa-miR-548a-5p -35.7143 hsa-miR-23a-3p -5.61798 hsa-miR-1182-5p -2.78552 
hsa-miR-323a-3p -32.2581 hsa-miR-1265-5p -5.34759 hsa-miR-876-3p -2.73973 
hsa-miRPlus-D1061 -27.7778 hsa-miR-148a-3p -5.29101 hsa-miR-296-3p -2.7027 
hsa-miR-34b-3p -27.027 hsa-miR-143-3p -5.2356 hsa-let-7a-2-3p -2.69542 
hsa-miR-487b-5p -25.641 hsa-miR-1267-5p -5.18135 hsa-miR-603-5p -2.68817 
hsa-miR-1238-5p -25.641 hsa-miR-376a-3p -5.05051 hsa-miR-411-3p -2.6738 
hsa-miR-409-3p -23.8095 hsa-miR-105-3p -5.02513 hsa-miR-144-5p -2.6738 
hsa-miR-135b-5p -23.2558 hsa-miR-1260a-5p -4.7619 hsa-miR-1538-5p -2.6455 
hsa-miR-614-5p -23.2558 hsa-miR-27a-5p -4.7619 hsa-miR-323-5p -2.6178 
hsa-miR-504-5p -22.7273 hsa-miR-125b-1-3p -4.71698 hsa-miR-758-5p -2.59067 
hsa-miR-1914-3p -22.2222 hsa-miR-380-5p -4.71698 hsa-miR-770-5p -2.55102 
hsa-miR-520d-3p -21.2766 hsa-miR-369-5p -4.6729 hsa-miR-15b-5p -2.55102 
hsa-miR-382-5p -20.8333 hsa-miR-572-5p -4.65116 hsa-miR-27b-5p -2.53165 
hsa-miR-1185-5p -20 hsa-miR-100-5p -4.5045 SNORD38B -2.51256 
hsa-miR-579-5p -19.6078 hsa-miR-1206-5p -4.44444 hsa-miR-1270-5p -2.5 
hsa-miR-659-5p -19.6078 hsa-miR-19b-2-3p -4.34783 hsa-miR-339-5p -2.48139 
hsa-miR-136-5p -18.1818 hsa-miR-138-2-3p -4.31034 hsa-miR-654-5p -2.47525 
hsa-miR-452-3p -17.5439 hsa-miR-598-5p -4.2735 hsa-miR-19b-5p -2.46914 
hsa-miR-377-5p -17.2414 hsa-miR-376c-5p -4.25532 hsa-miR-630-5p -2.45098 
hsa-miR-490-5p -16.9492 hsa-miR-31-5p -4.21941 hsa-miR-449b-3p -2.42131 
hsa-miR-936-5p -15.625 hsa-miR-376b-5p -4.14938 hsa-miR-1256-5p -2.40964 
hsa-miR-362-3p -13.8889 hsa-miR-1258-5p -4.13223 hsa-miR-378a-3p -2.40385 
hsa-miR-616-5p -12.5 hsa-miR-543-5p -3.90625 hsa-miR-212-5p -2.33645 
hsa-miR-432-5p -11.7647 hsa-miR-191-5p -3.87597 hsa-miR-142-5p -2.32019 
hsa-miR-619-5p -11.6279 hsa-miR-432-3p -3.74532 hsa-miR-302d-3p -2.24215 
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hsa-miR-509-3p -10.989 hsa-miR-181a-2-3p -3.74532 hsa-miR-100-3p -2.23214 
hsa-miR-1237-5p -10.5263 hsa-miR-302e-5p -3.74532 hsa-miR-555-5p -2.20264 
hsa-miR-541-3p -10.4167 hsa-miR-448-5p -3.67647 hsa-miR-23b-5p -2.1978 
hsa-miR-1179-5p -10.2041 hsa-miR-376a-5p -3.663 hsa-miR-146a-5p -2.17865 
hsa-miR-1236-5p -10 hsa-miR-1245a-5p -3.63636 hsa-miR-769-3p -2.17391 
hsa-miR-640-5p -9.52381 hsa-miR-493-3p -3.63636 hsa-miR-125a-3p -2.1322 
hsa-miR-135a-5p -8.19672 hsa-miR-649-5p -3.62319 hsa-miR-1253-5p -2.12314 
hsa-miR-888-3p -8.06452 hsa-miR-924-5p -3.59712 hsa-miR-34c-5p -2.11864 
hsa-miR-342-3p -7.87402 hsa-miR-191-3p -3.43643 hsa-miR-224-3p -2.10526 
hsa-miR-588-5p -7.69231 hsa-miR-875-3p -3.27869 hsa-miR-591-5p -2.08768 
hsa-miR-527-5p -7.57576 hsa-miR-218-1-3p -3.26797 hsa-miR-450b-5p -2.05339 
hsa-miR-141-3p -7.40741 hsa-miR-526b-3p -3.26797 hsa-miR-636-5p -2.04499 
hsa-miR-196b-3p -7.29927 hsa-miR-138-5p -3.22581 hsa-miR-720-5p -2.04082 
hsa-miR-125b-5p -6.89655 hsa-miR-21-5p -3.20513 hsa-miR-1914-5p -2.03252 
hsa-miR-516b-3p -6.84932 hsa-miR-1913-5p -3.16456 hsa-miR-203-5p -2.0284 
 
Gene Name 
Fold 
change Gene Name 
Fold 
change Gene Name 
Fold 
change 
hsa-miRPlusA1027 2.003 hsa-miR-200c-3p 3.487 hsa-miR-486-5p 9.078 
hsa-miR-126-5p 2.004 hsa-miR-188-5p 3.557 hsa-miR-570-5p 9.152 
hsa-miR-34c-3p 2.006 hsa-miR-642-5p 3.597 hsa-miR-195-3p 9.307 
hsa-miR-515-3p 2.007 hsa-miR-326-5p 3.606 hsa-miR-933-5p 9.341 
hsa-miR-621-5p 2.012 hsa-miR-490-3p 3.612 hsa-miR-663b-5p 9.506 
hsa-miR-34a-3p 2.015 hsa-miR-193b-3p 3.617 hsa-miR-337-5p 9.977 
hsa-miR-22-5p 2.026 hsa-miR-450a-5p 3.62 hsa-miR-551a-5p 10.377 
hsa-miR-365-5p 2.042 hsa-miR-181c-5p 3.65 hsa-miR-592-5p 10.486 
hsa-miR-491-5p 2.071 hsa-miR-208b-5p 3.741 hsa-miR-513c-5p 10.656 
hsa-miR-96-3p 2.084 hsa-miR-628-5p 3.746 hsa-miR-211-5p 10.954 
hsa-miR-1264-5p 2.092 hsa-miR-154-3p 3.751 hsa-miR-299-3p 11.371 
hsa-miR-141-5p 2.093 hsa-miR-7-1-3p 3.787 hsa-miR-623-5p 11.895 
hsa-miR-589-5p 2.094 hsa-miR-942-5p 3.83 hsa-miR-508-3p 12.437 
hsa-miR-26b-5p 2.105 hsa-miR-187-5p 3.83 hsa-miR-19b-1-3p 12.583 
hsa-miR-187-3p 2.157 hsa-miR-135a-3p 3.855 hsa-miR-517-3p 12.739 
hsa-miR-330-3p 2.168 hsa-miR-595-5p 3.858 hsa-miR-767-3p 12.925 
hsa-miR-32-5p 2.175 hsa-miR-1244-5p 3.885 hsa-miR-363-3p 13.28 
hsa-miR-885-3p 2.211 hsa-miR-558-5p 3.986 hsa-miR-662-5p 13.298 
hsa-miR-346-5p 2.219 hsa-miR-647-5p 4.044 hsa-miR-520b-5p 13.474 
hsa-miR-28-3p 2.227 hsa-miR-943-5p 4.137 hsa-miR-196a-5p 13.48 
hsa-miR-30a-3p 2.277 hsa-miR-34a-5p 4.183 hsa-miR-620-5p 13.515 
hsa-miR-668-5p 2.285 hsa-let-7d-5p 4.191 hsa-miR-518c-3p 13.62 
hsa-miR-628-3p 2.295 hsa-miR-429-5p 4.224 hsa-miR-3180-3p 13.753 
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hsa-miR-1205-5p 2.307 hsa-miR-675-3p 4.326 hsa-miR-562-5p 15.051 
hsa-miR-1296-5p 2.322 hsa-miR-548k-5p 4.433 hsa-miR-767-5p 15.266 
hsa-miR-30e-5p 2.327 hsa-miR-370-5p 4.444 hsa-miR-501-3p 15.48 
hsa-miR-200b-3p 2.34 hsa-miR-519e-5p 4.471 hsa-miR-486-3p 16.75 
hsa-miR-125b-2-3p 2.352 hsa-miR-520f-5p 4.509 hsa-miR-371-5p 16.886 
hsa-miR-526b-5p 2.391 hsa-miR-130a-5p 4.531 hsa-miR-106a-3p 17.1 
hsa-miR-502-5p 2.396 hsa-miR-580-5p 4.63 hsa-miR-338-5p 17.177 
hsa-miR-137-5p 2.417 hsa-miR-548i-5p 4.639 hsa-miR-33b-5p 17.468 
hsa-miR-214-5p 2.435 hsa-miR-890-5p 4.692 hsa-miR-616-3p 17.628 
hsa-miR-223-5p 2.437 hsa-miR-146a-3p 4.81 hsa-miR-374b-3p 17.749 
hsa-miR-744-5p 2.443 hsa-miR-583-5p 5.012 hsa-miRPlusA1031 17.818 
hsa-miR-325-5p 2.483 hsa-miR-188-3p 5.021 hsa-miR-1269-5p 17.957 
hsa-miR-7-5p 2.49 hsa-miR-222-3p 5.023 hsa-miR-372-5p 18.745 
hsa-miR-210-5p 2.497 hsa-miR-518b-5p 5.143 hsa-miR-557-5p 18.817 
hsa-miR-33b-3p 2.499 hsa-miR-548o-5p 5.164 hsa-miR-512-5p 19.327 
hsa-miR-518e-5p 2.514 hsa-miR-124-5p 5.174 hsa-miR-202-5p 19.695 
hsa-miR-1249-5p 2.515 hsa-miR-885-5p 5.175 hsa-miR-18b-3p 20 
hsa-miR-339-3p 2.528 hsa-miR-146b-3p 5.355 hsa-miRPlusD1033 20.163 
hsa-miR-760-5p 2.529 hsa-miR-600-5p 5.403 hsa-miR-675b-5p 21.361 
hsa-miR-30d-5p 2.555 hsa-miR-597-5p 5.554 hsa-miR-873-5p 21.467 
hsa-miR-1911-3p 2.561 hsa-miR-15b-3p 5.574 hsa-miR-1-5p 23.538 
hsa-miR-605-5p 2.583 hsa-miR-381-5p 5.729 hsa-miR-412-5p 23.833 
hsa-miR-148b-5p 2.601 hsa-miR-99a-5p 5.742 hsa-miR-491-3p 24.61 
hsa-miR-877-3p 2.603 hsa-miR-223-3p 5.753 hsa-miR-498-5p 25.427 
hsa-miR-200a-5p 2.655 hsa-miR-634-5p 5.801 hsa-miR-937-5p 26.513 
hsa-miR-421-5p 2.664 hsa-miR-518a-3p 5.86 hsa-miR-451-5p 27.084 
hsa-miR-499-5p 2.731 hsa-miR-596-5p 5.881 hsa-miR-520d-5p 27.591 
hsa-miR-1263-5p 2.741 hsa-miR-30c-1-3p 5.921 hsa-miR-556-5p 27.696 
hsa-miR-26a-1-3p 2.751 hsa-miR-516a-5p 6.019 hsa-miR-147-5p 27.998 
hsa-miR-25-3p 2.777 hsa-miR-335-3p 6.032 hsa-miR-92b-3p 28.949 
hsa-miR-564-5p 2.805 hsa-miR-554-5p 6.091 hsa-miR-515-5p 30.258 
hsa-miR-545-5p 2.807 hsa-miR-150-5p 6.103 hsa-miR-517c-5p 31.942 
hsa-miR-22-3p 2.811 hsa-miR-521-5p 6.14 hsa-miR-373-3p 34.484 
hsa-miR-548d-5p 2.836 hsa-miR-615-3p 6.17 hsa-miR-524-3p 34.725 
hsa-miR-891a 2.84 hsa-miR-551b-3p 6.242 hsa-miR-454-3p 35.91 
hsa-miR-26a-2-3p 2.88 hsa-miR-199a-3p 6.426 hsa-miR-133a-5p 37.907 
hsa-let-7c-5p 2.932 hsa-miR-10a-3p 6.566 hsa-miR-133b-5p 38.93 
hsa-miR-200a-3p 2.943 hsa-miR-497-5p 6.572 hsa-miR-181c-3p 42.935 
hsa-miR-30c-2-3p 3.05 hsa-miR-9-5p 6.676 hsa-miR-373-5p 45.111 
hsa-miR-184-5p 3.077 hsa-miR-516b-5p 6.816 hsa-miR-518f-5p 47.556 
hsa-miR-1271-5p 3.082 hsa-miR-525-3p 6.817 hsa-miR-921-5p 69.187 
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hsa-miR-302a-5p 3.167 hsa-miR-541-5p 7.187 hsa-miR-548l-5p 76.18 
hsa-miR-149-3p 3.175 hsa-miR-139-5p 7.456 hsa-miR-375-5p 81.495 
hsa-miR-552-5p 3.302 hsa-miR-129-3p 7.465 hsa-miR-143-5p 83.063 
hsa-miR-510-5p 3.344 hsa-miR-362-5p 7.488 hsa-miR-631-5p 85.097 
hsa-miR-10a-5p 3.349 hsa-miR-217-5p 7.616 hsa-miR-153-5p 100.736 
hsa-miR-130b-5p 3.361 hsa-miR-888-5p 7.62 hsa-miR-105-5p 131.645 
hsa-miR-96-5p 3.388 hsa-miR-301b-5p 7.815 hsa-miR-622-5p 147.739 
hsa-miR-608-5p 3.404 hsa-miR-1224-3p 7.95 hsa-miR-122-5p 198.567 
hsa-miR-485-3p 3.414 hsa-miR-519a-5p 8.064 hsa-miR-147b-5p 201.357 
hsa-miR-615-5p 3.421 hsa-miR-338-3p 8.159 hsa-miR-551b-5p 264.961 
hsa-miR-149-5p 3.432 hsa-miR-198-5p 8.234 hsa-miRPlusC1076 1046.216 
hsa-miR-302c-5p 3.435 hsa-miR-610-5p 8.235   
hsa-miR-130b-3p 3.448 hsa-miR-517a-5p 8.245   
hsa-miR-1255b-5p 3.461 hsa-miR-10b-5p 8.885   
 
The low inter- and intra-platform consistency of different miRNA profiling technologies 
is troubling. Because of this, it is considered good practice to validate one’s profiling results with 
another platform. In Chapter 1, we validated our urinary sequencing results with qRT-PCR but 
we did not have the time to validate each one of the large number of miRNAs profiled in Chapter 
2. So in the place of validation by qRT-PCR, a miRNA microarray representing the work of a 
previous graduate student in our laboratory is reproduced here. It duplicates the comparison 
between the P69 and M12 cell lines only. 
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Table 25: Detailed Legend for Figure 14 A) 
Gene 
Fold 
Change logCPM LR PValue 
hsa-mir-770 -0.57267 -1.19553 1.920108 0.165845 
hsa-mir-370 -0.57781 2.492108 15.97631 6.41E-05 
hsa-mir-493 -0.5778 2.704866 14.45822 0.000143 
hsa-mir-337 -0.09373 3.893152 0.623334 0.429811 
hsa-mir-665 -0.18132 -0.76107 0.376376 0.539549 
hsa-mir-431 -0.6881 2.211554 11.98578 0.000536 
hsa-mir-433 -0.15849 0.00032 0.458814 0.498179 
hsa-mir-127 -0.51892 9.065346 20.24933 6.80E-06 
hsa-mir-432 -0.62185 2.325647 16.24684 5.56E-05 
hsa-mir-136 -0.46398 5.538452 6.786174 0.009187 
hsa-mir-379 -0.7396 9.120118 32.63807 1.11E-08 
hsa-mir-299 -0.69771 1.538928 25.64819 4.10E-07 
hsa-mir-380 -0.36248 0.149918 3.385694 0.065764 
hsa-mir-323 -0.77066 0.807931 8.803072 0.003007 
hsa-mir-758 -0.49704 3.481703 17.2797 3.23E-05 
hsa-mir-329 -0.60551 -0.41015 6.291365 0.012133 
hsa-mir-494 -0.62473 0.275954 7.639594 0.00571 
hsa-mir-543 -0.55986 0.404564 9.750433 0.001793 
hsa-mir-495 -0.34241 2.271103 6.516373 0.010689 
hsa-mir-376c -0.61721 2.200399 14.08588 0.000175 
hsa-mir-376a -0.7518 -0.5099 9.54603 0.002004 
hsa-mir-654 -0.60883 4.34719 26.81406 2.24E-07 
hsa-mir-376b -0.55901 0.153324 7.20836 0.007256 
hsa-mir-300 0 -1.35774 0 1 
hsa-mir-381 -0.82828 5.675402 44.56851 2.46E-11 
hsa-mir-487b -0.73082 2.28629 24.35392 8.02E-07 
hsa-mir-539 -0.54821 1.786386 7.150319 0.007495 
hsa-mir-889 -1.04511 4.163797 48.04553 4.16E-12 
hsa-mir-544b 0.562399 -1.32198 1.530385 0.216055 
hsa-mir-655 -0.36388 0.647302 5.13758 0.023413 
hsa-mir-487a -0.07083 0.116702 0.133341   
hsa-mir-382 -0.44196 3.145041 11.75463 0.000607 
hsa-mir-134 -0.52931 7.002791 22.57249 2.02E-06 
hsa-mir-668 -1.08927 -1.16411 5.37052 0.02048 
hsa-mir-485 -0.49873 0.766485 8.732438 0.003126 
has-mir-453 NA NA NA NA 
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hsa-mir-154 -0.42403 2.25434 11.9715 0.00054 
hsa-mir-496 -0.69917 1.143297 20.75066 5.23E-06 
hsa-mir-377 -0.47003 1.446929 11.31949 0.000767 
hsa-mir-541 -1.51921 -0.58081 21.14076 4.27E-06 
hsa-mir-409 -0.09061 3.994212 0.545747 0.460061 
hsa-mir-412 -1.00977 1.501015 9.905115 0.001648 
hsa-mir-410 -0.55338 3.508668 18.49244 1.71E-05 
hsa-mir-656 -0.29756 -0.02532 1.917731 0.166107 
 
 
 
 
 
 
 
 
 
Table 26: Detailed Legend for Figure 14 B) 
Gene logFC logCPM LR P-value 
hsa-miR-127-3p -7.8541 8.32929 26.14608 3.17E-07 
hsa-miR-127-5p -4.60846 2.749087 3.722337 0.053689 
hsa-miR-134-5p -5.29173 5.857574 16.06363 6.12E-05 
hsa-miR-136-3p -7.86219 5.174953 15.66054 7.58E-05 
hsa-miR-136-5p -5.97326 3.613491 7.000483 0.008149 
hsa-miR-154-3p -4.34619 2.621537 3.187705 0.074194 
hsa-miR-299-3p -6.79296 4.220381 8.727155 0.003135 
hsa-miR-323a-3p -7.70687 5.011052 12.82824 0.000341 
hsa-miR-323b-3p -6.99059 4.390966 9.755046 0.001788 
hsa-miR-329-3p -5.52909 3.316172 5.974179 0.014517 
hsa-miR-337-3p -5.00872 2.970253 4.698453 0.03019 
hsa-miR-370-3p -11.4301 8.603022456 31.87442999 1.64E-08 
hsa-miR-376a-3p -5.06654 2.980456303 4.289050984 0.038358571 
hsa-miR-376c-3p -5.58019 3.330567 6.153677 0.013114 
hsa-miR-377-3p -6.02292 3.627183 6.614553 0.010115 
hsa-miR-379-3p -4.37378 2.626862 3.123234 0.077183 
hsa-miR-379-5p -10.5752 7.760063 27.68123 1.43E-07 
hsa-miR-382-3p -5.18441 3.071711 5.080347 0.024199 
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hsa-miR-382-5p -8.0011 5.28569 15.5985 7.83E-05 
hsa-miR-409-3p -10.0685 7.261611 26.51293 2.62E-07 
hsa-miR-409-5p -5.59927 3.335382 6.021738 0.014131 
hsa-miR-410-3p -5.90353 3.505032 5.272944 0.021659 
hsa-miR-431-3p -4.37504 2.626862 3.105295 0.078038 
hsa-miR-433-3p -6.37965 3.878968 6.847639 0.008876 
hsa-miR-485-3p -5.9428 3.562994 6.262382 0.012333 
hsa-miR-485-5p -4.83709 2.866527 4.101107 0.042855 
hsa-miR-487b-3p -5.39577 3.231627 5.629107 0.017665 
hsa-miR-493-3p -8.74440 5.989907002 22.46513627 2.14E-06 
hsa-miR-493-5p -9.76754 6.963052438 22.87421627 1.73E-06 
hsa-miR-494-3p -4.04009 2.487355 2.753955 0.097014 
hsa-miR-495-3p -6.93181 4.342174 9.656266 0.001887 
hsa-miR-539-3p -6.45383 3.967528 8.123694 0.004369 
hsa-miR-543 -9.50421 6.707409 23.09731 1.54E-06 
hsa-miR-654-3p -10.1712 7.363168 27.41589 1.64E-07 
hsa-miR-654-5p -7.0784 4.480912 10.64118 0.001106 
hsa-miR-656-3p -5.81706 3.486217 6.44361 0.011135 
hsa-miR-758-3p -7.72285 5.032793 13.41604 0.000249 
hsa-miR-889-3p -7.65758 4.965643 12.29348 0.000455 
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